ribavirin has been researched along with Recrudescence in 684 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.29) | 18.7374 |
| 1990's | 48 (7.02) | 18.2507 |
| 2000's | 279 (40.79) | 29.6817 |
| 2010's | 346 (50.58) | 24.3611 |
| 2020's | 9 (1.32) | 2.80 |
| Authors | Studies |
|---|---|
| Nagaraju, SP; Nair N, S; Pai, G; Prabhu, AR; Rajwar, E; Rao, IR; Reddy, NP; Suvarna, D; Venkatesh, BT | 1 |
| El-Marakby, MG; Sabri, NA; Solayman, MH | 1 |
| Albuquerque, AS; Atkinson, C; Breuer, J; Brown, JR; Brown, LK; Burns, SO; Clark, I; Cudini, J; Dervisevic, S; Karim, MY; Lowe, DM; Miller, J; Moore, J; Moreira, F; Neild, P; Patel, SY; Roy, S; Ruis, C; Seneviratne, SL; Toumpanakis, C; Williams, CA; Workman, S | 1 |
| Costa, J; Forns, X; García-López, M; Lens, S; Navasa, M; Pérez-Del-Pulgar, S; Sastre, L | 1 |
| Barbera, F; Conaldi, PG; Curcio, G; Gallo, A; Pietrosi, G; Russelli, G; Tuzzolino, F; Vizzini, G; Volpes, R | 1 |
| Cai, ZB; Chen, C; Huang, JS; Liu, F; Liu, Y; Niu, HY; Xu, AF; Yan, TB; Yu, WY; Zhang, Y | 1 |
| Masuda, T; Miyasaka, A; Okamoto, H; Suzuki, A; Takikawa, Y; Yoshida, Y | 1 |
| Kottilil, S; Masur, H; Meissner, EG; Orr, C; Xu, W | 1 |
| Dhanda, A; Moodley, P; Whyte, AF | 1 |
| Aldunate, F; Chiodi, D; Cristina, J; Echeverría, N; Hernández, N; López, P; Moratorio, G; Moreno, P; Sánchez-Cicerón, A; Soñora, M | 1 |
| Brainard, DM; Chung, R; Fierer, DS; Hollabaugh, K; Hughes, M; Kim, A; Kiser, JJ; Macbrayne, C; Marks, KM; McHutchison, JG; Naggie, S; Peters, MG; Roa, J; Symonds, B | 1 |
| Chowdhury, R; Tsen, A | 1 |
| Chevaliez, S; Fourati, S; François, M; Hézode, C; Mallat, A; Pawlotsky, JM; Roudot-Thoraval, F; Ruiz, I; Scoazec, G; Soulier, A; Varaut, A | 1 |
| Ali, A; Idrees, M; Rafique, S; Saleem, K; Wahid, B | 1 |
| Angiola, A; Caruso, A; Casari, S; Castelli, F; Festa, E; Gargiulo, F; Lanza, P; Nasta, P; Odolini, S; Rodella, A; Urbinati, L; Vavassori, A; Viganò, M; Zaltron, S | 1 |
| Applegate, TL; Backmund, M; Bruggmann, P; Cloherty, G; Conway, B; Cunningham, EB; Cunningham, P; Dalgard, O; Dore, GJ; Foster, GR; Grebely, J; Hajarizadeh, B; Lamoury, FMJ; Marks, P; Martinez, D; Robaeys, G; Soker, A; Swan, T | 1 |
| Chen, SC; Chen, YL; Chuang, WL; Dai, CY; Huang, CF; Huang, CI; Huang, JF; Lin, TY; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Elsharkawy, AM; Schmidt-Martin, D | 1 |
| Amin, J; Backmund, M; Bourgeois, S; Bruggmann, P; Bruneau, J; Conway, B; Cunningham, EB; Dalgard, O; Dore, GJ; Dunlop, A; Foster, GR; Grebely, J; Hajarizadeh, B; Hellard, M; Marks, PS; Midgard, H; Quiene, S; Robaeys, G; Thurnheer, MC; Weltman, M | 1 |
| Chen, PJ; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Kao, JH; Liu, CJ; Liu, TW; Su, TH; Wang, SC; Yeh, ML; Yu, ML | 1 |
| Carrai, P; Coppola, C; Cordone, G; Lenci, I; Lionetti, R; Martini, S; Melazzini, M; Montilla, S; Morelli, C; Pani, L; Petraglia, S; Piai, G; Pietrosi, G; Romano, A; Russo, FP; Russo, P; Tamé, M; Toniutto, P; Trotta, MP | 1 |
| Ahmad, I; Asad, MJ; Aziz, H; Irfan, J; Mehmood, A; Ovais, M; Raza, A; Zaman, N | 1 |
| Huang, JW; Liao, HT; Tan, P; Yuan, KF | 1 |
| Abdalla, U; Abdel-Khalek, EE; Abdel-Wahab, M; Al-Refaey, AK; Al-Shobari, M; Ali, M; El-Gilany, AH; Elghawalby, AN; Elmorshedi, M; Sadani, M; Salah, T; Shiha, U; Sultan, AM; Yassen, AM | 1 |
| Angelico, M; Biolato, M; Calvaruso, V; Carrai, P; Craxì, A; D'offizi, G; Fagiuoli, S; Guaraldi, G; Lenci, I; Lionetti, R; Loiacono, L; Mancusi, RL; Mazzarelli, C; Milana, M; Montalbano, M; Piccolo, P; Valente, G; Visco-Comandini, U | 1 |
| Al-Zoairy, R; Beinhardt, S; Ferenci, P; Graziadei, I; Hofer, H; Kozbial, K; Maieron, A; Rasoul-Rockenschaub, S; Stättermayer, AF; Stauber, R; Strasser, M; Trauner, M; Zoller, H | 1 |
| Morikawa, K; Ogawa, K; Sakamoto, N; Suda, G | 1 |
| Bunchorntavakul, C; Palecki, J; Reddy, KR; Tan Dat, H; Thu Thuy, PT | 1 |
| Fung, P; Lingiah, VA; Punnoose, M; Pyrsopoulos, N; Trilianos, P | 1 |
| Caroprese, M; Coppola, N; De Pascalis, S; Guerrera, B; Iovinella, V; Macera, M; Masarone, M; Minichini, C; Occhiello, L; Starace, M; Vitrone, M | 1 |
| Aghemo, A; Cresseri, D; Donato, FM; Fabrizi, F; Fraquelli, M; Lampertico, P; Messa, P; Moroni, G; Passerini, P | 1 |
| Abergel, A; Besch, C; Botta-Fridlund, D; Cagnot, C; Canva, V; Chevaliez, S; Coilly, A; Conti, F; D'Alteroche, L; De Ledinghen, V; Debette-Gratien, M; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Habersetzer, F; Houssel-Debry, P; Jezequel, C; Kamar, N; Lebray, P; Leroy, V; Martino, VD; Montialoux, H; Moreno, C; Pageaux, GP; Perre, P; Radenne, S; Rossignol, E; Silvain, C; Tran, A; Veislinger, A | 1 |
| Bandeira de Mello Brandao, A; Costabeber, AM; Cracco Cantisani, GP; Kiss, G; Leipnitz, I; Marroni, CA; Martini, J; Medeiros Fleck, A; Meine, MH; Mucenic, M; Sacco, FKF; Soares Schlindwein, E; Zanotelli, ML | 1 |
| Chae, HB; Jang, JW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Kim, YM; Ko, SY; Lee, BS; Lee, JD; Lee, SH; Lee, TH; Song, IH; Song, MJ | 1 |
| Asante-Appiah, E; Barr, E; Black, T; Brunhofer, J; Galloway, A; Haber, B; Hwang, P; Lahser, F; Palcza, J; Robertson, M; Wahl, J | 1 |
| Bacca, D; Cenderello, G; Copetti, M; De Stefano, G; Losappio, R; Mangia, A; Mazzola, M; Minerva, N; Palmieri, V; Piazzola, V; Potenza, D; Santoro, R; Sogari, F; Terreni, N | 1 |
| Aqel, B; Keaveny, AP; Leise, M; Pungpapong, S; Vargas, HE; Watt, KD; Zhang, N | 1 |
| Khaliq, S; Raza, SM | 1 |
| El-Hamamsy, M; El-Meteini, M; Mansy, AE; Montasser, IF; Nabet, DE | 1 |
| Ding, X; Fan, Z; Liu, J; Liu, S; Wang, F | 1 |
| Chen, M; Hu, P; Liu, K; Pan, Z; Peng, M; Qiu, K; Ren, H; Shen, Y; Xue, W | 1 |
| Arachchi, N; Bowden, S; Cameron, K; Doyle, J; Gow, P; Hellard, M; Iser, D; O'Keefe, J; Papaluca, T; Pianko, S; Sievert, W; Sinclair, M; Stoove, M; Thompson, A | 1 |
| Ataíde, EC; Boin, IFSF; Santos, AG; Stucchi, RSB; Zanaga, LP | 1 |
| Albrecht, JK; Barnard, RJ; Brass, CA; Chaudhri, E; Davis, MN; Gordon, SC; Hazuda, DJ; Howe, AY; Howe, JA; Jacobson, IM; Kwo, PY; Lawitz, EJ; McCone, J; Ogert, RA; Pedicone, LD; Pound, D; Qiu, P; Ralston, R; Ravendhran, N; Rossaro, L; Schiff, ER; Vierling, JM | 1 |
| Davis, GL; Klintmalm, GB; McKenna, GJ; O'Leary, JG | 1 |
| Banfi, G; Battista Fogazzi, G; Cresseri, D; Fabrizi, F; Francesca Donato, M; Martin, P; Messa, P | 1 |
| Hopwood, M | 1 |
| Jia, JD; Rakhda, MI; Wang, TI; Zhao, XY | 1 |
| Aghemo, A; Colombo, M; Cremonesi, E; Degasperi, E; Mantovani, S; Mele, D; Mondelli, MU; Oliviero, B; Rumi, MG; Tinelli, C; Varchetta, S | 1 |
| Jia, Z; Li, D; Liang, HJ; Ma, L; Wei, X; Yang, D | 1 |
| Fukuhara, T; Furusyo, N; Ikegami, T; Kato, M; Kotoh, K; Maehara, Y; Motomura, T; Shimoda, S; Shirabe, K; Soejima, Y; Yoshizumi, T | 1 |
| Fischer, L; Logge, C; Nashan, B; Sterneck, M; Vettorazzi, E | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Hsieh, MY; Huang, CF; Huang, JF; Juo, SH; Lin, YC; Lin, ZY; Wang, LY; Yeh, ML; Yu, ML | 1 |
| Aguilera, V; Berenguer, M; Vinaixa, C | 1 |
| Inglot, M; Malyszczak, K; Pawlowski, T; Radkowski, M; Szymczak, A; Zalewska, M | 1 |
| Auriemma, F; Caporaso, N; Donnarumma, L; Gaeta, L; Gentile, I; Granata, R; Guarino, M; Loperto, I; Morisco, F; Stroffolini, T | 1 |
| Hsu, SH; Wang, SN; Yeh, ML | 1 |
| Cariti, G; Ceretto, S; Ciancio, A; Ciccone, G; Colletta, C; De Blasi, T; Giordanino, C; Grasso, A; Marenco, S; Mazzucco, D; Picciotto, A; Pirisi, M; Rizzetto, M; Sacco, M; Saracco, G; Simondi, D; Smedile, A; Smirne, C; Traverso, A | 1 |
| Airoldi, A; Belli, LS; Bitetto, D; Burra, P; Cmet, S; Colpanij, M; Cussigh, A; De Feo, T; De Martin, E; Donato, MF; Fabris, C; Fagiuoli, S; Falleti, E; Gambato, M; Mantovani, M; Pasulo, L; Piccolo, G; Rigamonti, C; Toniutto, P; Viganò, R | 1 |
| Baldo, V; Carlotto, A; Del Bianco, T; Fabris, P; Floreani, A; Giordani, MT; Grasso, A; Malfatti, F; Miotti, MA; Tramarin, A | 1 |
| Christensen, P; Dalgard, O; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Lindh, M; Norkrans, G; Rauning Buhl, M; Rembeck, K; Westin, J | 1 |
| Barreiro, P; de Mendoza, C; Fernandez-Montero, JV; Labarga, P; Plaza, Z; Poveda, E; Soriano, V; Treviño, A; Vispo, E | 1 |
| Albrecht, JK; Bacon, B; Bárcena, R; Brass, CA; Deng, W; Esteban-Mur, R; Gordon, SC; Hadziyannis, SJ; Häussinger, D; Jacobson, IM; Manns, MP; Marcellin, P; Morgan, TR; Norkrans, G; Pedicone, LD; Pockros, PJ; Poynard, T; Schiff, ER; Schmidt, WN; Shaikh, OS; Shiffman, ML; Smith, CI | 1 |
| Bregigeon, S; Colson, P; Poizot-Martin, I; Solas, C; Tamalet, C; Tourres, C | 1 |
| Chen, DS; Chen, MY; Chen, PJ; Chen, TC; Kao, JH; Liu, CH; Liu, CJ; Su, TH | 1 |
| Abbasi, A; Bhutto, AR; Butt, N; Dhillo, AK; Munir, SM | 1 |
| Del Rio Martin, J; Fiel, MI; Satapathy, SK; Schiano, TD; Vanatta, JM | 1 |
| Everson, GT; Reddy, KR | 1 |
| Brochot, E; Duverlie, G; Guillemard, C; Mathurin, P; Nguyen-Khac, E; Plantier, JC; Riachi, G; Vabret, A | 1 |
| Ahmed, DS; Barua, R; Chowdhury, MS; Ishaque, SM; Masud, H; Parveen, S; Rahman, MA; Rahman, MZ | 1 |
| Andréjak, M; Bodeau, S; Brochot, E; Castelain, S; Durand-Maugard, C; Duverlie, G; François, C; Helle, F; Lemaire-Hurtel, AS; Nguyen-Khac, E | 1 |
| Arena, R; Azzaroli, F; Ballardini, G; Buonfiglioli, F; Calvanese, C; Cecinato, P; Colecchia, A; D'Errico, A; Del Gaudio, M; Lisotti, A; Mazzella, G; Pinna, AD; Quarneti, C; Tamè, M | 1 |
| Gerken, G; Herzer, K; Jochum, C; Papadopoulos-Köhn, A; Paul, A; Timm, J | 1 |
| Goto, S; Hayashi, N; Kato, M; Komada, Y; Seto, C | 1 |
| Forns, X; Solà, R | 1 |
| Fabri, M; Kiralj, K; Mikić, SS; Preveden, T; Ruzić, M; Vukadinov, T | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y | 1 |
| Ancuta, I; Aronsohn, A; Caruntu, F; Cheinquer, H; Coppola, C; Delic, D; Digiacomo, A; Dusheiko, GM; Korner, E; Lengyel, G; Marcellin, P; Orlandini, A; Pruthi, J; Schmitz, M; Silva, GF; Tallarico, L; Tatsch, F | 1 |
| Chiba, T; Fujimoto, Y; Haga, H; Ito, T; Kaido, T; Marusawa, H; Miyagawa-Hayashino, A; Mori, A; Ogawa, K; Ueda, Y; Uemoto, S; Yoshizawa, A | 1 |
| Ackefors, M; Gjertsen, H; Nyström, J; Sönnerborg, A; Weiland, O; Wernerson, A | 1 |
| Andonov, A; Lu, Y; Wong, DK | 1 |
| Mahale, P; Okhuysen, PC; Torres, HA | 1 |
| Burroughs, AK; Davidson, BR; Gurusamy, KS; Toon, CD; Tsochatzis, E; Xirouchakis, E | 1 |
| Bani-Sadr, F; Cacoub, P; Carrat, F; Fromentin, D; Goujard, C; Hessamfar, M; Krastinova, E; Perronne, C; Pol, S; Yazdanpanah, Y | 1 |
| Dekio, F; Malik, S; Wen, JW | 1 |
| Buhl, MR; Christensen, PB; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Lindh, M; Martner, A; Mørch, K; Nilsson, S; Norkrans, G; Nyström, K; Pedersen, C; Rembeck, K; Waldenström, J; Westin, J | 1 |
| Ascione, A; Ciancio, A; Craxì, A; Deodato, B; Golotta, C; Iannacone, C; Piccinino, F | 1 |
| Fabien, S; Filomena, C; Gautier, G; Khaldoun, G; Laurissa, O; Lynda, A; Nadira, D; Olivier, M; Vivian, V; Yvon, C | 1 |
| Angarano, G; Bruno, R; Capetti, A; Caputo, A; Cariti, G; Carosi, G; Galli, M; Gulminetti, R; Iannacone, C; Maida, I; Nasta, P; Pontali, E; Puoti, M; Raise, E; Ravasio, V; Verucchi, G | 1 |
| Arslan, F; Aslan, F; Ceylan, B; Fincanci, M; Özgüneş, N; Yardimci, C | 1 |
| Andreone, P; Beumont-Mauviel, M; Bronowicki, JP; Brown, A; De La Rosa, G; Forns, X; Gane, E; Horban, A; Kalmeijer, R; Lawitz, E; Lenz, O; Ouwerkerk-Mahadevan, S; Peeters, M; Scott, J; Sinha, R; Zeuzem, S | 1 |
| Goto, S; Hayashi, N; Izumi, N; Kato, M; Ki, R; Komada, Y; Kumada, H; Okanoue, T; Seto, C; Tsubouchi, H; Yatsuhashi, H | 1 |
| Angelico, M; Antonucci, G; Belli, L; Bertuzzo, V; Bitetto, D; Bringiotti, R; Burra, P; Colombo, M; Colpani, M; De Martin, E; De Ruvo, N; Di Benedetto, F; Di Leo, A; Di Paolo, D; Donato, MF; Ettorre, GM; Fagiuoli, S; Fornasiere, E; Gasbarrini, A; Gerunda, GE; Giannelli, V; Giusto, M; Iemmolo, RM; Lupo, L; Marino, M; Memeo, V; Merli, M; Miglioresi, L; Montalti, R; Morelli, MC; Pasulo, L; Pinna, AD; Pompili, M; Ponziani, FR; Rendina, M; Rigamonti, C; Rossi, G; Senzolo, M; Tisone, G; Toniutto, P; Vero, V; Viganò, R; Visco-Comandini, U; Zappimbulso, M | 1 |
| Bechstein, WO; Farnik, H; Ferreiros, N; Galle, PR; Geisslinger, G; Herrmann, E; Kronenberger, B; Labocha, S; Sarrazin, C; Welker, MW; Zeuzem, S; Zimmermann, T | 1 |
| Andronescu, CI; Andronescu, D; Diaconu, S; Purcarea, RM; Tiuca, N | 1 |
| Allen, R; Bau, S; Busuttil, RW; Durazo, F; El-Kabany, M; Goldstein, L; Han, S; Manne, V; Reynolds, JA; Saab, S | 1 |
| Nair, S; Waters, B | 1 |
| Fridell, JA; Ghabril, M; Joseph Tector, A; Kwo, PY; Lacerda, MA; Vianna, R | 1 |
| Agarwal, K; Berg, T; Bernstein, B; Campbell, AL; Collins, CA; Da Silva-Tillmann, B; Forns, X; Hezode, C; Kowdley, KV; Lovell, SS; Podsadecki, T; Poordad, F; Shiffman, ML; Trinh, R; Wedemeyer, H; Yoshida, EM; Zeuzem, S | 1 |
| Enomoto, N; Fujiwara, K; Izumi, N; Joh, T; Kurosaki, M; Kusakabe, A; Matsuura, K; Mizokami, M; Nojiri, S; Orito, E; Sakamoto, N; Shinkai, N; Tanaka, Y; Watanabe, T; Yatsuhashi, H | 1 |
| Fukuhara, T; Harimoto, N; Ikegami, T; Konishi, H; Maehara, Y; Matsumoto, Y; Motomura, T; Shirabe, K; Soejima, Y; Yoshizumi, T | 1 |
| Chusri, P; Kumthip, K; Maneekarn, N; Nelson, KE; O'Brien, A; Pantip, C; Thongsawat, S | 1 |
| Grewal, P; Kim, B; Thung, SN; Trivedi, A | 1 |
| Abdel-Aty, EF; Abdel-Ghaffar, AY; Abdel-Ghaffar, TY; Allam, AA; Behairy, BE; Ehsan, NA; El Naghi, S; El-Araby, HA; El-Guindi, MA; El-Hennawy, AM; El-Karaksy, H; El-Raziky, MS; El-Sebaie, H; Helmy, H; Sira, MM | 1 |
| Baruch, Y; Bernstein, D; Bhandari, BR; Box, TD; Caruntu, FA; Chulanov, V; Cohen, D; Cooper, C; Enayati, P; Ferenci, P; Gervain, J; Green, S; Hassanein, T; Janczewska, E; King, M; Lalezari, J; Luo, Y; Marinho, RT; Moreno, C; Nyberg, A; Planas, R; Podsadecki, T; Reddy, KR; Rizzardini, G; Sepe, T; Tam, E; Tsai, N; Xie, W; Younes, Z | 1 |
| Abdelrahman, T; Hughes, J; Main, J; McLauchlan, J; Thomson, E; Thursz, M | 1 |
| Bon, D; Fauci, AS; Herrmann, E; Hewitt, S; Kottilil, S; Masur, H; McHutchison, J; Meissner, EG; Osinusi, A; Polis, M; Porcella, S; Prokunina-Olsson, L; Sturdevant, D; Suffredini, AF; Virtaneva, K; Wang, H; Wu, D | 1 |
| Colić-Cvrlje, V; Kanizaj, TF; Mrzljak, A; Ostojić, R | 1 |
| Galle, PR; Knapstein, J; Wörns, MA; Zimmermann, T | 1 |
| Aghemo, A; Colombo, M; Donato, MF; Maggioni, M; Malinverno, F; Monico, S; Reggiani, P | 1 |
| Abradelo, M; Agüero, F; Aguilera, V; Antela, A; Barcena, R; Bernal, C; Castells, L; de la Rosa, G; Del Campo, S; Esteban-Mur, JI; Fernandez, JR; González-García, J; Laguno, M; Manzardo, C; Miro, JM; Montero, JL; Olivares, S; Perez, I; Rimola, A; Rodriguez, M; Salcedo, M; Suarez, F; Valdivieso, A; Xiol, X | 1 |
| Bureau, C; Danjoux, M; Delabaudière, C; Dörr, G; Izopet, J; Kamar, N; Lavayssière, L; Muscari, F; Peron, JM; Rostaing, L; Sallusto, F | 1 |
| Price, JC; Terrault, NA | 1 |
| Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Jochum, C; Papadopoulos-Köhn, A; Paul, A; Timm, J | 1 |
| Cai, L; Chen, Y; Liao, R; Liu, X; Lu, Q; Wang, X; Yang, X; Yang, Z; Zhang, L | 1 |
| Abravanel, F; Izopet, J; Kamar, N; Lhomme, S; Rostaing, L | 1 |
| Afdhal, N; Arterburn, S; Befeler, A; Brown, R; Chung, RT; Curry, MP; Denning, J; Everson, G; Fenkel, JM; Forns, X; Gane, E; Gordon, F; Kuo, A; McHutchison, JG; McNair, L; Moonka, D; O'Leary, J; Saab, S; Schiano, T; Schiff, E; Subramanian, GM; Svarovskaia, E; Symonds, WT; Terrault, NA | 1 |
| Arterburn, S; Brainard, D; Brown, RS; Charlton, M; Curry, MP; Denning, J; Dvory-Sobol, H; Fontana, RJ; Forns, X; Gane, E; Gilroy, R; Kirby, B; Kwo, PY; Manns, MP; McHutchison, JG; Muir, AJ; Samuel, D; Symonds, WT; Teperman, L; Terrault, NA | 1 |
| Agudelo, EZ; Campos-Varela, I; Carlson, L; Straley, S; Terrault, NA | 1 |
| Akamatsu, N; Aoki, T; Hasegawa, K; Izumi, N; Kaneko, J; Kokudo, N; Kurosaki, M; Sakamoto, Y; Sugawara, Y; Tamura, S; Tanaka, T | 1 |
| Lagging, M; Nyström, K; Waldenström, J | 1 |
| Fauci, AS; Kohli, A; Kottilil, S; Marti, MM; Masur, H; McHutchison, JG; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Silk, R; Subramanian, GM; Townsend, K; Zhang, X | 1 |
| Agarwal, K; Cohen, D; Podsadecki, T; Poordad, F; Xie, W; Younes, Z | 1 |
| Antonini, TM; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Haim-Boukobza, S; Roque-Afonso, AM; Samuel, D; Sebagh, M; Taburet, AM; Teicher, E; Vittecoq, D | 1 |
| Firpi, RJ; Hilgenfeldt, E | 1 |
| Charlton, MR; Gallegos-Orozco, JF | 1 |
| Baumert, TF; Brainard, D; Brandt-Sarif, T; Castells, L; Chang, P; Charlton, M; Coilly, A; Denning, J; Fontana, RJ; Forns, X; Habersetzer, F; Kivett, V; Londoño, MC; McHutchison, JG; Prieto, M; Symonds, WT | 1 |
| Färkkilä, M | 1 |
| Ackefors, M; Castedal, M; Dahlgard, O; Gjertsen, H; Verbaan, H; Weiland, O; Wernerson, A | 1 |
| Ahn, JH; Baek, YH; Han, SY; Jo, YM; Kim, SY; Kim, WJ; Lee, JY; Lee, SW | 1 |
| Chen, MH; Chou, CT; Huang, DF; Huang, YH; Lin, HY; Tsai, CY | 1 |
| Aqel, B; Chervenak, AE; Henry, TM; Keaveny, AP; Leise, M; Murphy, JL; Pungpapong, S; Ryland, K; Vargas, HE; Watt, KD; Werner, KT | 1 |
| Akhtar, N; Bilal, M; Khan, A; Khan, MA; Rizwan, M | 1 |
| Eguchi, S; Hidaka, M; Kuroki, T; Miyaaki, H; Nakao, K; Soyama, A; Takatsuki, M; Yamashita, M | 1 |
| Gaytán-Martínez, JE; Huerta García, G; Mata-Marín, JA; Sandoval-Ramirez, JL | 1 |
| Faisal, N; Lilly, LB; Marquez, M; Mumtaz, K; Renner, EL | 1 |
| Hirohashi, K; Kanazawa, A; Kubo, S; Tanaka, S; Uenishi, T; Yamamoto, T | 1 |
| Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D | 2 |
| Chtioui, H; Decosterd, LA; Giostra, E; Majno, PE; Moradpour, D; Pascual, M; Vionnet, J | 1 |
| Harada, N; Harimoto, N; Ikegami, T; Itoh, S; Kawanaka, H; Kimura, Y; Maehara, Y; Oki, E; Saeki, H; Shirabe, K; Soejima, Y; Takeishi, K; Tsujita, E; Uchiyama, H; Yamashita, YI; Yoshizumi, T | 1 |
| Egawa, H; Hashimoto, E; Kogiso, T; Kotera, Y; Omori, A; Shiratori, K; Taniai, M; Tokushige, K; Yamamoto, M | 1 |
| Gao, Y; Li, H; Liu, Z; Su, H; Sun, Y; Tang, R; Zhang, D; Zhang, M; Zhou, S; Zhou, X | 1 |
| Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Papadopoulos-Köhn, A; Paul, A; Timm, J; Walker, A | 1 |
| Ahmad, J; Bach, N; Chang, C; Chernyiak, M; Doucette, JT; Fiel, MI; Florman, SS; Grewal, P; Khaitova, V; Kim-Schluger, L; Lim, KB; Liu, L; Odin, J; Perumalswami, P; Schiano, TD; Sima, HR | 1 |
| Böker, KH; Cordes, HJ; Cornberg, M; Gonnermann, A; Hardtke, S; Heidrich, B; Klinker, H; Koch, A; Kraus, MR; Manns, MP; Möller, B; Naumann, U; Roggel, C; Rössle, M; Schuchmann, M; Stoehr, A; Trein, A; Wedemeyer, H | 1 |
| Charlton, MR; Dhanasekaran, R; Mounajjed, T; Sanchez, W; Watt, KD; Wiesner, RH | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K | 1 |
| Barcan, LA; Gadano, AC; Galdame, OA; Marciano, S | 1 |
| Dusheiko, G; Kalafateli, M; Manousou, P | 1 |
| Bau, S; Busuttil, RW; Durazo, F; El Kabany, M; Goo, T; Han, S; Jimenez, M; Kaldas, F; Saab, S; Tong, MJ; Zhao, D | 1 |
| Kim, HJ; Lee, HW; Lee, YJ; Park, SJ; Yang, SY; Yoo, KY | 1 |
| Ascione, A; Bruno, S; Coppola, C; Deodato, B; Mangia, A; Orlandini, A; Puoti, M; Schmitz, M | 1 |
| Abravanel, F; Alric, L; Anty, R; Bureau, C; Gérolami, R; Guillaume, M; Izopet, J; Kamar, N; Nana, J; Pariente, A; Péron, JM; Renou, C; Robic, MA; Vinel, JP | 1 |
| Albert, ML; Casrouge, A; Decalf, J; Duffy, D; Kottilil, S; Masur, H; Meissner, EG | 1 |
| Ballestri, S; Bertolotti, M; Lonardo, A; Marrazzo, A; Romagnoli, D | 1 |
| Altus, R; Colman, A; Dan, YY; Fragomelli, V; Galhenage, S; Guan, R; Jones, T; Lee, YM; Leembruggen, N; Lim, SG; Luman, W; Mason, S; Mollison, L; Morales, B; Nazareth, S; Pham, T; Piratvisuth, T; Sendall, C; Sukeepaisarnjaroen, W; Sutedja, D; Tan, SS; Tanwandee, T; Teo, EK; Than, YM; Totten, L; Wigg, A | 1 |
| Abdel-Hamid, M; Amr, KS; Esmail, MA; Ghazawy, ER; Hassuna, NA | 1 |
| Nair, S; Pai, G; Prabhu, RA; Reddy, NP; Suvarna, D | 1 |
| Bjøro, K; Dalgard, O; Marcellin, P; Martinot-Peignoux, M; Ring-Larsen, H; Verbaan, H | 1 |
| Brainard, DM; Clark, PJ; Estep, M; Hunt, S; McHutchison, JG; Negro, F; Patel, K; Paulson, M; Song, Q; Stamm, LM; Stepanova, M; Subramanian, GM; Younossi, ZM | 1 |
| Beckebaum, S; Bester, C; Heinzow, H; Hüsing, A; Kabar, I; Schmidt, HH; Seifert, LL; Stahl, M; Vorona, E | 1 |
| Bhangui, P; Choudhary, NS; Gautam, D; Goja, S; Lipi, L; Menon, PB; Ramachandra, SK; Rastogi, A; Saigal, S; Saraf, N; Soin, AS | 1 |
| Hayashi, N; Howe, AY; Kumada, H; Ludmerer, SW; Mobashery, N; Nakamuta, M; Takase, A; Takehara, T | 1 |
| Abrignani, S; Aghemo, A; Balistreri, F; Bianco, A; Cheroni, C; Colombo, M; D'Ambrosio, R; De Francesco, R; Donnici, L; Neddermann, P; Pagani, M; Rumi, MG; Soffredini, R; Zanoni, V | 1 |
| Kilvert, L; Lee, SS; Liu, H; Trepanier, J | 1 |
| Kattakuzhy, S; Kottilil, S; Tang, L; Ward, H; Wilson, E | 1 |
| Gonzalez, YS; Huber, C; Juday, T; Saab, S; Wang, A | 1 |
| Biggins, SW; Burton, JR; Everson, GT; Gralla, J; Nordstrom, EM; Rosen, HR | 1 |
| Carneiro, BM; Frick, DN; Hanson, AM; Mukherjee, S; Nogueira, ML; Provazzi, PJ; Rahal, P | 1 |
| Boyer-Darrigand, N; D'alteroche, L; Dao, MT; Ducancelle, A; Fouchard-Hubert, I; Larrey, D; Le Guillou-Guillemette, H; Loustaud-Ratti, V; Lunel-Fabiani, F; Picard, N; Saulnier, P; Veillon, P | 1 |
| Fontana, RJ; Hughes, EA; Landis, C; McPhee, F; Noviello, S; Poordad, F; Schiff, ER; Swenson, ES; Vierling, JM; Yang, R | 1 |
| Cooke, GS; Hill, A; Riley, RD; Saleem, J; Simmons, B | 1 |
| Bailey, R; Cooper, C; Drolet, M; Elkashab, M; Farley, J; Feinman, SV; Marotta, P; Peltekian, K; Poliquin, M; Rampakakis, E; Witt-Sullivan, H | 1 |
| Bahirwani, R; Berg, C; Brown, RS; Castells, L; Chacko, KR; Durand, CM; ElSharkawy, AM; Emond, B; Ferenci, P; Fontana, RJ; Herzer, K; Ionescu-Ittu, R; Jafri, SM; Joshi, S; Knop, V; Lionetti, R; Loiacono, L; Londoño, MC; Montalbano, M; Moreno-Zamora, A; Mubarak, A; Pellicelli, AM; Prieto, M; Reddy, KR; Stadler, B; Stauber, RE; Stenmark, S; Torti, C; Vekeman, F; Weiland, O | 1 |
| Barve, A; Brock, G; Buchanan, LA; Cave, B; Cave, MC; Crittenden, NE; Davis, EG; Gedaly, R; Jones, CM; Kuns-Adkins, CB; Marsano, L; Marvin, MR; McClain, CJ; Pinkston, CM; Rosenau, J; Shah, MB | 1 |
| Gonzalez, HC; Nair, S; Satapathy, SK | 1 |
| Chayama, K; Fujimoto, G; Howe, AY; Karino, Y; Kumada, H; Ludmerer, SW; Mobashery, N; Mochida, S; Nakamura, K; Suzuki, F | 1 |
| Aljudaibi, B; Bilodeau, M; Congly, SE; Cooper, C; Faisal, N; Ghali, MP; Hirsch, G; Hussaini, T; Leonard, J; Lilly, LB; Ma, MM; Peltekian, K; Renner, EL; Yoshida, EM | 1 |
| Agarwal, R; Ahmad, J; Bach, N; Bansal, M; Bichoupan, K; Branch, A; Chang, C; Dieterich, D; Friedman, S; Gardenier, D; Grewal, P; Harty, A; Im, G; Khaitova, V; Kim-Schluger, L; Ku, L; Leong, J; Liu, L; Motamed, D; Ng, M; Odin, J; Patel, N; Perumalswami, P; Schiano, T; Yalamanchili, R | 1 |
| Alkhouri, N; Apfel, T; Hanouneh, IA; Hanouneh, M; Jackson, WE; John, BV; Zein, NN; Zervos, X | 1 |
| Chen, XH; Gao, L; Geng, JB; Hao, KY; Li, P; Wang, J; Wang, M; Wang, MR; Wang, SM; Xie, F; Xiong, X; Yang, ZG; Zhang, X; Zheng, WK | 1 |
| Cai, WP; Chen, XJ; He, Y; Hu, FY; Ke, YC; Lan, Y; Li, LH; Tang, XP | 1 |
| Baños, I; Bellot, P; Bhamidimarri, KR; Brainard, DM; Campos-Varela, I; Castells, L; Grewal, P; Guaraldi, G; Hasson, H; McHutchison, JG; Morbey, A; Moreno, A; Terrault, NA | 1 |
| Cooper, C; Dieterich, D; Dvory-Sobol, H; Han, L; McHutchison, JG; Naggie, S; Pang, PS; Saag, M; Stamm, LM; Sulkowski, M; Yang, JC | 1 |
| Aggarwal, R; Bhadauria, DS; Goel, A; Gupta, A; Kaul, A; Prasad, N; Rai, P; Sharma, RK | 1 |
| Baruch, Y; Ben Ari, Z; Bhanja, S; Bruck, R; Gane, E; Howe, AY; Hwang, P; Mollison, L; Robertson, MN; Wahl, J; Zhao, Y; Zuckerman, E | 1 |
| Bogomolov, P; Cooney, E; Critelli, L; Olveira, A; Pol, S; Reesink, HW; Santagostino, E; Srinivasan, S; van Erpecum, K; Xu, D | 1 |
| Aguilera, A; Arias, A; Benítez-Gutiérrez, L; Cuervas-Mons, V; de Mendoza, C; Lledó, G; Navarro, D; Otero, E; Peña, JM; Soriano, V; Treviño, A | 1 |
| Amoroso, A; Arese, D; Cocchis, D; Dell Olio, D; Magistroni, P; Martini, S; Mirabella, S; Moschini, P; Ottobrelli, A; Rizza, G; Rizzetto, M; Romagnoli, R; Sacco, M; Salizzoni, M; Saracco, GM; Stradella, D; Strona, S; Tandoi, F | 1 |
| Abergel, A; Besch, C; Botta-Fridlund, D; Canva, V; Coilly, A; Conti, F; d'Alteroche, L; de Ledinghen, V; di Martino, V; Diallo, A; Duclos-Vallée, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Rohel, A; Rossignol, E; Samuel, D; Tran, A | 1 |
| Durlik, M; Hreńczuk, M; Kosieradzki, M; Małkowski, P; Pacholczyk, M; Sowińska, R; Tronina, O | 1 |
| Asselah, T; Buggisch, P; Buti, M; Craxí, A; Foster, GR; Gschwantler, M; Lenz, O; Lonjon-Domanec, I; Moreno, C; Ryan, R; Sarrazin, C; Schlag, M; Scott, J; Van Dooren, G | 1 |
| Aba Alkhail, F; Ajlan, A; Al-Hamoudi, W; Al-Jedai, A; Al-Sebayel, M; Alarieh, R; Alkortas, D; Broering, D; Elsiesy, H | 1 |
| Ahn, SH; Han, KH; Kim, BK; Kim, do Y; Kim, HS; Kim, JK; Kim, MN; Kim, SU; Park, JY | 1 |
| Ahn, J; Branch, A; Gripshover, J; Hassan, MA; Kwok, RM; Lee Sang, M; Patel, N; Potosky, DR; Robertazzi, S; Rodigas, C; Satoskar, R; Schiano, TD; Smith, CI; Te, HS; Tierney, A; Wiegel, J | 1 |
| Drago, F; Gasparini, G; Marenco, S; Parodi, A; Picciotto, A | 1 |
| Abushouk, AI; Ahmed, H; Attia, A; Elgebaly, A; Hammad, AM; Negida, A | 1 |
| Abou Mrad, R; Alkhouri, N; Carey, WD; Eghtesad, B; Elfeki, MA; Hanouneh, IA; Modaresi Esfeh, J; O'Shea, R; Zein, NN; Zervos, X | 1 |
| Damrah, I; Eurich, D; Gül-Klein, S; Pratschke, J; Raschzok, N; Reutzel-Selke, A; Sauer, IM; Schott, E; Stockmann, M; Strücker, B | 1 |
| Canbay, A; Gerken, G; Herzer, K; Paul, A; Timm, J; Treckmann, J; Willuweit, K | 1 |
| Bang, BR; Chopra, S; Cook, L; Elmasry, S; Feng, Z; Harper, T; Jerome, KR; Kahn, JA; Kanel, G; Kim, B; Saito, T; Wadhwa, S | 1 |
| Berardi, S; Bhoori, S; Caraceni, P; Donato, MF; Iemmolo, RM; Invernizzi, F; Lenci, I; Martini, S; Mazzarelli, C; Montalbano, M; Morelli, C; Pieri, G; Romagnoli, R | 1 |
| Eurich, D; Globke, B; Pratschke, J; Raschzok, N; Schott, E; Teegen, EM | 1 |
| Huysentruyt, K; Leclercq, G; Scheers, I; Smets, F; Sokal, EM; Stephenne, X; Varma, S | 1 |
| Berg, T; Ferenci, P; Herzer, K; Hinrichsen, H; Inderson, A; Jimenez-Exposito, MJ; Klinker, H; Peck-Radosavljevic, M; Spengler, U; Welzel, TM; Zeuzem, S; Zhao, Y | 1 |
| Cammà, C; D'Offizi, G; DeMasi, R; Janssen, K; Lionetti, R; Palma, M; Schlag, M; Taibi, C; Weber, K; Witek, J | 1 |
| Buti, M; Esteban, R | 2 |
| Beck, R; Berg, CP; Dietz, J; Klag, T; Lauer, UM; Malek, NP; Sarrazin, C; Schwarz, JM; Werner, CR | 1 |
| Burra, P; Zanetto, A | 1 |
| Andreoni, M; Angelico, M; Antonucci, F; Aragri, M; Babudieri, S; Barbaliscia, S; Bellocchi, MC; Bertoli, A; Brancaccio, G; Calvaruso, V; Caporaso, N; Ceccherini-Silberstein, F; Cento, V; Cozzolongo, R; Craxì, A; Di Biagio, A; Di Maio, VC; Francioso, S; Gianserra, L; Grieco, A; Landonio, S; Lenci, I; Loggi, E; Magni, CF; Masetti, C; Mastroianni, CM; Melis, M; Merli, M; Micheli, V; Morisco, F; Pace Palitti, V; Paoloni, M; Parruti, G; Pasquazzi, C; Pellicelli, AM; Perno, CF; Picciotto, A; Puoti, M; Rizzardini, G; Romagnoli, D; Rossi, P; Santopaolo, F; Sarmati, L; Siciliano, M; Taliani, G; Tarquini, P; Teti, E; Vecchiet, J; Verucchi, G; Vullo, V | 1 |
| Akamatsu, N; Eguchi, S; Goto, R; Ikegami, T; Kitagawa, Y; Kokudo, N; Maehara, Y; Okajima, H; Shinoda, M; Soyama, A; Taketomi, A; Ueda, Y; Uemoto, S; Yoshizumi, T | 1 |
| Akremi, R; Bennai, Y; Botta-Fridlund, D; Bourliere, M; Boyer, N; Bronowicki, JP; D'Alteroche, L; De Ledinghen, V; Di Martino, V; Fedchuk, L; Filipovics, A; Fontaine, H; Guyader, D; Hézode, C; Hubert-Fouchard, I; Larrey, D; Lebray, P; Leroy, V; Nguyen-Khac, E; Rosa, I; Silvain, C; Zhao, Y; Zoulim, F | 1 |
| Castedal, M; Cederberg, S; Segenmark, M; Skoglund, C; Weiland, O | 1 |
| Bhasin, D; Pollinger, H; Rubin, RA; Shrestha, R; Stein, L; Tracy, B | 1 |
| Almarzooqi, S; Emery, JS; Feld, JJ; Janssen, HLA; Kowgier, M; Kuczynski, M; La, D; Shah, H; Wong, D | 1 |
| Andreone, P; Berenguer, M; Calleja, JL; Cieciura, T; Donato, MF; Durlik, M; Fagiuoli, S; Forns, X; Herzer, K; Janssen, K; Jessner, W; Kalmeijer, R; Lenz, O; Mariño, Z; Ouwerkerk-Mahadevan, S; Peeters, M; Shukla, U; Sterneck, M; Verbinnen, T | 1 |
| Guillevin, L; Pagnoux, C | 1 |
| Becheanu, G; Gheorghe, L; Herlea, V; Hrehoret, D; Iacob, S; Popescu, I | 1 |
| Egawa, H; Haga, H; Ito, T; Takada, Y; Tanaka, K; Ueda, Y; Uemoto, S | 1 |
| Diepolder, H; Gruener, NH; Heeg, M; Jung, MC; Loehe, F; Nitschko, H; Raziorrouh, B; Schirren, CA; Thiel, M; Ulsenheimer, A; Zachoval, R | 1 |
| Fragopanagou, E; Giannakoulas, NC; Lampropoulou-Karatza, Ch; Mimidis, K; Pallasopoulou, M; Thomopoulos, K; Tsamandas, AC | 1 |
| Jiménez-Rivera, J; Marxuach-Cuétara, A; Ortiz-Lasanta, G; Purcell-Arevalo, D; Ríos-Bedoya, CF; Rodríguez-Torres, M | 1 |
| Conway, B; deVlaming, S; Duncan, F; Grebely, J; Viljoen, M | 1 |
| Eason, J; Lipscomb, J; Nair, S | 1 |
| Bärthel, E; Habrecht, O; Kornberg, A; Küpper, B; Settmacher, U; Tannapfel, A; Thrum, K | 1 |
| Charlton, MR; Hay, JE; Heimbach, JK; Kremers, WK; Poterucha, JJ; Rosen, CB; Veldt, BJ; Watt, KD; Wiesner, RH | 1 |
| de Felipe, B; Gutiérrez, A; Leal, M; López-Cortés, L; Molina-Pinelo, S; Soriano-Sarabia, N; Vallejo, A | 1 |
| Chan, A; Everson, GT; Fried, MW; Ghalib, R; Godofsky, E; Harrison, S; Hill, G; Nelson, D; Nyberg, L; Pockros, P; Rodriguez-Torres, M; Shiffman, ML | 1 |
| Bacosi, D; Baldelli, F; Belfiori, B; Chiodera, A; Ciliegi, P; Francisci, D; Tosti, A | 1 |
| Agostinacchio, E; Andriulli, A; Bacca, D; Carretta, V; Cozzolongo, R; Mangia, A; Minerva, N; Petruzzellis, D; Ricci, GL; Romano, M; Scotto, G; Sogari, F; Vinelli, F | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Duncea, I; Pepene, CE | 1 |
| Ganslmayer, M; Hahn, EG; Herold, C; Zopf, S | 1 |
| Chang, SH; Choe, WH; Han, HS; Kim, BK; Ko, SY; Kwon, SY; Lee, CH | 1 |
| Chen, DS; Chen, JH; Chen, PJ; Chen, SI; Hsu, SJ; Hung, PH; Kao, JH; Lai, MY; Liang, CC; Lin, JW; Liu, CH; Liu, CJ; Tsai, HB | 1 |
| Clavien, PA; Dinges, S; Dufour, JF; Giostra, E; Heim, M; Mentha, G; Morard, I; Müllhaupt, B; Negro, F | 1 |
| Ankoma-Sey, V; Hamzeh, FM; Jeffers, LJ; Martin, P; Rodriguez-Torres, M; Rossaro, L; Sheikh, MY | 1 |
| Gordon, FD; Kwo, P; Vargas, HE | 1 |
| Aberle, JH; Gangl, A; Holzmann, H; Kohrgruber, N; Kundi, M; Peck-Radosavljevic, M; Reiberger, T; Rieger, A | 1 |
| Carrión, JA; Crespo, G; Forns, X; García-Valdecasas, JC; Martínez-Bauer, E; Navasa, M; Pérez-del-Pulgar, S; Ramírez, S | 1 |
| Bailey, RJ; Bain, VG; Cooper, CL; Deschênes, M; Krajden, M; Lee, SS; Marotta, PJ; Peltekian, K; Sherman, M; Usaty, C; Witt-Sullivan, H; Yoshida, EM | 1 |
| Jeong, S; Kim, CH; Kim, HG; Kim, YS; Kwon, KS; Lee, DH; Lee, JI; Lee, JW; Park, BD; Shin, YW | 1 |
| Basso, M; Blanchi, S; Giannini, EG; Picciotto, A; Savarino, V; Torre, F | 1 |
| Agoglia, L; Balbi, E; Cariús, LP; Covelo, MC; Enne, M; Gonzalez, AC; Leal, CR; Oliveira, PV; Pacheco-Moreira, LF; Pousa, FS; Roma, J | 1 |
| Alam, J; Everson, GT; Gordon, SC; Jacobson, IM; Kauffman, R; McHutchison, JG; McNair, L; Muir, AJ; Sulkowski, M | 1 |
| Alam, J; Bengtsson, L; Bourlière, M; Bronowicki, JP; Dusheiko, G; Ferenci, P; Forestier, N; George, S; Gharakhanian, S; Goeser, T; Hézode, C; Kauffman, RS; Kieffer, T; Kwong, A; McNair, L; Pawlotsky, JM; Pol, S; Zeuzem, S | 1 |
| Ferenci, P; Rizzetto, M; Shiffman, ML; Zeuzem, S | 1 |
| Hagiwara, H; Hayashi, N; Hijioka, T; Hiramatsu, N; Igura, T; Imai, Y; Imanaka, K; Inoue, Y; Inui, Y; Ito, T; Kaneko, A; Kanto, T; Kasahara, A; Katayama, K; Kato, M; Kiso, S; Mita, E; Mochizuki, K; Nagase, T; Ohkawa, K; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshida, Y; Yoshihara, H | 1 |
| Firbas, C; Hinrichsen, H; Hofmann, WP; Jilma, B; Klade, CS; Manns, MP; Schiefke, I; Schlaphoff, V; Schuller, E; Stauber, RE; Tauber, E; Thursz, M; Wedemeyer, H; Wiegand, J; Zeuzem, S | 1 |
| Ahya, SN; Baker, T; Levitsky, J; Norvell, JP; Van Wagner, LB; Wang, E | 1 |
| Houlihan, DD; Lee, JM; Storan, ER | 1 |
| Ansaldi, F; Borro, P; Gentile, R; Icardi, G; Ravetti, G; Sumberaz, A; Testino, G | 1 |
| Bahra, M; Bayraktar, S; Berg, T; Neuhaus, P; Neumann, U; Pratschke, J; Schmeding, M; Schmidt, SC | 1 |
| Cabrera, R; Chen, C; Clark, VC; Firpi, RJ; Levy, C; Michaels, A; Morelli, GG; Nelson, DR; Soldevila-Pico, C; Suman, A | 1 |
| Almerighi, C; Angelico, M; Anselmo, A; De Luca, L; Lenci, I; Lionetti, R; Monaco, A; Palmieri, G; Tariciotti, L; Tisone, G | 1 |
| Hsu, CS; Kao, JH | 1 |
| Askar, M; Avery, R; Corey, R; Eghtesad, B; Fung, J; Lopez, R; Miller, C; Pidwell, D; Thomas, D; Zein, NN | 1 |
| Berg, T; Potthoff, A; Wedemeyer, H | 1 |
| Chen, XY; Zhang, YH | 1 |
| Chen, LJ; Li, MH; Lu, Y; Qiu, GH; Xie, Y; Xu, DZ | 1 |
| Basso, M; Giannini, EG; Picciotto, A; Savarino, V | 1 |
| Adeyi, O; Girgrah, N; Herath, C; Kashfi, A; Levy, GA; Lilly, L; Renner, EL; Selzner, M; Selzner, N; Therapondos, G | 1 |
| Fukuhara, T; Ikegami, T; Kato, M; Kotoh, K; Maehara, Y; Shimoda, S; Soejima, Y; Taketomi, A; Yoshizumi, T | 1 |
| Parkinson, E | 1 |
| Asselah, T; Boyer, N; Cardoso, AC; Castelnau, C; El Ray, A; Giuily, N; Leclere, L; Marcellin, P; Martinot-Peignoux, M; Maylin, S; Moucari, R; Ripault, MP; Stern, C | 1 |
| Burroughs, AK; Davidson, BR; Gurusamy, KS; Tsochatzis, E; Xirouchakis, E | 1 |
| Barreiro, P; Labarga, P; Martín-Carbonero, L; Medrano, J; Morello, J; Pinilla, J; Rodríguez-Novoa, S; Soriano, V; Tuma, P; Vispo, E | 1 |
| Chiba, T; Egawa, H; Marusawa, H; Takada, Y; Ueda, Y; Uemoto, S | 1 |
| Szalay, F | 1 |
| Dessouki, O; Kamiya, Y; Nagahama, H; Okada, S; Sasaki, Y; Suzu, S; Tanaka, M | 1 |
| Andreoli, A; Arcuri, P; Barbarini, G; Barbaro, G; Barlattani, A; Bonaventura, ME; D'Ambrosio, C; Mazzoni, E; Mecenate, F; Nosotti, L; Paffetti, A; Pellicelli, AM; Picardi, A; Romano, M; Soccorsi, F | 1 |
| Bailly, F; Trepo, C | 1 |
| Hrstić, I; Ostojić, R; Vucelić, B | 1 |
| Colić Cvrlje, V; Filipec Kanizaj, T; Mrzljak, A; Ostojić, R | 1 |
| Galdame, O; Manero, E; Reggiardo, V | 1 |
| Bain, VG; Balshaw, R; Cooper, CL; Deschênes, M; Krajden, M; Lee, SS; Marotta, PJ; Peltekian, KM; Sherman, M; Usaty, C; Yoshida, EM | 1 |
| Cañete, N; Crespo, M; Jou, A; Mira, JA; Pahissa, A; Pineda, JA; Podzamczer, D; Solà, R; Tiraboschi, JM; Tural, C; Van den Eynde, E | 1 |
| de la Cruz-Lombardo, J; Jiménez-Pérez, M; Lozano-Rey, JM; Pérez-Daga, JA; Rodrigo-López, JM; Sáez-Gómez, AB | 1 |
| Bruix, J; Forns, X | 1 |
| Roche, B; Samuel, D | 3 |
| Chan, KM; Cheng, SS; Chou, HS; Lee, CF; Lee, WC; Wu, TJ | 1 |
| Beld, MG; Gelderblom, HC | 1 |
| Colucci, G; Hadziyannis, SJ; Ishida, H; Lin, A; Sarrazin, C; Shiffman, ML; Zeuzem, S | 1 |
| Berg, J; Biesenbach, G; Bodlaj, G; Hubmann, R; Saleh, K; Stojakovic, T | 1 |
| Fuchsteiner, H; Hackl, F; Luger, C; Maieron, A; Metz-Gercek, S; Mittermayer, H; Schöfl, R; Ziachehabi, A | 1 |
| Kabieszová, L; Kloudová, A; Kůrková, J; Mrázek, J; Orságová, I; Petrousová, L; Pospísek, M; Roznovský, L | 1 |
| Behrens, R; Enninger, A; Gerner, P; Hilbich, J; Kliemann, G; Walther, F; Wenzl, TG; Wirth, S | 1 |
| Berenguer, M; Rubin, A | 1 |
| Hunt, DR; McClune, A; Saab, S; Stone, MA; Tong, MJ | 1 |
| Cao, F; Cheng, X; Donlin, MJ; Tavis, JE; Turner, K | 1 |
| Cho, MS; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Shin, SR; Sinn, DH; Yoo, BC | 1 |
| Bonkovsky, HL; De Santo, JL; Di Bisceglie, AM; Dienstag, JL; Ghany, MG; Kim, HY; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Morishima, C; Shiffman, ML; Snow, KK | 1 |
| Bate, JP; Colman, AJ; Frost, PJ; Harley, HA; Shaw, DR | 1 |
| Conway, B; Dore, GJ; Duncan, F; Gallagher, L; Genoway, KA; Grebely, J; Knight, E; Krajden, M; Ngai, T; Raffa, JD; Storms, M | 1 |
| Belkahla, N; Chaabouni, H; Chouaib, S; Hariz, FB; Kchir, H; Maamouri, N; Mami, NB; Ouerghi, H | 1 |
| Cheng, WS; Crawford, D; Dore, GJ; Marks, PS; McCaughan, G; Rawlinson, W; Rizkalla, B; Roberts, SK; Sievert, W; Thommes, J; Weltman, M; Yoshihara, M | 1 |
| Bacca, D; Carretta, V; Goldstein, DB; Mangia, A; McHutchison, JG; Minerva, N; Mottola, L; Patel, K; Petruzzellis, D; Piazzolla, V; Santoro, R; Shianna, KV; Thompson, AJ; Tillmann, HL | 1 |
| Batista-Neves, S; de Oliveira, IR; Galvão-de Almeida, A; Guindalini, C; Lyra, AC; Miranda-Scippa, A; Paraná, R; Quarantini, LC | 1 |
| Aikata, H; Chayama, K; Hashimoto, Y; Hiraga, N; Hiramatsu, A; Imamura, M; Katamura, Y; Kawakami, Y; Kawaoka, T; Kimura, Y; Mitsui, F; Nagaoki, Y; Ohdan, H; Takahashi, S; Takaki, S; Tashiro, H; Tsuge, M; Waki, K | 1 |
| Ceccherini-Silberstein, F; Cento, V; Di Masi, F; Manzoli, L; Mazzotta, E; Mercurio, F; Parruti, G; Perno, CF; Pieri, A; Polilli, E; Sozio, F; Tontodonati, M | 1 |
| Abe, T; Fukuhara, T; Maehara, Y; Matsuura, Y; Motomura, T; Ninomiya, A; Okano, S; Shirabe, K; Soejima, Y; Taketomi, A; Uchiyama, H | 1 |
| Marroni, CA | 1 |
| Black, M; Burke, M; Jain, AB; Singhal, A | 1 |
| Kaur, A; Mehta, V; Midha, V; Mittal, R; Sharma, S; Sood, A; Sood, N; Thara, A | 1 |
| Ferenci, P; Ferlitsch, A; Gangl, A; Homoncik, M; Peck-Radosavljevic, M; Pramhas, S; Scherzer, T | 1 |
| Heller, T; Liang, TJ; Raghuraman, S; Rehermann, B; Veerapu, NS | 1 |
| Lee, VS; Levitsky, J; Pillai, AA; Rinella, ME; Wang, E | 1 |
| Hong, GH; Hu, YJ; Mao, Q; Wang, XH; Zhang, XQ; Zhou, YQ; Zhu, Y | 1 |
| Chiba, T; Egawa, H; Haga, H; Hatano, E; Kaido, T; Marusawa, H; Miyagawa-Hayashino, A; Mori, A; Ogawa, K; Ogura, Y; Oike, F; Takada, Y; Ueda, Y; Uemoto, S; Yoshizawa, A | 1 |
| Antonino, AT; Bechstein, WO; Bibert, S; Bochud, PY; Doehring, A; Farnik, H; Hansmann, ML; Hofmann, WP; Lange, CM; Lehr, HA; Lötsch, J; Moench, C; Moradpour, D; Müllhaupt, B; Pascual, M; Sarrazin, C; Shi, Y; Zeuzem, S | 1 |
| Abd el-Meguid, M; Anany, MA; Bader el-Din, NG; Barakat, A; el-Awady, MK; el-Zayady, AR; Esmat, G; Helmy, A; Tabll, AA; Zayed, N | 1 |
| Aleem, AA; El Hadad, H; Essawy, M; Fouad, YM; Gomaa, W; Ibrahim, M; Ibrahim, Y; Shatat, M | 1 |
| Borro, P; Testino, G | 1 |
| Abaalkhail, F; Abdo, A; Al-Hamoudi, W; Al-Jedai, A; Al-Masri, N; Al-Sebayel, M; Al-Sofayan, M; Allam, N; Alqahtani, S; Kamel, Y; Khalaf, H; Mohamed, H | 1 |
| Ikegami, T; Masuda, Y; Matsuda, K; Mita, A; Miwa, S; Miyagawa, S; Nakazawa, Y; Ohno, Y; Sano, K; Urata, K | 1 |
| Ahmed, A; Ahmed, H; Ali, L; Ali, M; Idrees, M | 1 |
| Abu-Mouch, S; Buggisch, P; Chen, R; Cornberg, M; Faruqi, R; Hinrichsen, H; Horban, A; Ilan, Y; Klinker, H; Lurie, Y; Manns, M; Mauss, S; Merican, I; Müller, TH; Pedicone, LD; Rössle, M; Sood, A; Wedemeyer, H; Welsch, C; Zeuzem, S | 1 |
| Fukuda, K; Haruna, Y; Hayashi, N; Hiramatsu, N; Hosui, A; Imai, Y; Inoue, A; Inoue, Y; Kanto, T; Kasahara, A; Kiso, S; Mita, E; Miyagi, T; Mochizuki, K; Oze, T; Takehara, T; Tatsumi, T; Yakushijin, T; Yoshida, Y | 1 |
| Abbacchi, A; Adewuyi, SA; Debold, C; Hong, BA; Lisker-Melman, M; North, CS; Pollio, DE | 1 |
| Canva, V; Castel, H; Corouge, M; Deltenre, P; Dharancy, S; Henrion, J; Lazrek, M; Louvet, A; Mathurin, P; Moreno, C; Wartel, F | 1 |
| Casas Rodrigo, M; Cebollero Agustí, A; Dalmau Obrador, B; Gallach Montero, M; Gavarró Puig, A; Gil Prades, M; Miquel Planas, M; Puig Del Castillo, I; Sánchez Delgado, J; Tomás Tutusaus, R; Vergara Gómez, M | 1 |
| Furusyo, N; Hayashi, J; Hayashi, T; Ihara, T; Ikezaki, H; Kainuma, M; Koga, T; Murata, M; Ogawa, E; Toyoda, K | 1 |
| Pellicelli, AM; Zoli, V | 1 |
| Choi, MS; Gwak, GY; Kim, YJ; Koh, KC; Lee, JH; Lee, ST; Paik, SW; Sinn, DH; Yoo, BC | 1 |
| Bzowej, N; Charlton, MR; Everson, GT; Nelson, DR; Prabhakar, A; Teng, LL; Terrault, NA | 1 |
| Bae, SH; Choi, JY; Jeong, SW; Kim, JD; Kwon, JH; Lee, JE; Song, MJ; Yoon, NR; Yoon, SK | 1 |
| Barreiro, P; Benito, JM; Camacho, A; Caruz, A; Labarga, P; Mira, JA; Neukam, K; Pineda, JA; Pinilla, J; Rallón, N; Rivero, A; Rodriguez-Novoa, S; Soriano, V; Vispo, E | 1 |
| Bahra, M; Berg, T; Biermer, M; Boas-Knoop, S; Eurich, D; Neuhaus, P; Neuhaus, R; Neumann, U | 1 |
| Chapman, S; Cozen, M; Cunningham, F; Currie, SL; Monto, A; Shen, H; Tortorice, K; Yee, HS | 1 |
| Horiguchi, N; Kakizaki, S; Mori, M; Namikawa, M; Sato, K; Takagi, H; Yamazaki, Y; Yata, Y | 1 |
| Antoniazzi, S; Baldo, V; Baldovin, T; Cazzagon, N; Egoue, J; Floreani, A; Furlan, P; Minola, E | 1 |
| Brown, A; Foster, GR; Freshwater, D; Marley, R; Moreea, S; Mutimer, D; Rowe, IA; Sabin, CA; Shoeb, D; Sood, R | 1 |
| Andreone, P; Beumont, M; Boogaerts, G; De Meyer, S; Diago, M; Ferenci, P; Focaccia, R; Foster, GR; Horban, A; Lawitz, E; Luo, D; Müllhaupt, B; Nevens, F; Picchio, G; Pockros, P; Pol, S; Polo, R; Roberts, S; Shouval, D; Terg, R; Van Heeswijk, R; van Hoek, B; Weiland, O; Younossi, Z; Zeuzem, S | 1 |
| Agúndez, JA; Carballo, M; Devesa, MJ; Díaz-Rubio, M; Fernández, C; Ladero, JM; Martin, EG; Martínez, C; Suárez, A | 1 |
| Bonardi, R; Ciancio, A; Manca, A; Pellicano, R; Rizzetto, M; Tabone, M | 1 |
| Asahina, Y; Enomoto, N; Hoshioka, Y; Hosokawa, T; Itakura, J; Izumi, N; Kato, T; Kurosaki, M; Kuzuya, T; Matsuura, K; Mizokami, M; Nakanishi, H; Nishida, N; Sugauchi, F; Suzuki, Y; Takahashi, Y; Tamaki, N; Tanaka, K; Tanaka, Y; Tokunaga, K; Tsuchiya, K; Ueda, K; Yasui, Y | 1 |
| de Knegt, RJ; Heijens, A; Janssen, HL; Roomer, R; Schutten, M; van Vuuren, AJ | 1 |
| Aikata, H; Chayama, K; Hashimoto, Y; Hiraga, N; Hiramatsu, A; Imamura, M; Katamura, Y; Kawakami, Y; Kawaoka, T; Miki, D; Nagaoki, Y; Ochi, H; Ohdan, H; Takahashi, S; Takaki, S; Tashiro, H; Tsuge, M; Waki, K | 1 |
| Higuchi, K; Hirose, S; Honma, T; Ishikawa, T; Kamimura, T; Kubota, T; Seki, K; Suzuki, Y; Tasaki, K; Yoshida, T | 1 |
| Attili, AF; Biliotti, E; Corradini, SG; Gentili, F; Giannelli, V; Giusto, M; Lionetto, L; Merli, M; Rossi, M; Simmaco, M; Taliani, G | 1 |
| Aikata, H; Chayama, K; Hiraga, N; Hiramatsu, A; Imamura, M; Kawakami, Y; Kawaoka, T; Miki, D; Ochi, H; Ohdan, H; Takahashi, S; Takaki, S; Tashiro, H; Tsuge, M; Waki, K | 1 |
| Clark, PJ; Thompson, AJ | 1 |
| Berg, T; Böhm, S; Buggisch, P; Gerlach, T; Hinrichsen, H; Klinker, H; Möller, B; Neumann, K; Rasenack, J; Sarrazin, C; Spengler, U; Teuber, G; Weich, V; Wiegand, J | 1 |
| Arends, JE; Fransen, JH; Hoepelman, AI; Mudrikova, T; Schellens, IM; Spijkers, SN; Sprenger, HG; Stek, CJ; van Assen, S; van Baarle, D; Wensing, AM | 1 |
| Bull, RA; Dore, GJ; Grebely, J; Hellard, M; Kaldor, J; Lloyd, A; Matthews, GV; Petoumenos, K; Pham, ST; Rawlinson, W; White, PA; Yeung, B | 1 |
| Adda, N; Berg, T; Dusheiko, G; Ferenci, P; George, S; Heathcote, EJ; Kauffman, RS; Martin, EC; McHutchison, JG; Muir, AJ; Pawlotsky, JM; Poordad, FF; Reesink, HW; Shiffman, ML; Zeuzem, S | 1 |
| Aulakh, VS; Hoefs, JC; Ilagan, BJ | 1 |
| Beinhardt, S; Ferenci, P; Hofer, H; Kerschner, H; Popow-Kraupp, T; Rutter, K; Scherzer, TM; Stättermayer, AF; Steindl-Munda, P | 1 |
| El-Shamy, A; Fujinami, A; Hasegawa, Y; Hotta, H; Imoto, S; Kasugai, H; Kawada, T; Kim, KI; Kim, SR; Kimura, N; Komaki, T; Konishi, E; Kudo, M; Makino, T; Morikawa, T; Muramatsu, A; Nagata, Y; Nakajima, T; Nakamura, A; Ohta, M; Saito, J; Sakashita, M; Sasase, N; Sasatani, K; Sugano, M; Tanaka, Y; Tsuchida, S | 1 |
| Croner, R; Demir, R; Hohenberger, W; Müller, V; Perrakis, A; Schellerer, V; Schuhmann, S; Yedibela, S | 1 |
| Forestier, N; Zeuzem, S | 1 |
| Bacon, BR; Khalid, O | 1 |
| Clark, V; Nelson, DR | 1 |
| Adhoute, X; Benali, S; Bourlière, M; Castellani, P; Khaloun, A; Oules, V; Portal, I; Wartelle-Bladou, C | 1 |
| Hamzeh, FM; Jensen, D; Lentz, E; Reau, N; Zhou, X | 1 |
| Chaudhri, E; Chemello, L; Craxi, A; Diago, M; Faruqi, R; Koutsounas, S; Maticic, M; Ogurtsov, P; Pedicone, LD; Tartaglione, MT; Torras, J; Witthoeft, T; Yu, X; Zuckerman, E | 1 |
| Bali, D; Cullufi, P; Dervishi, E; Durro, V; Velmishi, V | 1 |
| Dimitrova, DI; Eley, T; Everson, GT; Gardiner, DF; Ghalib, R; Grasela, DM; Guo, T; Lawitz, E; Lok, AS; Martorell, C; McPhee, F; Pasquinelli, C; Persson, A; Reindollar, R; Rustgi, V; Wind-Rotolo, M; Zhu, K | 1 |
| Allende, H; Bes, M; Campos-Varela, I; Castells, L; Charco, R; Esteban, JI; Esteban, R; Rodríguez-Frías, F; Sapisochin, G | 1 |
| Hiramatsu, N; Iwasaki, M; Izumi, N; Kakinuma, S; Kurosaki, M; Matsuura, K; Nakagawa, M; Sakamoto, M; Sakamoto, N; Sugauchi, F; Suzuki, Y; Tamori, A; Yatsuhashi, H | 1 |
| de Moraes, CF; De Pauli, DS; Grotto, RM; Marangon, AV; Moliterno, RA; Pardini, MC; Sell, AM; Silva, GF; Visentainer, JE | 1 |
| Antoniazzi, S; Bergasa, NV; Floreani, A; Mescoli, C | 1 |
| De Martin, E; Di Paolo, D; Donato, MF; Fagiuoli, S; Farcomeni, A; Giannelli, V; Giusto, M; Iemmolo, RM; Merli, M; Miglioresi, L; Morelli, MC; Pasulo, L; Pompili, M; Ponziani, FR; Rendina, M; Toniutto, P; Viganò, R | 1 |
| Alberti, AB; Belli, LS; Burra, P; Burroughs, AK; Cillo, U; De Carlis, L; De Martin, E; Fagiuoli, S; Graziadei, I; Gridelli, B; Guido, M; Lerut, J; Pasulo, L; Pinzello, G; Starkel, P; Vogel, W; Volpes, R | 1 |
| Aikata, H; Chayama, K; Hiraga, N; Hiramatsu, A; Imamura, M; Kawakami, Y; Kawaoka, T; Miki, D; Ochi, H; Ohdan, H; Onoe, T; Takahashi, S; Takaki, S; Tashiro, H; Tsuge, M; Waki, K | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kotoh, K; Maruyama, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y | 1 |
| Babudieri, S; Fois, AG; Madeddu, G; Molicotti, P; Mura, MS; Muredda, AA; Murino, M; Pirina, P; Soddu, A; Zanetti, S | 1 |
| Adinolfi, LE; Guerrera, B; Restivo, L; Ruggiero, L; Zampino, R | 1 |
| Bruguera, M; Esteban, R; Forns, X; Planas, R; Quer, JC; Solà, R; Vergara, M | 1 |
| Amemiya, F; Enomoto, N; Inoue, T; Kadokura, M; Kanayama, A; Kitamura, T; Komase, K; Komatsu, N; Maekawa, S; Miura, M; Nakayama, Y; Ohmori, T; Okada, S; Sakamoto, M; Shindo, H; Shindo, K; Sueki, R; Takano, S; Yamaguchi, T | 1 |
| Boillot, O; Botta-Fridlund, D; Boudjema, K; Calmus, Y; Chazouillères, O; Dharancy, S; Durand, F; Duvoux, C; Gugenheim, J; Néau-Cransac, M; Pageaux, G; Rostaing, L; Samelson, L; Samuel, D; Vanlemmens, C; Wolf, P | 1 |
| Aghemo, A; Colombo, M; D'Ambrosio, R; De Nicola, S; Degasperi, E; Grancini, V; Orsi, E; Prati, GM; Rumi, MG; Soffredini, R | 1 |
| Appelman, H; Bifano, M; Dimitrova, D; Fontana, RJ; Hindes, R; Hughes, EA | 1 |
| Boyer, N; Castelnau, C; Marcellin, P; Martinot-Peignoux, M; Ripault, MP; Stern, C; Valla, D | 1 |
| Abbas, Z; Hamid, S; Jafri, W; Raza, S | 1 |
| Bartels, DJ; Beumont, M; Daems, B; De Meyer, S; Dierynck, I; Ghys, A; Kieffer, TL; Picchio, G; Sullivan, JC; Van Baelen, B; Zeuzem, S | 1 |
| Andreone, P; Bertuzzo, VR; Cescon, M; Cucchetti, A; D'Errico-Grigioni, A; Dazzi, A; Del Gaudio, M; Di Gioia, P; Ercolani, G; Lorenzini, S; Morelli, MC; Pinna, AD; Ravaioli, M; Tamè, M | 1 |
| Al-Osaimi, AM; Brown, RS; Everhart, JE; Everson, GT; Gillespie, BW; Kulik, LM; Lok, AS; Rodrigo, del R; Saab, S; Shiffman, ML; Terrault, NA | 1 |
| Ackefors, M; Gjertsen, H; Weiland, O; Wernerson, A | 1 |
| Bessede, T; Buffet, C; Charpentier, B; Durrbach, A; Hassan, Q; Roche, B; Samuel, D | 1 |
| Antonini, TM; Barau, C; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Noël, C; Roche, B; Roque-Afonso, AM; Samuel, D; Taburet, AM | 1 |
| Berg, CP; Egetemeyr, DP; Königsrainer, A; Lauer, UM; Malek, NP; Nadalin, S; Werner, CR | 1 |
| Azzouz, MM; El Bouchtili, S; Hamzaoui, L; Mahmoudi, M; Siai, K | 1 |
| Hu, YJ; Li, QR; Tan, ZX; Wang, XH; Xiong, YL; Yuan, J; Zhang, CJ; Zhu, Y | 1 |
| Atsukawa, M; Fukuda, T; Hashimoto, S; Itokawa, N; Kanazawa, H; Kidokoro, H; Kobayashi, T; Kondo, C; Matsushita, Y; Nakatsuka, K; Narahara, Y; Sakamoto, C; Tsubota, A | 1 |
| Devrajani, BR; Kalhoro, M; Shaikh, S | 1 |
| Camacho, A; Caruz, A; Macias, J; Mira, JA; Neukam, K; Perez-Camacho, I; Pineda, JA; Rivero, A; Rivero-Juarez, A; Torre-Cisneros, J | 1 |
| Flemming, JA; Terrault, NA | 1 |
| Aghemo, A; Colombo, M; Degasperi, E; Ferrari, B; Lotta, LA; Peyvandi, F | 1 |
| Drago, F; Javor, S; Parodi, A | 1 |
| Biliotti, E; Gallinaro, V; Giusto, M; Grieco, S; Merli, M; Spaziante, M; Taliani, G; Zacharia, S | 1 |
| Asselah, T | 2 |
| Burra, P; Cescon, M; Donato, MF; Fagiuoli, S; Gasbarrini, A; Iemmolo, RM; Merli, M; Miglioresi, L; Milani, A; Paolo, DD; Pasulo, L; Pompili, M; Ponziani, FR; Rendina, M; Toniutto, P; Viganò, R; Zaccaria, R | 1 |
| Enomoto, N; Hashimoto, S; Imazeki, F; Inao, M; Inoue, T; Izumi, N; Kaito, M; Kudo, M; Mochida, S; Nishiguchi, S; Tanaka, A; Tsuchiya, K; Ueda, T; Yatsuhashi, H; Yokosuka, O | 1 |
| Chmura, A; Cieciura, T; Lisik, W; Pacholczyk, M; Tronina, O; Wasiak, D; Łągiewska, B | 1 |
| Coilly, A; Roche, B; Samuel, D | 1 |
| Arai, M; Fujiwara, K; Imazeki, F; Kanda, T; Kato, K; Maruoka, D; Mikami, S; Miyamura, T; Nakamoto, S; Nishino, T; Takada, N; Tanaka, T; Tsubota, A; Wu, S; Yokosuka, O | 1 |
| Chao, YC; Chen, CL; Chen, DS; Chen, PJ; Chuang, WL; Kao, JH; Kuo, HT; Lee, CM; Liao, LY; Lin, CL; Liu, CH; Liu, CJ; Lu, SN; Su, WW; Tung, SY; Wu, SS; Yang, HC; Yang, SS; Yu, ML | 1 |
| Ho, HJ; Hsu, YC; Lin, JT; Wu, CY; Wu, MS | 1 |
| Szabó, A; Tusnádi, A | 1 |
| Barbui, A; Bobbio, A; David, E; Fadda, M; Franchello, A; Lavezzo, B; Ottobrelli, A; Rizzetto, M; Salizzoni, M; Smedile, A; Torrani, M; Zamboni, F | 1 |
| Bizollon, T; Trepo, C | 1 |
| Lucidarme, D | 1 |
| Zoulim, F | 1 |
| Hilleret, MN; Leroy, V | 1 |
| Feray, C; Roche, B; Samuel, D | 1 |
| Durand, F | 1 |
| Grube, T; Hommann, M; Kornberg, A; Scheele, J; Schotte, U; Tannapfel, A | 1 |
| Andreoni, M; Biglino, A; Carenzi, S; Cariti, G; Ciancio, A; Ciccone, G; Croce, G; Manca, A; Olivero, A; Orsi, PG; Rizzetto, M; Roffi, L; Saracco, G; Smedile, A; Tabone, M; Tappero, G | 1 |
| Gane, E | 2 |
| Samuel, D | 1 |
| Angelico, M; Araco, A; Bergamini, A; Bolacchi, F; Cepparulo, M; Ombres, D; Rocchi, G; Tisone, G | 1 |
| Balan, V; Brass, C; Conjeevaram, H; Crippin, J; Demetris, AJ; Gish, R; Kwo, P; McGuire, B; Rakela, J; Shakil, AO; Teperman, L; Wright, TL | 1 |
| Abdelmalek, MF; Crawford, JM; Davis, GL; Firpi, RJ; Hemming, A; Howard, R; Lauwers, G; Liu, C; Nelson, DR; Reed, A; Soldevila-Pico, C; Van Der Werf, W | 1 |
| Malfertheiner, P | 1 |
| Ahmed, SN; Baulieux, J; Bizollon, T; Chevallier, M; Chevallier, P; Ducerf, C; Guichard, S; Parvaz, P; Radenne, S; Trepo, C; Zoulim, F | 1 |
| Carenzi, S; Ciancio, A; Olivero, A; Rizzetto, M; Saracco, G | 1 |
| Calvo, F; Córdoba, J; Garijo, R; Gobernado, M; Jaén, J; López, L; Martínez, F; Molina, JM; Olaso, V; Siles, MS | 1 |
| Bau, I; Beltrán, B; Calvo, F; Córdoba, J; Gobernado, M; López, B; Martínez, B; Molina, JM; Monte, E; Olaso, V; Siles, MS | 1 |
| Ahmed, SN; Albrecht, JK; Baulieux, J; Bismuth, H; Bizollon, T; Chevallier, M; Cohard, M; Ducerf, C; Feray, C; Geffner, M; Lemonnier, C; Reynes, M; Roche, B; Samuel, D; Trepo, C | 1 |
| Busuttil, RW; Durazo, F; Farmer, DG; Ghobrial, RM; Goldstein, LI; Han, S; Hu, R; Ibrahim, AB; Kunder, G; Lassman, C; Saab, S; Yersiz, H | 1 |
| Abbati, G; Boccia, S; Castagnetti, E; Distasi, M; Fabris, P; Fattovich, G; Felder, M; Fornaciari, G; Giusti, M; Lomonaco, L; Minola, E; Montanari, R; Pantalena, M; Paternoster, C; Redaelli, A; Rizzo, C; Rovere, P; Scattolini, C; Suppressa, S; Tagger, A; Tonon, A; Tositti, G; Zagni, I | 1 |
| Farrell, GC; George, J; Kumar, D; Liddle, C; Lin, R; Samarasinghe, D; Wallington-Beddoe, C | 1 |
| Chang, TT; Chen, CY; Cheng, PN; Chow, NH; Hu, SC; Jen, CM; Young, KC | 1 |
| Castedal, M; Friman, S; Olausson, M; Siewert-Delle, A | 1 |
| Gopal, DV; Rosen, HR | 1 |
| Blazek, J; Eason, J; Khan, S; Lipscomb, J; Loss, G; Mason, A; Nair, S | 1 |
| Poo, JL | 1 |
| Beld, MG; Dijkgraaf, MG; Reesink, HW; Sentjens, RE; Weegink, CJ | 1 |
| Abergel, A; Alleman, I; Arpurt, JP; Bailly, F; Bernard, PH; Blanc, F; Botta-Fridlund, D; Botti, G; Bourlière, M; Caroli-Bosc, F; Chazouillères, O; Couzigou, P; De Lédinghen, V; Debonne, JM; Doll, F; Ducloux, S; Eugène, C; Gauthier, AP; Gérolami, A; Gérolami, V; Gouvernet, J; Grimaud, JC; Halfon, P; Khiri, H; Larrey, D; Mathieu-Chandelier, C; Moreau, X; Ouzan, D; Picon, M; Pol, S; Portal, I; Sogni, P; Thiefin, G; Vetter, D; Zamora, C | 1 |
| Abraczinskas, DR; Bhan, AK; Chung, RT; Cosimi, AB; Leung, JY; Pascual, M; Terella, AM | 1 |
| Connor, K; Davis, L; Heffron, TG; Martinez, E; Smallwood, GA; Stieber, AC | 1 |
| Saab, S; Wang, V | 1 |
| Boucher, EJ; Brissot, P; Canva, V; Colimon, R; Deugnier, Y; Guyader, D; Jacquelinet, C; Jacquelinet, S; Turlin, B | 1 |
| Brunner, H; Datz, C; Ferenci, P; Gangl, A; Gschwantler, M; Hackl, F; Hofer, H; Jessner, W; Nachbaur, K; Rosenbeiger, M; Stauber, R; Steindl-Munda, P; Vogel, W | 1 |
| Lam, WK; Tsang, KW | 1 |
| Baracetti, S; Bianchini, D; Comar, C; Donada, C; Donadon, V; Mazzaro, C; Nascimben, F; Pozzato, G; Zorat, F | 1 |
| Maier, KP | 1 |
| Degertekin, H; Kilinc, N; Yalcin, K; Yildiz, F | 1 |
| Beckebaum, S; Broelsch, CE; Cicinnati, VR; Dirsch, O; Erim, Y; Frilling, A; Gerken, G; Karliova, M; Malago, M; Treichel, U | 1 |
| Chau, TN; Chiu, MC; Choi, KW; Lai, JY; Lai, ST; Lam, BH; Lee, PO; Lim, W; Ng, TK; Tong, WL; Tsang, OT; Tso, EY; Yu, WC | 1 |
| Duncan, M; Younossi, Z | 1 |
| Everson, GT; Shiffman, ML; Vargas, HE | 1 |
| Sorrell, M; Villamil, F; Wiesner, RH | 1 |
| Everson, GT | 1 |
| Neuberger, J | 1 |
| Wright, TL | 1 |
| Busuttil, RW; Saab, S | 1 |
| August-Jörg, BS; Borovicka, J; Dufour, JF; Gonvers, JJ; Henz, S; Hermann, R; Meyenberger, C; Renner, EL; Weitz, M | 1 |
| Mukherjee, S; Rogge, J; Schafer, DF; Weaver, L | 1 |
| Balan, V; De Petris, G; Douglas, DD; Hansen, K; Khatib, A; Moss, A; Mulligan, D; Ortiz, J; Rakela, J; Rodriguez-Luna, H; Sharma, P; Vargas, HE; Williams, JW | 1 |
| Fehér, J; Fehérvári, I; Görög, D; Kóbori, L; Lengyel, G; Nemes, B; Patonai, A; Perner, F; Sárváry, E; Varga, M | 1 |
| Abdelmalek, MF; Crawford, JM; Davis, GL; Firpi, RJ; Hemming, AW; Liu, C; Nelson, DR; Reed, AI; Soldevila-Pico, C | 1 |
| Goyal, A; Guptan, RC; Hashmi, AZ; Kumar, S; Malhotra, V; Sakhuja, P; Sarin, SK | 1 |
| Khokhar, N | 1 |
| Benedict Cosimi, A; Bhan, AK; Chung, RT; Pascual, M; Ross, AS; Thiim, M | 1 |
| Boillot, O; Chevallier, P; Dumortier, J; Scoazec, JY | 1 |
| Bekkering, FC; Bourgeois, N; Brouwer, JT; Delwaide, J; Hansen, BE; Henrion, J; Lefebvre, V; Nevens, F; Schalm, SW; Van Hattum, J; Van Vlierberghe, H; Weegink, CJ | 1 |
| Bahr, MJ; Manns, MP | 1 |
| Clavien, PA; Egger, HP; Fried, R; Giostra, E; Hadengue, A; Keller, W; Kraehenbuhl, S; Kullak-Ublick, GA; Locher, S; Mentha, G; Morel, P; Negro, F; Vanlemmens, C | 1 |
| Bejarano, PA; Cirocco, R; de Medina, M; Hill, MA; Khaled, AS; Montalbano, M; Neff, GW; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Tzakis, AG | 1 |
| Mukherjee, S | 2 |
| García-Samaniego, J; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V | 1 |
| Gudinaviciene, I; Jonaitis, L; Kupcinskas, L; Petrenkiene, V | 1 |
| Cholongitas, E; Papatheodoridis, GV | 1 |
| Ashworth, A; Contos, M; Cotterell, AH; Fisher, RA; Heuman, DM; Luketic, VA; Maluf, D; Mills, AS; Posner, MP; Sanyal, AJ; Shiffman, ML; Sterling, RK; Stravitz, RT | 1 |
| Busuttil, RW; Durazo, F; Farmer, DG; Gajjar, NA; Ghobrial, RM; Goldstein, LI; Han, S; Hiatt, J; Kalmaz, D; Lassman, CR; Saab, S; Yersiz, H | 1 |
| Beckebaum, S; Broelsch, CE; Cicinnati, VR; Dirsch, O; Erim, Y; Frilling, A; Gerken, G; Malago, M; Zhang, X | 1 |
| Charlton, M; Wiesner, R | 1 |
| Hayashi, N; Iyoda, K; Kato, M; Yamamoto, K; Yuki, N | 1 |
| Iyoda, K; Kato, M | 1 |
| Makuuchi, M; Sugawara, Y | 1 |
| Apollonio, L; Avellini, C; Caldato, M; Fabris, C; Fumo, E; Mariuzzi, L; Minisini, R; Pirisi, M; Toniutto, P | 1 |
| Barreiro, P; Camino, N; Garcia-Samaniego, J; González-Lahoz, J; Maida, I; Martin-Carbonero, L; Núñez, M; Romero, M; Soriano, V | 1 |
| Gonzalez, SA; Jacobson, IM | 1 |
| Berenguer, J; Berenguer, M; Calvo, F; Carrasco, D; Palau, A; Prieto, M; Rayón, JM | 1 |
| Bejarano, PA; De Medina, M; Khaled, AS; Lee, M; Montalbano, M; Neff, GW; Nery, J; Nishida, S; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Slapak-Green, G; Tzakis, A | 1 |
| Bell, H; Bjøro, K; Dalgard, O; Hellum, KB; Myrvang, B; Raknerud, N; Ritland, S; Skaug, K | 1 |
| Davis, GL | 4 |
| Fredrick, RT; Hassanein, TI | 1 |
| Lyden, E; McCashland, TM; Mukherjee, S; Schafer, DF | 1 |
| delaGarza, J; Madariaga, J; Neff, GW; Nishida, S; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, E; Shire, N | 1 |
| Adham, M; Baulieux, J; Bizollon, T; Chevallier, M; Ducerf, C; Pradat, P; Trepo, C; Zoulim, F | 1 |
| Chang, JJ; Chang, LC; Chen, LW; Lee, TS; Liu, CJ; Yen, CL | 1 |
| den Hollander, JG; Rijnders, BJ; van der Ende, ME; van Doornum, GJ | 1 |
| Apollonio, L; Avellini, C; Caldato, M; Fabris, C; Fumo, E; Minisini, R; Pirisi, M; Toniutto, P | 1 |
| Bernstein, DE; Brown, RS; Herrine, SK; Lentz, E; Ondovik, MS; Te, H | 1 |
| Kato, T; Levi, D; Madariaga, J; Martinez, E; Moon, J; Nishida, S; Ruiz, P; Sadfar, K; Schiff, E; Selvaggi, G; Tzakis, A; Yoshida, H | 1 |
| Allende, H; Bilbao, I; Castells, L; Esteban, R; Guardia, J; Luis Lázaro, J; Margarit, C; Vargas, V | 1 |
| Germain, J; Ghany, M; Heller, T; Hoofnagle, JH; Hsu, HH; Jake Liang, T; Lutchman, G; Park, Y; Soza, A | 1 |
| de Rave, S; Schalm, SW; Vrolijk, JM | 1 |
| Zeuzem, S | 2 |
| Bárcena, R; Blázquez, J; Foruny, JR; García, M; Gil-Grande, L; Moreno, A; Moreno, J; Otón, E; Sánchez, J | 1 |
| Barrios Peinado, C; Boullosa Graña, E; Cuervas-Mons Martinez, V; Garrido Botella, A; Jiménez Garrido, M; Lucena Poza, JL; Moreno Planas, JM; Rubio Gonzalez, E; Sanchez Turrion, V | 1 |
| Andriulli, A; Annese, M; Bacca, D; Carretta, V; Mangia, A; Minerva, N; Persico, M; Ricci, GL; Romano, M; Santoro, R; Scotto, G; Sogari, F; Spirito, F; Vinelli, F; Zechini, F | 1 |
| Alric, L; Izopet, J; Kamar, N; Rostaing, L | 1 |
| Bertrand, JJ; Germain, S; Halfon, P; Harafa, A; Larroque, O; Martin, S; Muller, P; Renou, C | 1 |
| Adham, M; Baulieux, J; Bizollon, T; Chevallier, M; Ducerf, C; Mabrut, JY; Pradat, P; Radenne, S; Souquet, JC; Trepo, C; Zoulim, F | 1 |
| Hohenberger, W; Meyer, T; Müller, V; Schellerer, V; Schuppan, D; Tannapfel, A; Yedibela, S | 1 |
| Everson, GT; Fey, B; Forman, L; Halprin, A; Kugelmas, M; Ray, C; Trotter, J | 1 |
| Avci, A; Erhardt, A; Häussinger, D; Heintges, T; Lörke, J | 1 |
| Fischinger, J; Hass, HG; Kaiser, S; Kreysel, C; Menzel, J | 1 |
| Friedrich-Rust, M; Sarrazin, C; Zeuzem, S | 1 |
| Pawłowska, M | 1 |
| Fung, J; Jain, A; Kashyap, R; Marcos, A; Vekatramanan, R; Yelochan, B | 1 |
| Ołdakowska-Jedynak, U; Paczek, L | 1 |
| Ahmed, F; Aytaman, A; Berman, DH; Bini, EJ; Bodenheimer, HC; Bräu, N; Brodsky, N; Brown, RS; Cerulli, MA; Chait, M; Edlin, BR; Ehrlich, J; Esposito, SP; Gardner, PW; Geders, JM; Gonzalez, SA; Jacobson, IM; Klion, FM; Lebovics, E; Min, AD; Rahmin, MG; Rovner, D; Russo, MW; Spivack, JE; Tobias, H | 1 |
| Encke, J; Kraus, T; Mehrabi, A; Sauer, P; Stremmel, W | 1 |
| Friman, S | 1 |
| Andreone, P; Bernardi, M; Biselli, M; Bonvicini, F; Cursaro, C; Gramenzi, A; Loggi, E; Lorenzini, S | 1 |
| Akamatsu, N; Kaneko, J; Kishi, Y; Kokudo, N; Makuuchi, M; Sugawara, Y; Tamura, S | 1 |
| Bodenheimer, H; Bodian, C; Branch, AD; Cheng, B; Chung, RT; Fiel, MI; Gutierrez, JA; Schiano, TD; Schwartz, ME; Thung, SN; Walewski, JL | 1 |
| Barcena, R; Blesa, C; Foruny, JR; Garcia-Garzon, S; Garcia-Gonzalez, M; Moreno, A; Moreno-Zamora, A; Oton, E; Ruiz, P | 1 |
| Bruno, M; Coccoli, P; Cordone, G; Parrilli, G | 1 |
| Hodo, Y; Honda, M; Kaneko, S; Mizukoshi, E; Nakamoto, Y; Sakai, A; Tsuji, K; Yamashita, T | 1 |
| Bergholz, U; Ferenci, P; Formann, E; Gurguta, C; Hofer, H; Jessner, W; Steindl-Munda, P | 1 |
| Boyanova, Y; Calmus, Y; Conti, F; Pissaia, A; Soubrane, O | 1 |
| Shiffman, ML | 2 |
| Hoepffner, N; Nikodem, AB; Paul, KA; Teuber, G | 1 |
| Batool, U; Qureshi, S | 1 |
| Alshuth, U; Berg, T; Buggisch, P; Gerlach, T; Goeser, T; Heintges, T; Kallinowski, B; Klinker, H; Martus, P; Nasser, S; Pape, GR; Rasenack, J; Sarrazin, C; Schmidt, WE; Spengler, U; von Wagner, M; Zeuzem, S | 1 |
| Boninsegna, S; Brolese, A; Burra, P; Canova, D; D'Aloiso, C; Fagiuoli, S; Germani, G; Guido, M; Masier, A; Pevere, S; Targhetta, S; Tomat, S | 1 |
| Halota, W; Palewicz, E; Pawłowska, M | 1 |
| Lyden, E; Mukherjee, S | 1 |
| Berg, C; Bernstein, DE; Cooksley, G; Diago, M; Goncales, FL; Graham, P; Jensen, DM; Rasenack, J; Sette, H | 1 |
| Bejarano, PA; Casanova-Romero, PY; Martinez, EJ; Mindikoglu, AL; Regev, A; Schiff, ER; Tzakis, AG | 1 |
| Andreone, P; Berardi, S; Bernardi, M; Biselli, M; Bontadini, A; D'Errico, A; Gramenzi, A; Grazi, G; Lenzi, M; Lodato, F; Mazzella, G; Morelli, MC; Pinna, AD; Piscaglia, F; Sama, C; Tamè, MR | 1 |
| Bahra, M; Berg, T; Langrehr, JM; Neuhaus, P; Neuhaus, R; Neumann, U; Puhl, G | 1 |
| Barcena, R; Barrios, C; Blesa, C; Boullosa-Graña, E; Cuervas-Mons, V; Garcia-Garzon, S; Garcia-Gonzalez, M; Mateos, ML; Moreno, A; Moreno-Planas, JM; Moreno-Zamora, A; Oton, E; Rubio-Gonzalez, EE | 1 |
| Fireman, M; Hauser, P; Matthews, AM; Sobel, M; Zucker, B | 1 |
| Chiba, T; Egawa, H; Ikeda, K; Iwai, A; Marusawa, H; Nabeshima, M; Takada, Y; Uemoto, S | 1 |
| Ansaldi, F; Gentile, R; Icardi, G; Ravetti, G; Sumberaz, A; Testino, G | 1 |
| Chang, WY; Chen, SC; Chiu, CF; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, JF; Lee, LP; Lin, ZY; Wang, LY; Yu, ML | 1 |
| Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Takeda, Y; Umeshita, K | 1 |
| Artioli, S; Azzola, E; Basso, M; Blanchi, S; Grasso, A; Pelli, N; Percario, G; Picciotto, A; Torre, F | 1 |
| Alaimo, G; Almasio, PL; Calvaruso, V; Craxì, A; D'Angelo, F; Di Marco, V; Di Stefano, R; Ferraro, D; Porrovecchio, S | 1 |
| Accadia, L; Andriulli, A; Annicchiarico, BE; Bombardieri, G; Caruso, N; Iacobellis, A; Leandro, G; Perri, F; Siciliano, M | 1 |
| Ballesteros, AL; Clotet, B; Ferrer, MJ; Fumaz, CR; Fuster, D; Gómez, G; Masmitjà, E; Muñoz-Moreno, JA; Paredes, R; Pérez-Alvarez, N; Salas, A; Tural, C | 1 |
| Abradelo, M; Castellano, G; Colina, F; Fernández, I; Fuertes, A; García, I; Lumbreras, C; Meneu, JC; Moreno, E; Muñoz, R; Solís-Herruzo, JA | 1 |
| Beckebaum, S; Broelsch, CE; Cicinnati, VR; Gerken, G | 1 |
| Asselah, T; Bourlière, M; Boyer, N; Cazals-Hatem, D; El Ray, A; Marcellin, P; Martinot-Peignoux, M; Moucari, R; Oulès, V; Ripault, MP; Valla, D; Vidaud, D | 1 |
| Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Gretch, DR; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Shiffman, ML; Wright, EC | 1 |
| Bolkhir, A; Brunt, EM; Hayashi, PH; Solomon, HS | 1 |
| Buti, M; Crespo, M; Esteban, JI; Esteban, R; Falco, V; Guardia, J; Ocaña, I; Pahissa, A; Ribera, E; Sauleda, S | 1 |
| Allende, H; Bilbao, I; Castells, L; Esteban, JI; Esteban, R; Guardia, J; Len, O; Margarit, C; Pahissa, A; Piron, M; Ribera, E; Sauleda, S; Vargas, V | 1 |
| Manz, M; Steuerwald, M | 1 |
| Ciuffreda, D; Fontana, M; Moradpour, D; Pascual, M | 1 |
| Angelico, M; Burra, P; Donato, MF; Lenci, I; Lionetti, R; Merli, M; Petrolati, A; Strazzabosco, M; Tisone, G | 1 |
| Barreiros, AP; Biesterfeld, S; Böcher, WO; Galle, PR; Greif-Higer, G; Kanzler, S; Lohse, AW; Mönch, C; Otto, G; Schuchmann, M; Sprinzl, MF; Wörns, MA; Zimmermann, A; Zimmermann, T | 1 |
| Annicchiarico, BE; Avolio, AW; Bombardieri, G; Grillo, RL; Siciliano, M | 1 |
| Barreiro, P; Berdún, MA; Galindo, MJ; Hernandez-Burruezo, JJ; Mariño, A; Martin-Carbonero, L; Miralles, C; Núñez, M; Sola, J; Soriano, V | 1 |
| Córdoba López, A; Monterrubio Villar, J | 1 |
| Goldmann, G; Kalff, JC; Oldenburg, J; Rockstroh, JK; Sauerbruch, T; Speidel, N; Spengler, U; Vogel, M; Voigt, E; Wojcik, K | 1 |
| Arjal, RR; Burton, JR; Rosen, HR; Villamil, F | 1 |
| Busuttil, RW; Durazo, F; Farmer, DG; Ghobrial, RM; Goldstein, LI; Han, S; Ibrahim, AB; Oh, MK; Saab, S; Tong, MJ; Yersiz, H | 1 |
| Agarwal, K; Emre, S; Fiel, MI; Kontorinis, N; Schiano, TD; Stanca, CM | 1 |
| Akyazi, Z; Erhardt, A; Häussinger, D; Heintges, T; Oette, M; Sagir, A | 1 |
| Gjertsen, H; Hörnfeldt, E; Weiland, O | 1 |
| Berberat, PO; Encke, J; Gotthardt, D; Mehrabi, A; Merle, U; Riediger, C; Sauer, P; Stremmel, W; Weiss, KH | 1 |
| Lengyel, G; Tulassay, Z | 1 |
| Angelico, M; Di Paolo, D; Francioso, S; Galante, A; Lenci, I; Piccolo, P | 1 |
| Fiel, MI; Saraf, N; Schiano, TD; Shukla, D; Xu, R | 1 |
| Doros, A; Fazakas, J; Fehér, J; Fehérvári, I; Gálffy, Z; Gerlei, Z; Görög, D; Járay, J; Lengyel, G; Lotz, G; Máthé, Z; Nagy, P; Nemes, B; Németh, A; Pár, A; Sárváry, E; Schaff, Z; Schuller, J; Telegdy, L | 1 |
| Chen, DS; Kao, JH; Liu, CH | 1 |
| Manfredi, R; Sabbatani, S | 1 |
| Bärthel, E; Kornberg, A; Küpper, B; Settmacher, U; Tannapfel, A; Thrum, K | 1 |
| Adam, R; Azoulay, D; Bismuth, H; Castaing, D; Duclos-Vallée, JC; Féray, C; Roche, B; Roque-Afonso, AM; Samuel, D; Sebagh, M; Teicher, E; Vittecoq, D | 1 |
| Ahn, CS; Choi, KM; Chung, YH; Hwang, S; Kim, KH; Lee, SG; Lee, YS; Moon, DB; Park, JI; Suh, DJ | 1 |
| Aucejo, F; Hanouneh, IA; Lopez, R; Miller, C; Quinn, MK; Zein, NN | 1 |
| Cacoub, P; Fois, E; Halfon, P; Landau, DA; Marcellin, P; Martinot-Peignoux, M; Saadoun, D | 1 |
| Cacoub, P; Saadoun, D; Sène, D | 1 |
| Buggisch, P; Cornberg, M; Steffen, M | 1 |
| Baldo, V; Baldovin, T; Carderi, I; Floreani, A; Minola, E; Rizzotto, ER | 1 |
| Bahra, M; Berg, T; Kahl, A; Kiessling, A; Neuhaus, P; Neuhaus, R; Neumann, U; Puhl, G; Schmitz, V | 1 |
| Chiba, T; Egawa, H; Haga, H; Ito, T; Marusawa, H; Nabeshima, M; Takada, Y; Tanaka, K; Ueda, Y; Uemoto, S | 1 |
| Carriero, D; Dieterich, DT; Fabrizi, F; Martin, P; Park, J; Uriel, AJ | 1 |
| Bischof, M; Brunner, H; Ferenci, P; Fischer, G; Gschwantler, M; Hofer, H; Laferl, H; Löschenberger, K; Maieron, A; Scherzer, TM; Stauber, R; Staufer, K; Steindl-Munda, P; Strasser, M | 1 |
| Aurora, R; Cannon, NA; Donlin, MJ; Fan, X; Tavis, JE | 1 |
| Nicholson, KG | 1 |
| Galbraith, A; Oxford, JS | 1 |
| Davis, GL; Lau, JY; Lim, HL | 1 |
| Cameron, R; Cattral, MS; Chung, SW; Greig, PD; Krajden, M; Levy, GA; Rezig, M; Wanless, IR | 1 |
| Barbara, L; Brillanti, S; Miglioli, M | 1 |
| Bizollon, T; Ducerf, C; Trépo, C | 1 |
| Benhamou, JP; Boyer, N; Castelnau, C; Erlinger, S; Marcellin, P; Martinot, M; Pouteau, M | 1 |
| Andersson, J; Aschan, J; Björkstrand, B; Hägglund, H; Ljungman, P; Lönnqvist, B; Ringdén, O; Winiarski, J | 1 |
| Adahm, M; Baulieux, J; Bizollon, T; Ducerf, C; Trepo, C | 1 |
| Bailly, F; Bizollon, T; Trepo, C | 1 |
| Bruguera, M | 1 |
| Falsey, AR; Mlinaric-Galinovic, G; Walsh, EE | 1 |
| Belghiti, J; Benhamou, JP; Bernuau, J; Degott, C; Durand, F; Erlinger, S; Marcellin, P; Molas, G; Sauvanet, A; Sicot, C | 1 |
| Dieterich, D; Diflo, T; Harren, P; Rudow, DL; Teperman, LW | 1 |
| Baulieux, J; Bizollon, T; Chevallier, M; Ducerf, C; Elliott, M; Palazzo, U; Pouyet, M; Trepo, C | 1 |
| McHutchison, JG | 1 |
| Cattral, MS; Greig, PD; Hemming, AW; Levy, G; Lilly, LB; Philosophe, B; Superina, RA | 1 |
| Girard, PM; Guessant, S; Maslo, C; Rozenbaum, W; Urban, T | 1 |
| Abdulla, A; al-Sebayel, M; al-Traif, I; Hammad, A; Kizilisik, TA; Ramirez, CG | 1 |
| Barker, WH; Hall, CB; Long, CE; Voter, KZ | 1 |
| Renner, EL | 1 |
| McBride, JT; McConnochie, KM | 1 |
| Gane, EJ; Lau, JY; Lo, SK; Naoumov, NV; Portmann, BC; Riordan, SM; Williams, R | 1 |
| Bletry, O; Cacoub, P; Cosserat, J; Cretel, E; Durand, JM; Frances, C; Godeau, P; Kaplanski, G; Lunel-Fabiani, F; Soubeyrand, J | 1 |
| Berg, T; Götz, G; Haefker, A; Hopf, U; Neuhaus, P; Neuhaus, R; Schön, MR | 1 |
| Borque, MJ; Fernández-Bermejo, M; García-Buey, L; García-Monzón, C; Iacono, LO; Moreno-Monteagudo, JA; Moreno-Otero, R; Sanz, P | 1 |
| Azoulay, D; Charpentier, B; Debuire, B; Ducret, F; Féray, C; Gigou, M; Lemoine, A; Paradis, V; Pham, HP; Samuel, D | 1 |
| Hug, B | 1 |
| Albrecht, J; Craxi, A; Davis, GL; Esteban-Mur, R; Gordon, SC; Hoefs, J; Ling, MH; Rustgi, V; Shiffman, ML; Trepo, C; Zeuzem, S | 1 |
| Caselmann, WH; Manns, MP; Wedemeyer, H | 1 |
| Al Ashgar, H; Cattral, MS; Greig, PD; Hemming, AW; Krajden, M; Levy, GA; Lilly, L; Wanless, IR | 1 |
| Maddrey, WC | 1 |
| Bayliss, MS; Cort, S; Neary, MP; Ware, JE | 1 |
| Casalino, C; Genchi, C; Mariano, N; Maselli, R; Milella, M; Pastore, G; Pietromatera, G; Santantonio, T | 1 |
| Chapman, RW; Christie, JM | 1 |
| Annese, M; Bacca, D; Barbarini, G; Barbaro, G; Barelli, A; Belloni, G; Calleri, G; Del Poggio, P; Di Lorenzo, G; Ferrari, L; Francavilla, R; Fruttaldo, L; Grisorio, B; Gualandi, G; Mongiò, F; Paiano, A; Poltronieri, I; Rizzo, G; Rocchetto, P; Scotto, G | 1 |
| Görög, D; Horányi, M; Schaff, Z; Telegdy, L | 1 |
| Rizzetto, M; Saracco, G | 1 |
| Albrecht, J; Goodman, Z; Ling, MH; McHutchison, J; Poynard, T | 1 |
| Lavezzo, B; Rizzetto, M | 1 |
| Jacobson, I | 1 |
| Albrecht, JK; Goodman, Z; Hong, Z; Kato, T; Lai, VC; Lau, JY; Mizokami, M; Orito, E | 1 |
| Berenguer, M; Wright, TL | 2 |
| Davis, GL; Pauker, SG; Wong, JB | 1 |
| Mast, EE; Seeff, LB; Sulkowski, MS; Thomas, DL | 1 |
| Burns, DA; Taylor, C; Wiselka, MJ | 1 |
| Fukumoto, T; Iwasaki, T; Ku, Y; Kuroda, Y; Kusunoki, N; Muramatsu, S; Tominaga, M; Yoon, S | 1 |
| Bar-Nathan, N; Ben-Ari, Z; Mor, E; Shaharabani, E; Shapira, Z; Tur-Kaspa, R | 1 |
| Alberti, A; Belussi, F; Bernardinello, E; Casarin, P; Cavalletto, L; Chemello, L; Donada, C; Gatta, A; Marino, F; Pontisso, P | 1 |
| McHutchison, JG; Pianko, S | 1 |
| Kwo, PY | 1 |
| Cuccorese, G; Miglietta, A; Modeo, ME; Spinazzola, AM; Tursi, A | 1 |
| Almasio, P; Cataldo, MG; Craxì, A; Di Marco, V; Di Stefano, R; Ferraro, D; Parisi, P; Vaccaro, A | 1 |
| Benhamou, Y; Bochet, M; Bréchot, C; Chaix, ML; Fontaine, H; Katlama, C; Lagneaux, JL; Landau, A; Pialoux, G; Pol, S; Poynard, T; Zylberberg, H | 1 |
| Diago, M; Enríquez, J; Gallego, A; García-Samaniego, J; Luján, MS; Pérez-Olmeda, T; Soriano, V; Torras, X | 1 |
| Carlsson, T; Lindahl, K; Reichard, O; Schvarcz, R; Shev, S; Uhnoo, I; Wejstal, R | 1 |
| Braun, F; Ramadori, G; Ringe, B; Wietzke, P | 1 |
| Albillos, A; Calleja, JL; Domper, F; Escartín, P; Martínez, JL; Moreno, R; Rossi, I | 1 |
| Bastani, B; Philipneri, M | 1 |
| Cote, J; Dagenais, M; Hassoun, Z; Lapointe, R; Letourneau, R; Marleau, D; N'Guyen, B; Roy, A; Villeneuve, JP; Willems, B | 1 |
| Albrecht, JK; Bayliss, MS; Cort, S; McHutchison, JG; Neary, MP; Pianko, S; Ware, JE; Yang, I | 1 |
| Bacon, BR; Brunt, EM; Di Bisceglie, AM; Smith-Wilkaitis, N; Thompson, J | 1 |
| Lagging, LM; Lindh, M; Nenonen, N; Norkrans, G; Wejstål, R; Westin, J | 1 |
| Berk, BS; Chou, S; Corless, CL; Gopal, DV; Olyaei, A; Orloff, SL; Rabkin, JM; Rosen, HR | 1 |
| Davis, L; De Vera, ME; Heffron, TG; Martinez, E; Rosado, K; Sharma, S; Smallwood, GA; Stieber, AC | 1 |
| Reddy, KR | 1 |
| Goeser, T; Kallinowski, B; Liehr, H; Moeller, B; Stremmel, W; Wechsler, JG; Wiese, M | 1 |
| Bartlett, SE; Chapman, BA; Edgar, CL; Frampton, CM; Jennings, LC; Scahill, SL; Stace, NH | 1 |
| Goodman, Z; Gramlich, T; Mayes, J; Ong, JP; Sarbah, S; Yen-Lieberman, B; Younossi, ZM | 1 |
| Backmund, M; Eichenlaub, D; Meyer, K; Von Zielonka, M | 1 |
| Couzigou, P; De Ledinghen, V; Foucher, J | 1 |
| García-Samaniego, J; Pérez-Olmeda, M; Rodríguez-Rosado, R; Soriano, V | 1 |
| Ahmad, J; Demetris, AJ; Dodson, SF; Fung, JJ; Shakil, AO | 1 |
| Airoldi, A; Alberti, AB; Belli, LS; Cernuschi, A; D'Amico, M; de Carlis, L; Forti, D; Minola, E; Pinzello, G; Rondinara, G; Vangeli, M | 1 |
| Gluud, C; Kjaergard, LL; Krogsgaard, K | 1 |
| Chen, DS; Chen, PJ; Cheng, YM; Kao, JH; Lai, MY | 1 |
| Andreone, P; Bernardi, M; Biselli, M; Cavallari, A; Cursaro, C; D'Errico, A; Di Giammarino, L; Galli, S; Gramenzi, A; Grazi, GL; Jovine, E; Mazziotti, A | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Lai, MY | 1 |
| Rodés, J; Sánchez Tapias, JM | 1 |
| Borque, MJ; Castro, A; De Pedro, A; Fernández-Bermejo, M; García-Buey, L; Lopez, S; Lorenzo, JA; Moreno-Monteagudo, JA; Moreno-Otero, R; Pedreira, JD | 1 |
| Buti, M; Esteban-Mur, R; Guardia, J; Olivé, G | 1 |
| Berenguer, M | 1 |
| Barbarini, G; Barbaro, G | 1 |
| Burgart, LJ; Charlton, M; El-Amin, OM; Kremers, WK; Narayanan Menon, KV; Poterucha, JJ; Rosen, CB; Wiesner, RH | 1 |
| Nĕmecek, V; Rýzlová, M; Stránský, J; Stríteský, J | 1 |
| Grube, T; Hommann, M; Kornberg, A; Scheele, J; Schotte, U; Tannapfel, A; Voigt, R; Wagner, T | 1 |
111 review(s) available for ribavirin and Recrudescence
| Article | Year |
|---|---|
Interventions for dialysis patients with hepatitis C virus (HCV) infection.
Topics: Antiviral Agents; Chronic Disease; Hepacivirus; Hepatitis C; Humans; Interferons; Recurrence; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin | 2023 |
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study.
Topics: Anilides; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmacovigilance; Recurrence; Ribavirin; Ritonavir; Sofosbuvir; Sustained Virologic Response | 2023 |
Hepatitis B virus reactivation after successful treatment of hepatitis C virus with sofosbuvir and ribavirin: A case report and literature review.
Topics: Antiviral Agents; Female; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Middle Aged; Recurrence; Ribavirin; Sofosbuvir | 2020 |
Ledipasvir + Sofosbuvir for Liver Transplant Recipients With Recurrent Hepatitis C: A Systematic Review and Meta-analysis.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2017 |
Treatment of hepatitis C in special populations.
Topics: Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Immunocompromised Host; Interferons; Liver Transplantation; Postoperative Period; Protease Inhibitors; Recurrence; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin | 2018 |
Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.
Topics: Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Pakistan; Prevalence; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2018 |
A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation?
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
Antiviral therapy of symptomatic HCV-mixed cryoglobulinemia after liver transplant: case report and literature review.
Topics: Antiviral Agents; Cryoglobulinemia; Drug Substitution; Drug Therapy, Combination; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome | 2013 |
Immunoglobulin G4-associated de novo autoimmune hepatitis after liver transplantation for chronic hepatitis B- and C-related cirrhosis and hepatocellular carcinoma: a case report with literature review.
Topics: Antiviral Agents; Azathioprine; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Immunoglobulin G; Immunosuppressive Agents; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prednisone; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome | 2013 |
The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Odds Ratio; Oligopeptides; Polyethylene Glycols; Publication Bias; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Risk; RNA, Viral; Serine Proteinase Inhibitors; Treatment Outcome; Viral Load; Viremia | 2013 |
[Progress in hepatitis C treatment].
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Eruptions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Multicenter Studies as Topic; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pruritus; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2013 |
New insights in recurrent HCV infection after liver transplantation.
Topics: Antibodies, Neutralizing; Antiviral Agents; Glucocorticoids; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Failure; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Viral Envelope Proteins; Virus Internalization | 2013 |
[Telaprevir in HCV-monoinfected patients with failure to prior treatment].
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Multicenter Studies as Topic; Oligopeptides; Patient Selection; Polyethylene Glycols; Protease Inhibitors; Recurrence; Ribavirin; Treatment Failure; Treatment Outcome | 2013 |
Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Reoperation; Ribavirin | 2013 |
Association of rs12979860 and rs8099917 polymorphisms near IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: a meta-analysis.
Topics: Antiviral Agents; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Liver Transplantation; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; Transplantation, Homologous | 2014 |
Hepatitis C management in post-transplant patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load | 2015 |
[New drugs for hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Europe; Hepatitis C; Humans; Interferons; Oligopeptides; Recurrence; Ribavirin; Risk Factors | 2014 |
Management of post transplant hepatitis C in the direct antiviral agents era.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Transplantation; Oligopeptides; Postoperative Complications; Proline; Protease Inhibitors; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2015 |
Interventions for dialysis patients with hepatitis C virus (HCV) infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin; Withholding Treatment | 2015 |
Dual sofosbuvir and ribavirin therapy for chronic hepatitis C infection.
Topics: Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Failure; Liver Transplantation; Recurrence; Renal Insufficiency; Ribavirin; Sofosbuvir | 2016 |
News and challenges in the treatment of hepatitis C in liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin | 2016 |
Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.
Topics: Adolescent; Adult; Antiviral Agents; Coinfection; Drug Users; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Male; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Sustained Virologic Response; Viral Load; Young Adult | 2016 |
Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.
Topics: Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Publication Bias; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2017 |
Liver transplantation from HCV RNA-positive donors in the era of interferon-free HCV therapeutics: a re-examination of the situation.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Tissue Donors; Viral Load | 2017 |
Management of direct antiviral agent failures.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir | 2016 |
[Treatment of systemic vasculitides].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Azathioprine; Churg-Strauss Syndrome; Clinical Trials as Topic; Cryoglobulinemia; Cyclophosphamide; Drug Therapy, Combination; Etanercept; Granulomatosis with Polyangiitis; Hepatitis B; Humans; Immunoglobulin G; Immunoglobulins, Intravenous; Immunosuppressive Agents; Interferons; Plasma Exchange; Polyarteritis Nodosa; Prognosis; Prospective Studies; Receptors, Tumor Necrosis Factor; Recurrence; Ribavirin; Risk; Severity of Illness Index; Time Factors; Tumor Necrosis Factor-alpha; Vasculitis; Virus Diseases | 2008 |
Current approaches to HCV infection in current and former injection drug users.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferons; Patient Care Team; Recurrence; Ribavirin; Substance Abuse, Intravenous | 2008 |
Treatment of hepatitis C in liver transplant recipients.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2009 |
Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2009 |
Antiviral therapy for recurrent liver graft infection with hepatitis C virus.
Topics: Amantadine; Antiviral Agents; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Randomized Controlled Trials as Topic; Recurrence; Ribavirin | 2010 |
Host genomics and HCV treatment response.
Topics: Animals; Antiviral Agents; Coinfection; Drug Therapy, Combination; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recurrence; Ribavirin; Treatment Outcome | 2012 |
Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Treatment Failure; Treatment Outcome; Virus Replication; Young Adult | 2012 |
Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders.
Topics: Anemia; Antiviral Agents; Clinical Trials, Phase III as Topic; Drug Substitution; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Skin Diseases; Standard of Care; Treatment Failure | 2012 |
The role of ribavirin in direct acting antiviral drug regimens for chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Viral Load | 2012 |
Future treatment of patients with HCV cirrhosis.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Viral Load | 2012 |
Hepatitis C virus treatment pre- and post-liver transplantation.
Topics: Antiviral Agents; Disease Progression; Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Proline; Recombinant Proteins; Recurrence; Ribavirin; Serine Proteinase Inhibitors; Time Factors; Viral Load | 2012 |
Current management and perspectives for HCV recurrence after liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Serine Proteinase Inhibitors; Time Factors; Treatment Outcome; Viral Load | 2013 |
Ribavirin and interferon combination for recurrent post-transplant hepatitis C: which benefit beyond 6 months?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin | 2002 |
[Hepatitis C and drug use: epidemiology, screening, natural history and treatment].
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Follow-Up Studies; France; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heroin Dependence; Humans; Interferons; Prevalence; Prisons; Prognosis; Prospective Studies; Recurrence; Ribavirin; Risk Factors; Substance Abuse, Intravenous; Substance-Related Disorders; Time Factors | 2002 |
[Treatment of patients with chronic hepatitis C who relapsed or did not respond to a previous treatment].
Topics: Amantadine; Antiviral Agents; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Transaminases; Treatment Failure; Viral Load | 2002 |
[Evaluation of response to treatment in chronic hepatitis C].
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Biopsy; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferons; Liver; Liver Neoplasms; Meta-Analysis as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Transaminases; Viremia | 2002 |
[Treatment of hepatitis C after liver transplantation].
Topics: Acute Disease; Animals; Drug Therapy, Combination; Follow-Up Studies; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Immunoglobulins; Immunosuppression Therapy; Interferons; Liver Transplantation; Pan troglodytes; Postoperative Care; Postoperative Complications; Preoperative Care; Prognosis; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Virus Replication | 2002 |
Consensus conference. Treatment of hepatitis C.
Topics: Adult; Aged; Alcoholism; Amantadine; Antiviral Agents; Body Weight; Child; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Mental Disorders; Middle Aged; Monitoring, Physiologic; Quality of Life; Recurrence; Ribavirin; Risk Factors; Substance-Related Disorders; Time Factors | 2002 |
[Chronic hepatitis C: what to do if the first treatment failed?].
Topics: Amantadine; Animals; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Ethanol; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Mice; Mice, Transgenic; Multicenter Studies as Topic; Obesity; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; Smoking; Time Factors | 2002 |
[Hepatitis C and liver transplantation].
Topics: Aged; Antiviral Agents; Carcinoma, Hepatocellular; Clinical Enzyme Tests; Clinical Trials as Topic; Drug Therapy, Combination; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Pilot Projects; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Tissue Donors; Transaminases | 2002 |
Treatment of recurrent hepatitis C.
Topics: Animals; Antiviral Agents; Drug Therapy, Combination; Graft Rejection; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2002 |
Therapy of chronic hepatitis C: a critical review.
Topics: Age Factors; Alanine Transaminase; Animals; Blood Coagulation Disorders, Inherited; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Pregnancy; Recurrence; Renal Insufficiency; Ribavirin; Treatment Outcome | 2003 |
[Treatment of patients with recurrence or who do not respond to the first treatment against hepatitis C].
Topics: Antiviral Agents; Hepatitis C; Humans; Interferons; Recurrence; Ribavirin | 2002 |
Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2003 |
[Hepatitis: associated diseases. Risk groups -- prevention -- treatment].
Topics: Adenine; Adult; Antiviral Agents; Child; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C; Hepatitis C, Chronic; Humans; Infant; Infant, Newborn; Interferons; Lamivudine; Liver Cirrhosis; Male; Mutation; Organophosphonates; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors | 2003 |
Treatment options for nonresponders and relapsers to initial therapy for hepatitis C.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Neoplasms; Recurrence; Retreatment; Ribavirin | 2003 |
Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Patient Selection; Practice Guidelines as Topic; Recurrence; Reoperation; Ribavirin; Risk Factors | 2003 |
Treatment of hepatitis C virus infection in the allograft.
Topics: Antiviral Agents; Contraindications; Cost of Illness; Drug Therapy, Combination; Graft Survival; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Transplantation, Homologous | 2003 |
Practical management of liver transplant recipients for hepatitis C.
Topics: Antiviral Agents; Combined Modality Therapy; Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Reoperation; Ribavirin; Treatment Outcome | 2003 |
Changing faces-natural course and treatment of hepatitis C after liver transplantation.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2004 |
Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options.
Topics: Amantadine; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon-alpha; Recurrence; Ribavirin | 2004 |
Natural history and management of hepatitis C infection after liver transplantation.
Topics: Disease Progression; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoglobulins; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2004 |
[Two-step interferon rebound therapy].
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Cytokines; Drug Administration Schedule; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
[Efficacy of and indications for IFN retreatment of patients with chronic hepatitis C].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Interferons; Japan; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Treatment Outcome | 2004 |
[Liver transplantation for hepatitis C virus cirrhosis--present status and future prospects].
Topics: Antiviral Agents; Brain Death; Combined Modality Therapy; Drug Therapy, Combination; Graft Survival; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Liver Cirrhosis; Liver Transplantation; Living Donors; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors | 2004 |
The role of hematopoietic growth factors in special populations with chronic hepatitis C: patients with HIV coinfection, end-stage renal disease, or liver transplantation.
Topics: Anemia; Antiviral Agents; Clinical Trials as Topic; Comorbidity; Drug Therapy, Combination; Erythropoietin; Forecasting; Granulocyte Colony-Stimulating Factor; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Kidney Failure, Chronic; Liver Transplantation; Neutropenia; Patient Compliance; Recombinant Proteins; Recurrence; Renal Dialysis; Ribavirin | 2004 |
Treatment of acute and chronic hepatitis C.
Topics: Amantadine; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Recurrence; Ribavirin | 1997 |
Role of growth factors in the treatment of patients with HIV/HCV coinfection and patients with recurrent hepatitis C following liver transplantation.
Topics: Antiviral Agents; Growth Substances; Hematologic Diseases; Hematopoiesis; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin; United States | 2005 |
[Treatment of hepatitis C virus infection].
Topics: Acute Disease; AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Longitudinal Studies; Meta-Analysis as Topic; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Viral Load | 2005 |
[Current treatment of hepatitis C virus infection].
Topics: Acute Disease; Amantadine; Animals; Antiviral Agents; Hepacivirus; Hepatitis B; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Transaminases; Treatment Failure; Viral Envelope Proteins; Viral Hepatitis Vaccines | 2005 |
Current therapy for hepatitis C.
Topics: Algorithms; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Recurrence; Ribavirin | 2007 |
[Retreatment strategies for the patients with HCV infection].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome | 2005 |
[The course of hepatitis C infection after liver transplantation].
Topics: Antiviral Agents; Genotype; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin; Treatment Outcome | 2005 |
Treatment of hepatitis C virus reinfection after liver transplantation.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Recombinant Proteins; Recurrence; Ribavirin | 2005 |
Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Viral Load | 2006 |
[High dose repeat therapy in previously treated patients with chronic hepatitis C].
Topics: Amantadine; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2006 |
Liver transplantation for hepatitis C.
Topics: Hepatitis C; Humans; Immunosuppression Therapy; Interferons; Liver Transplantation; Recurrence; Ribavirin | 2006 |
[Recurrent disease after liver transplantation. A therapeutic dilemma or treatable?].
Topics: Age Factors; Antiviral Agents; Carcinoma, Hepatocellular; Cholestasis, Intrahepatic; Disease-Free Survival; Follow-Up Studies; Hepatitis B; Hepatitis C; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Incidence; Interferon-alpha; Liver Diseases; Liver Diseases, Alcoholic; Liver Neoplasms; Liver Transplantation; Middle Aged; Patient Compliance; Prognosis; Recurrence; Ribavirin; Risk Factors; Time Factors | 2006 |
Review article: the treatment of hepatitis C virus recurrence after liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Transplantation; Male; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk Factors; Treatment Outcome | 2007 |
Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation.
Topics: Antiviral Agents; Fibrosis; Hepatitis B, Chronic; Hepatitis, Chronic; Humans; Immunoglobulins; Interferons; Liver Transplantation; Polyethylene Glycols; Recurrence; Ribavirin; Treatment Outcome | 2007 |
[Treatment of recurrent hepatitis C virus infection after liver transplantation].
Topics: Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2007 |
[Cryoglobulinemia].
Topics: Alcohol Drinking; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C; Humans; Immunologic Factors; Interferon-alpha; Liver Cirrhosis; Male; Recurrence; Ribavirin; Rituximab; Sex Factors; Vasculitis | 2008 |
Treatment of chronic hepatitis C with consensus interferon in relapsers and non-responders to interferon-based therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Recurrence; Ribavirin; Treatment Failure | 2007 |
Antiviral therapy. Respiratory infections, genital herpes, and herpetic keratitis.
Topics: Acyclovir; Adult; Amantadine; Antiviral Agents; Child; Female; Herpes Genitalis; Humans; Idoxuridine; Infant; Infant, Newborn; Influenza, Human; Keratitis, Dendritic; Male; Picornaviridae Infections; Recurrence; Respiratory Syncytial Viruses; Respiratory Tract Infections; Respirovirus Infections; Rhinovirus; Ribavirin; Rimantadine; Trifluridine; Vidarabine | 1984 |
Antiviral activity of amantadine: a review of laboratory and clinical data.
Topics: Amantadine; Animals; Antiviral Agents; Culture Techniques; Drug Resistance, Microbial; Hemagglutinins; Humans; Influenza Vaccines; Interferons; Orthomyxoviridae; Peptides; Recurrence; Ribavirin; Vaccination; Virus Replication | 1980 |
Therapy for chronic hepatitis C.
Topics: Chronic Disease; DNA, Viral; Dose-Response Relationship, Drug; Hepatitis C; Humans; Interferons; Recurrence; Ribavirin; RNA, Viral; Time Factors | 1994 |
[Factors of response to treatment with interferon-alpha in patients with chronic hepatitis C. Therapeutic perspectives].
Topics: Age Factors; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Hepatitis, Chronic; Humans; Interferon-alpha; Liver; Male; Recurrence; Ribavirin; Sex Factors | 1995 |
New approaches to treatment of recurrent hepatitis C virus following liver transplantation using ribavirin.
Topics: Adult; Antiviral Agents; Diagnosis, Differential; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin; RNA, Viral | 1996 |
Treatment of chronic hepatitis C: another therapeutic option.
Topics: Antiviral Agents; Chronic Disease; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Polymerase Chain Reaction; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 1996 |
[Treatment of chronic hepatitis C: still many problems pending].
Topics: Adrenal Cortex Hormones; Aged; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Cholagogues and Choleretics; Chronic Disease; Clinical Enzyme Tests; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Indomethacin; Interferons; Ofloxacin; Phlebotomy; Recurrence; Ribavirin; Time Factors; Ursodeoxycholic Acid | 1997 |
Respiratory syncytial virus infection in the elderly.
Topics: Aged; Antiviral Agents; Disease Transmission, Infectious; Humans; Recurrence; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Ribavirin; Vaccination | 1996 |
[Therapy of chronic hepatitis C: facing a breakthrough?].
Topics: Amantadine; Clinical Trials as Topic; Combined Modality Therapy; Hepatitis C, Chronic; Humans; Interferon Type I; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 1998 |
Use of high-dose interferon in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 1999 |
Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C.
Topics: Antiviral Agents; Drug Administration Routes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 1999 |
[Interferon-alpha and ribavirin: advances in the therapy of chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Immunocompromised Host; Interferon-alpha; Recurrence; Ribavirin | 1999 |
Combination therapy for chronic hepatitis C: interferon and ribavirin.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Recombinant Proteins; Recurrence; Ribavirin | 1999 |
[International consensus conference on hepatitis C. Conclusions. Organized under the auspices of the European Association for the Study of the Liver (EASL)].
Topics: Adult; Age Factors; Aged; AIDS-Related Opportunistic Infections; Alcoholism; Antiviral Agents; Child; Child, Preschool; Clinical Trials as Topic; Diagnosis, Differential; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Substance-Related Disorders; Viral Hepatitis Vaccines | 1999 |
[Chronic viral hepatitis caused by B and C virus: diagnostic and therapeutic trends].
Topics: Antiviral Agents; DNA, Viral; Genotype; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferons; Lamivudine; Polymerase Chain Reaction; Recurrence; Ribavirin; RNA, Viral | 1999 |
Retreatment of interferon relapse patients with chronic hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Recurrence; Ribavirin | 1999 |
Treatment of recurrent hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Recurrence; Ribavirin | 1999 |
Hepatitis C virus in the transplant setting.
Topics: Antiviral Agents; Combined Modality Therapy; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferons; Liver Failure; Liver Transplantation; Recurrence; Ribavirin; RNA, Viral; Survival Rate; Time Factors; Tissue Donors | 1998 |
Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Hepatitis C; Humans; Interferon-alpha; Recurrence; Ribavirin | 2000 |
Current therapy for chronic hepatitis C.
Topics: Antiviral Agents; Drug Resistance; Hepatitis C, Chronic; Humans; Interferons; Monitoring, Physiologic; Recurrence; Ribavirin | 2000 |
Pre- and post-transplant treatment of hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Recurrence; Ribavirin | 2000 |
Treatment of hepatitis C with interferon and ribavirin.
Topics: Acute Disease; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Recurrence; Ribavirin | 2000 |
Treatment of chronic hepatitis C in nonresponders to interferon monotherapy.
Topics: Alanine Transaminase; Antiviral Agents; Black or African American; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Iron; Liver; Recurrence; Ribavirin; RNA, Viral | 2000 |
Kidney disease in patients with chronic hepatitis C.
Topics: Antigen-Antibody Complex; Antiviral Agents; Disease Progression; Glomerulonephritis; Hepatitis C, Chronic; Humans; Interferon-alpha; Kidney Diseases; Kidney Transplantation; Postoperative Complications; Recurrence; Ribavirin; Treatment Outcome | 2001 |
A case of giant cell hepatitis recurring after liver transplantation and treated with ribavirin.
Topics: Adult; Antiviral Agents; Giant Cells; Hepatitis; Humans; Liver; Liver Cirrhosis; Liver Transplantation; Male; Recurrence; Ribavirin | 2000 |
Combination treatment with interferon and ribavirin for chronic hepatitis C.
Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferons; Liver Transplantation; Recurrence; Ribavirin | 1999 |
Treatment strategies for recurrent hepatitis C after liver transplantation.
Topics: Hepatitis C; Humans; Interferons; Liver Transplantation; Recurrence; Reoperation; Ribavirin | 1999 |
Transplantation for chronic hepatitis B and C: strategies for prevention and treatment of recurrent disease.
Topics: Antiviral Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Immunoglobulins; Interferon-alpha; Liver Transplantation; Recurrence; Ribavirin | 2001 |
[Chronic viral hepatitis C: current therapy and perspectives].
Topics: Antiviral Agents; Cytokines; Drug Therapy, Combination; Hepatitis C, Chronic; Interferons; Recurrence; Ribavirin | 2001 |
Management of hepatitis C in HIV-infected persons.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Carcinoma, Hepatocellular; Disease Management; Disease Transmission, Infectious; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Liver Neoplasms; Recurrence; Ribavirin | 2001 |
Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Morbidity; Randomized Controlled Trials as Topic; Recurrence; Ribavirin; Risk | 2001 |
[Treatment of chronic hepatitis C relapse].
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Interferons; Recombinant Proteins; Recurrence; Ribavirin | 2000 |
[Treatment of recurrent hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Liver Transplantation; Recurrence; Ribavirin | 2000 |
160 trial(s) available for ribavirin and Recrudescence
| Article | Year |
|---|---|
Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Killer Cells, Natural; Longitudinal Studies; Male; Neutrophils; Recurrence; Ribavirin; Sofosbuvir; T-Lymphocytes; Transcriptome; Treatment Outcome | 2020 |
Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.
Topics: Adult; Antiviral Agents; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Opiate Substitution Treatment; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk-Taking; Secondary Prevention; Substance Abuse, Intravenous; Young Adult | 2017 |
12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation.
Topics: Adult; Aged; Belgium; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; France; Graft Survival; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse.
Topics: Amides; Antiviral Agents; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.
Topics: Amino Acid Substitution; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Female; Genotype; Health Care Costs; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2013 |
Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin.
Topics: Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Polymorphism, Genetic; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Taiwan; Time Factors; Treatment Outcome | 2014 |
Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2014 |
Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.
Topics: Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2013 |
Impact of age on viral kinetics of peginterferon alfa-2a/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2014 |
Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response.
Topics: Adult; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome | 2014 |
Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrophosphatases; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin | 2014 |
CD49b, a major marker of regulatory T-cells type 1, predicts the response to antiviral therapy of recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Biopsy; Demography; Female; Gene Expression Regulation; Hepatitis C; Humans; Integrin alpha2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; T-Lymphocytes, Regulatory; Treatment Outcome | 2014 |
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
Topics: Adult; Aged; Antiviral Agents; Asia; Biomarkers; Double-Blind Method; Drug Therapy, Combination; Europe; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Male; Middle Aged; North America; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Time Factors; Treatment Outcome; Viral Load; Viral Nonstructural Proteins; Young Adult | 2014 |
Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Interferon-alpha; Japan; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Simeprevir; Sulfonamides; Young Adult | 2014 |
Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant.
Topics: Adult; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Prognosis; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Risk Factors; Viral Load | 2014 |
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Ribavirin; Sulfonamides; Valine | 2014 |
Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.
Topics: Administration, Oral; Adolescent; Age Factors; Antiviral Agents; Biomarkers; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Male; Pichia; Polyethylene Glycols; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Tertiary Care Centers; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Ribavirin; RNA, Viral; Sulfonamides; Valine | 2014 |
Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.
Topics: Antiviral Agents; Chemokine CXCL10; Drug Therapy, Combination; Endopeptidases; Gene Expression; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver; Recurrence; Ribavirin; RNA, Messenger; Sofosbuvir; Treatment Outcome; Ubiquitin Thiolesterase; Uridine Monophosphate | 2014 |
Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Topics: Aged; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; New Zealand; Pilot Projects; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load; Waiting Lists | 2015 |
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; New Zealand; Pilot Projects; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Spain; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2015 |
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutation; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate | 2014 |
Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation.
Topics: Antiviral Agents; Compassionate Use Trials; Female; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Severity of Illness Index; Sofosbuvir; Treatment Failure; Uridine Monophosphate | 2015 |
Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial.
Topics: Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Recurrence; Ribavirin; Surveys and Questionnaires; Treatment Outcome | 2015 |
Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Fatigue; Female; Genotype; Headache; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Recurrence; Republic of Korea; Ribavirin; RNA, Viral; Treatment Outcome | 2015 |
Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
Topics: Adult; Antiviral Agents; Benzimidazoles; Chemokine CXCL10; Convalescence; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Protein Processing, Post-Translational; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load; Virus Replication | 2015 |
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Isoindoles; Japan; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Sulfonamides; Treatment Outcome; Young Adult | 2016 |
Boceprevir and peginterferon α-2b plus ribavirin therapy of HCV genotype 3 relapsers: A pilot study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load | 2016 |
Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?
Topics: Adult; Alanine Transaminase; Anemia; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Erythropoietin; Female; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2016 |
Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Valine | 2016 |
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
Topics: Adult; Aged; Antiviral Agents; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Isoindoles; Lactams, Macrocyclic; Leucine; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sulfonamides; Viral Load; Young Adult | 2016 |
Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Topics: Adult; Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quinoxalines; Recurrence; Ribavirin; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2016 |
Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin.
Topics: Adult; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Valine; Young Adult | 2016 |
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
Topics: Aged; Antiviral Agents; Belgium; Carbamates; Compassionate Use Trials; Female; France; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Protease Inhibitors; Pyrrolidines; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2016 |
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Recurrence; Ribavirin; Simeprevir; Treatment Outcome; Young Adult | 2016 |
Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Period; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome | 2016 |
The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.
Topics: Administration, Oral; Aged; Antiviral Agents; Biopsy; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Liver; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Tacrolimus; Transaminases; Valine | 2016 |
Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.
Topics: Adolescent; Adult; Aged; Albumins; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Young Adult | 2017 |
Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cyclosporine; Drug Therapy, Combination; Female; Genotype; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Tacrolimus; Treatment Outcome; Valine; Viral Load | 2017 |
Effects of double-filtration plasmapheresis combined with interferon plus ribavirin for recurrent hepatitis C after living donor liver transplantation.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Pilot Projects; Plasmapheresis; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2008 |
Efficacy of interferon based antiviral therapy for recurrent hepatitis C in patients who received steroid free immunosuppression for liver transplantation.
Topics: Amantadine; Antibodies, Monoclonal; Antilymphocyte Serum; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Sustained clearance of serum hepatitis C virus-RNA independently predicts long-term survival in liver transplant patients with recurrent hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Female; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Survival Rate; Treatment Outcome | 2009 |
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Liver; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Viral Load; White People; Young Adult | 2009 |
Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load; Young Adult | 2009 |
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load; Young Adult | 2009 |
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.
Topics: Adult; Aged; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome; Vaccines, Subunit; Viral Hepatitis Vaccines; Young Adult | 2009 |
Pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C: role of steatosis and body mass index.
Topics: Adult; Antiviral Agents; Biopsy; Body Mass Index; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2009 |
The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study.
Topics: Antiviral Agents; Cyclosporine; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Tacrolimus | 2010 |
Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin.
Topics: Antiviral Agents; Comorbidity; Drug Therapy, Combination; Follow-Up Studies; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2009 |
Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Young Adult | 2010 |
Re-treatment of children with chronic hepatitis C who did not respond to interferon-alpha treatment.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis B; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Recurrence; Retreatment; Ribavirin; RNA, Viral; Viral Load | 2010 |
Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Severity of Illness Index; Survival Rate; Treatment Outcome; United States | 2010 |
Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Female; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2010 |
An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
Topics: Adult; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Italy; Logistic Models; Male; Odds Ratio; Polyethylene Glycols; Polymorphism, Genetic; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
von Willebrand factor antigen: a novel on-treatment predictor of response to antiviral therapy in chronic hepatitis C genotypes 1 and 4.
Topics: Administration, Oral; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Recurrence; Ribavirin; von Willebrand Factor | 2010 |
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.
Topics: Adult; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors | 2011 |
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Biopsy; End Stage Liver Disease; Female; Fibrosis; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2011 |
Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome | 2011 |
Telaprevir for retreatment of HCV infection.
Topics: Adult; Aged; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Sequence Analysis, DNA; Serine Proteinase Inhibitors; Viral Load; Young Adult | 2011 |
Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2011 |
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome; Young Adult | 2011 |
Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response.
Topics: Adolescent; Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2012 |
Preliminary study of two antiviral agents for hepatitis C genotype 1.
Topics: Adult; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Valine | 2012 |
Age and total ribavirin dose are independent predictors of relapse after interferon therapy in chronic hepatitis C revealed by data mining analysis.
Topics: Adult; Age Factors; Aged; Antiviral Agents; Biomarkers, Pharmacological; Cohort Studies; Data Mining; Drug Dosage Calculations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Reproducibility of Results; Ribavirin; RNA, Viral; Viral Load | 2012 |
Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Chi-Square Distribution; Disease Progression; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load | 2012 |
Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.
Topics: Antiviral Agents; Cyclosporine; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Induction Chemotherapy; Interferon-alpha; Kidney; Liver Cirrhosis; Liver Transplantation; Logistic Models; Maintenance Chemotherapy; Male; Middle Aged; Placebos; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Treatment Outcome; Viral Load | 2012 |
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Body Mass Index; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Homeostasis; Humans; Insulin Resistance; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Models, Biological; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Failure; Viral Load | 2012 |
Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non-responders and relapsers.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2012 |
Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.
Topics: Antiviral Agents; Chi-Square Distribution; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Inhibitory Concentration 50; Interferon-alpha; Kaplan-Meier Estimate; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure | 2012 |
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Preoperative Care; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2013 |
Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation.
Topics: Adult; Aged; Darbepoetin alfa; Drug Monitoring; Drug Therapy, Combination; Erythropoietin; Female; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Confidence Intervals; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hepacivirus; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2013 |
Efficacy of PEG-interferon based treatment in patients with hepatitis C refractory to previous conventional interferon-based treatment.
Topics: Antiviral Agents; Biopsy; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Hospitals, Teaching; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Pakistan; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load | 2012 |
Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2002 |
Combination therapy/prophylaxis with interferon and ribavirin for recurrent hepatitis C after liver transplantation: long-term effects on graft function and morphology.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Leukopenia; Liver Function Tests; Liver Transplantation; Recombinant Proteins; Recurrence; Ribavirin; Time Factors | 2002 |
A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Multivariate Analysis; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2002 |
Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo.
Topics: Adjuvants, Immunologic; Antiviral Agents; CD4-Positive T-Lymphocytes; CD40 Ligand; Cells, Cultured; Cytokines; Female; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Lymphocyte Activation; Male; Middle Aged; Mitogens; Monocytes; Recurrence; Ribavirin; RNA, Viral; Viral Core Proteins | 2002 |
A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Patient Dropouts; Pilot Projects; Postoperative Complications; Recurrence; Ribavirin; Treatment Outcome | 2002 |
Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2002 |
Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Chronic Disease; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Liver; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
[Retreatment with interferon plus ribavirin in chronic hepatitis C patients with genotype 1 who had no response or a relapse with a previous interferon treatment. Long term follow-up].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Time Factors | 2002 |
Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.
Topics: Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Postoperative Care; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Safety; Treatment Outcome | 2003 |
Efficacy of prolonged 5 million units of interferon in combination with ribavirin for relapser patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Clinical comparison of high-dose interferon-alpha2b with or without ribavirin for treatment of interferon-relapsed chronic hepatitis C.
Topics: Adult; Antiviral Agents; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral | 2002 |
Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study.
Topics: Adult; Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2003 |
High rate of long-term virological response after a 1-year course of interferon +/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2003 |
Impact of high-dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2003 |
Interferon plus ribavirin in patients with hepatitis C virus positive mixed cryoglobulinemia resistant to interferon.
Topics: Adult; Antiviral Agents; Biopsy; Complementarity Determining Regions; Cryoglobulinemia; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2003 |
Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Prospective Studies; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Time Factors; Treatment Outcome | 2003 |
Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2004 |
Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Period; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2004 |
A randomized trial of a 4- vs 12-week daily interferon dose regimen combined with ribavirin in treatment of patients with chronic hepatitis C.
Topics: Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; India; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Probability; Recombinant Proteins; Recurrence; Reference Values; Ribavirin; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2004 |
Reduction of relapse rates by 18-month treatment in chronic hepatitis C. A Benelux randomized trial in 300 patients.
Topics: Adult; Antiviral Agents; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors | 2004 |
Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2004 |
Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: preliminary results of an open prospective study.
Topics: Adult; Alanine Transaminase; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2004 |
Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Predictive Value of Tests; Recurrence; Ribavirin; RNA, Viral | 2004 |
Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Multivariate Analysis; Pilot Projects; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2004 |
Triple antiviral therapy with amantadine for IFN-ribavirin nonresponders with recurrent posttransplantation hepatitis C.
Topics: Adult; Amantadine; Antiviral Agents; Blood Cell Count; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Survival Analysis | 2005 |
Peginterferon alpha-2a combination therapies in chronic hepatitis C patients who relapsed after or had a viral breakthrough on therapy with standard interferon alpha-2b plus ribavirin: a pilot study of efficacy and safety.
Topics: Alanine Transaminase; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mycophenolic Acid; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome; Viral Load | 2005 |
Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiviral Agents; Daclizumab; Drug Therapy, Combination; Female; Graft Rejection; Hepatitis C; Humans; Immunoglobulin G; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load | 2005 |
Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors | 2005 |
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
Topics: Adult; Analysis of Variance; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2005 |
Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Survival Rate; Time; Transaminases | 2005 |
High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy.
Topics: Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2005 |
Ribavirin levels in post liver transplant patients treated for recurrent hepatitis C viral infection.
Topics: Adult; Aged; Antiviral Agents; Epoetin Alfa; Erythropoietin; Female; Hematinics; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin | 2005 |
A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.
Topics: Antiviral Agents; Black or African American; Drug Carriers; Drug Combinations; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; White People | 2005 |
Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients.
Topics: Adult; Antiviral Agents; Biopsy; Female; Hepatitis B; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2005 |
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2006 |
[Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C].
Topics: Adolescent; Antiviral Agents; Child; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
Impact of pegylated interferon alpha-2B and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series.
Topics: Adult; Aged; Biopsy; Cohort Studies; Drug Therapy, Combination; Drug Tolerance; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2006 |
Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Graft Rejection; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2006 |
A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Sensitivity and Specificity; Time Factors; Treatment Outcome; White People | 2007 |
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon Type I; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2006 |
Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Survival Analysis; Treatment Outcome | 2007 |
Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Weight; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Time Factors | 2007 |
Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2007 |
Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; DNA, Mitochondrial; Female; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2006 |
A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Maximum Tolerated Dose; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome | 2007 |
Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2008 |
Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: pilot study.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Recurrence; Ribavirin; Serologic Tests; Time Factors; Treatment Outcome | 2007 |
Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2008 |
Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Dropouts; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Renal Dialysis; Renal Insufficiency; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2008 |
A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Tolerance; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Pilot Projects; Recurrence; Ribavirin; RNA, Viral | 1996 |
Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience.
Topics: Antiviral Agents; Aspartate Aminotransferases; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon Type I; Italy; Liver; Male; Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Reference Values; Ribavirin; RNA, Viral | 1995 |
Hepatitis C recurrence in liver transplant recipients.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Drug Therapy, Combination; Follow-Up Studies; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Recurrence; Ribavirin; RNA, Viral; Survival Rate; Time Factors | 1997 |
Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo.
Topics: Antiviral Agents; Child; Child, Preschool; Female; Follow-Up Studies; Growth; Hospitalization; Humans; Male; Recurrence; Respiratory Syncytial Virus Infections; Respiratory Tract Infections; Ribavirin | 1997 |
A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation.
Topics: Adult; Aged; Aspartate Aminotransferases; Female; Hemolysis; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral | 1998 |
Ribavirin in hepatitis C related cryoglobulinemia.
Topics: Aged; Antiviral Agents; Cryoglobulinemia; DNA, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Transaminases; Treatment Outcome; Viral Load | 1998 |
Treatment of recurrent hepatitis C virus infection after liver transplantation with interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Middle Aged; Pilot Projects; Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 1998 |
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Double-Blind Method; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 1998 |
Outcome of long-term ribavirin therapy for recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Drug Administration Schedule; Female; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Transplantation; Treatment Outcome | 1999 |
Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
Topics: Adolescent; Alanine Transaminase; Antiviral Agents; Biopsy; Double-Blind Method; Drug Administration Routes; Drug Hypersensitivity; Drug Therapy, Combination; Female; Follow-Up Studies; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Leukocyte Count; Male; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Safety; Treatment Outcome | 1999 |
Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Quality of Life; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Surveys and Questionnaires; Treatment Outcome | 1999 |
Retreatment of non-responder or relapser chronic hepatitis C patients with interferon plus ribavirin vs interferon alone.
Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Statistics, Nonparametric; Treatment Failure; Treatment Outcome | 1999 |
Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis C, Chronic; Humans; Immunoblotting; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Failure; Treatment Outcome | 1999 |
TT virus infection in patients with chronic hepatitis C virus infection--effect of primers, prevalence, and clinical significance. Hepatitis Interventional Therapy Group.
Topics: Adult; Antiviral Agents; DNA Virus Infections; DNA Viruses; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Phylogeny; Polymerase Chain Reaction; Prevalence; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Retreatment; Ribavirin | 2000 |
Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Life Expectancy; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Survival Analysis; Treatment Outcome; United States | 2000 |
The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Male; Middle Aged; Prognosis; Recurrence; Remission Induction; Retreatment; Ribavirin; Treatment Outcome | 2000 |
Biochemical and virological changes in serum of nonresponder or relapser chronic hepatitis C patients retreated with interferon and ribavirin followed by interferon alone.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biomarkers; Drug Administration Routes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2000 |
Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months.
Topics: Adult; Anti-Bacterial Agents; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2000 |
Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Load | 2000 |
HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin.
Topics: Adult; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Treatment Outcome | 2000 |
Interferon Alfa-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Cause of Death; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Survival Rate; Time Factors; Treatment Outcome | 2000 |
The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Quality of Life; Recombinant Proteins; Recurrence; Ribavirin | 2001 |
Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Drug Resistance; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Male; Middle Aged; Recurrence; Retreatment; Ribavirin; RNA, Viral | 2001 |
Interferon-alpha2a/ribaviran versus interferon-alpha2a alone for the retreatment of hepatitis C patients who relapse after a standard course of interferon.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Recurrence; Retreatment; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral | 2001 |
Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
Topics: Administration, Oral; Adult; Antiviral Agents; Chi-Square Distribution; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Middle Aged; Probability; Recurrence; Ribavirin; Treatment Outcome | 2001 |
Prolonged interferon treatment after combination interferon and ribavirin therapy in patients with chronic hepatitis C: a clinical trial of interferon relapsers and non-responders.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Viral Load | 2001 |
Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome | 2002 |
413 other study(ies) available for ribavirin and Recrudescence
| Article | Year |
|---|---|
A comprehensive characterization of chronic norovirus infection in immunodeficient hosts.
Topics: Adult; Antigens, CD19; Antiviral Agents; B-Lymphocytes; Caliciviridae Infections; Cells, Cultured; Common Variable Immunodeficiency; Enterocolitis; Female; Humans; Immunocompromised Host; Male; Middle Aged; Nitro Compounds; Norovirus; Programmed Cell Death 1 Receptor; Recurrence; Ribavirin; Species Specificity; T-Lymphocytes; Thiazoles; Treatment Outcome; Up-Regulation | 2019 |
The challenge of chronic hepatitis E in liver transplant recipients: Failure of sofosbuvir plus ribavirin therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Burkitt Lymphoma; Common Variable Immunodeficiency; Drug Therapy, Combination; Fatal Outcome; Focal Nodular Hyperplasia; Hepatitis E; Hepatitis E virus; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Kidney Transplantation; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir | 2020 |
Direct-acting antivirals ability to clear intestinal HCV-RNA in liver transplant patients.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir | 2020 |
Repeated COVID-19 relapse during post-discharge surveillance with viral shedding lasting for 67 days in a recovered patient infected with SARS-CoV-2.
Topics: Aftercare; COVID-19; COVID-19 Drug Treatment; Female; Hospitalization; Humans; Lopinavir; Middle Aged; Patient Discharge; Recurrence; Ribavirin; RNA, Viral; SARS-CoV-2; Thorax; Virus Shedding | 2021 |
Recurrent Chronic HEV in Severe Combined Immunodeficiency.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Chronic Disease; Female; Hepatitis E; Hepatitis E virus; Humans; Immunoglobulin G; Immunoglobulin M; Janus Kinase 3; Recurrence; Ribavirin; RNA, Viral; Severe Combined Immunodeficiency; T-Lymphocytes | 2021 |
Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2021 |
Recurrent Mixed Cryoglobulinemia Despite Sustained Virologic Response to Treatment: A Case Report.
Topics: Antiviral Agents; Cryoglobulinemia; Hepatitis C; Humans; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
Sofosbuvir-Daclatasvir-Simeprevir Plus Ribavirin in Direct-Acting Antiviral-Experienced Patients With Hepatitis C.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Rising relapse rate in hepatitis C virus type 3a-infected patients against sofosbuvir and ribavirin combination therapy: a Pakistani experience.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sofosbuvir; Treatment Failure | 2017 |
Hepatitis B virus reactivation after effective sofosbuvir and ribavirin treatment in a patient with occult hepatitis B virus infection.
Topics: Aged; Anti-Inflammatory Agents; Antiviral Agents; Cryoglobulinemia; DNA, Viral; Female; Guanine; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Immunologic Factors; Prednisolone; Recurrence; Ribavirin; Rituximab; Sofosbuvir; Viral Load | 2017 |
Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse.
Topics: Adult; Antiviral Agents; Drug Users; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antigens; Humans; Immunoassay; Male; Middle Aged; Molecular Diagnostic Techniques; Recurrence; Ribavirin; RNA, Viral; Sensitivity and Specificity; Sustained Virologic Response; Treatment Outcome; Viral Core Proteins; Viral Load; Viremia | 2017 |
Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Secondary Prevention; Transplant Recipients; Treatment Outcome | 2017 |
Editorial: is ribavirin needed in the treatment of post-transplant hepatitis C recurrence?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Recombinant Proteins; Recurrence; Ribavirin | 2017 |
Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Sustained Virologic Response; Taiwan; Viral Load; Young Adult | 2018 |
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes.
Topics: Analysis of Variance; Antiviral Agents; Cohort Studies; Compassionate Use Trials; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Italy; Liver Cirrhosis; Liver Function Tests; Logistic Models; Male; Multivariate Analysis; Prognosis; Recurrence; Ribavirin; Risk Assessment; Severity of Illness Index; Sofosbuvir; Treatment Outcome | 2017 |
The Absence of HCV RNA and NS5A Protein in Peripheral Blood Mononuclear Cells Is a Prognostic Tool for Sustained Virological Response.
Topics: Adult; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Pakistan; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2017 |
Predictors of hepatitis C virus recurrence after living donor liver transplantation: Mansoura experience.
Topics: Adult; Age Factors; Antiviral Agents; Cold Ischemia; Drug Therapy, Combination; Female; Graft Survival; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Warm Ischemia; Young Adult | 2017 |
Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Imidazoles; Italy; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prognosis; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Valine | 2018 |
Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
Topics: Aged; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Sofosbuvir-ledipasvir with or without ribavirin for chronic hepatitis C genotype-1 and 6: real-world experience in Vietnam.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Patient Safety; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Uridine Monophosphate; Vietnam; Viral Load | 2018 |
The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Uridine Monophosphate; Virus Activation | 2018 |
HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era.
Topics: 2-Naphthylamine; Aged; Amino Acid Substitution; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoenzymes; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Polymorphism, Genetic; Proline; Recurrence; Ribavirin; Sulfonamides; Treatment Failure; Uracil; Valine; Viral Load; Viral Nonstructural Proteins | 2018 |
Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Diseases; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome | 2018 |
Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study.
Topics: Aged; Anemia; Antiviral Agents; Dizziness; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Male; Middle Aged; Protease Inhibitors; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2018 |
Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection.
Topics: Adult; Amino Acid Substitution; Antiviral Agents; Benzofurans; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; Follow-Up Studies; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Polymorphism, Genetic; Quinoxalines; Recurrence; Ribavirin; Serine Proteases; Treatment Failure; Viral Load; Viral Nonstructural Proteins | 2018 |
Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Liver Cirrhosis; Polymorphism, Genetic; Prospective Studies; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; United States; Uridine Monophosphate; Viral Load | 2018 |
Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
Topics: Adult; Aged; Antiviral Agents; Calcineurin Inhibitors; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Tacrolimus; Young Adult | 2019 |
HCV core antigen is a useful predictor during pegylated-interferon/ribavirin therapy in patients with hepatitis C virus genotype 1b.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; ROC Curve; Sustained Virologic Response; Treatment Outcome | 2019 |
Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2019 |
Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients.
Topics: Antiviral Agents; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sirolimus; Treatment Outcome; Virus Activation | 2013 |
Perspectives of a self-selected sample of former patients on the long-term health outcomes of interferon-based hepatitis C treatments: an exploratory study.
Topics: Adult; Aftercare; Anorexia; Antiviral Agents; Attitude of Health Personnel; Chronic Disease; Cognition Disorders; Depression; Female; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Neurotoxicity Syndromes; New South Wales; Patient Education as Topic; Qualitative Research; Quality of Life; Recurrence; Ribavirin; Sarcoidosis; Self Report; Severity of Illness Index; Treatment Outcome; Victoria | 2013 |
Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection.
Topics: Antibody-Dependent Cell Cytotoxicity; Antiviral Agents; Biomarkers; CD56 Antigen; GPI-Linked Proteins; Hepatitis C, Chronic; Humans; Immunity, Innate; Immunophenotyping; Interferon-alpha; Killer Cells, Natural; Natural Cytotoxicity Triggering Receptor 3; Perforin; Polyethylene Glycols; Pore Forming Cytotoxic Proteins; Prospective Studies; Receptors, IgG; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2013 |
Impact of conversion from pegylated interferon-α2b to interferon-α2a for treating recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2013 |
Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.
Topics: Antiviral Agents; Cost-Benefit Analysis; Decision Support Techniques; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Quality-Adjusted Life Years; Recurrence; Ribavirin; Treatment Outcome | 2013 |
Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Treatment Outcome | 2013 |
Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recurrence; Ribavirin; RNA, Viral; Young Adult | 2013 |
Sustained virological response: a milestone in the treatment of chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Biopsy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon alpha-2; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2013 |
Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Glucose Metabolism Disorders; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Kaplan-Meier Estimate; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2014 |
Interaction between calcineurin inhibitors and IL-28B rs12979860 C>T polymorphism and response to treatment for post-transplant recurrent hepatitis C.
Topics: Alleles; Antiviral Agents; Calcineurin Inhibitors; DNA; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2013 |
Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient.
Topics: Antiviral Agents; Cluster Analysis; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon-alpha; Male; Middle Aged; Phylogeny; Recurrence; Ribavirin; RNA, Viral; Sequence Analysis, DNA | 2013 |
Liver histology of chronic hepatitis C patients who relapsed or not responded to conventional interferon and ribavirin therapy.
Topics: Adult; Antiviral Agents; Biopsy; Female; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Male; Middle Aged; Recurrence; Ribavirin; Treatment Failure | 2013 |
Recurrent hepatitis C virus infection and outcome after living-donor liver transplant.
Topics: Adult; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Incidence; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2013 |
Treatment of chronic hepatitis C with protease inhibitor-based therapy after liver transplantation.
Topics: Antiviral Agents; Drug Interactions; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Treatment Outcome | 2013 |
Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Viral Load | 2013 |
Sustained virological response after treatment in patients with chronic hepatitis C infection--a five year follow up.
Topics: Adult; Antiviral Agents; Bangladesh; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2013 |
The end-of-treatment ribavirin concentration predicts hepatitis C virus relapse.
Topics: Adult; Antiviral Agents; Area Under Curve; Chromatography, Liquid; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Sensitivity and Specificity; Tandem Mass Spectrometry; Time Factors; Treatment Outcome | 2013 |
Long-term leukocyte natural α-interferon and ribavirin treatment in hepatitis C virus recurrence after liver transplantation.
Topics: Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Graft Survival; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Kaplan-Meier Estimate; Liver Transplantation; Logistic Models; Male; Middle Aged; Odds Ratio; Prospective Studies; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Virus Activation | 2013 |
[HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy].
Topics: Adult; Antiviral Agents; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load | 2013 |
Treatment of chronic hepatitis C in injecting drug users--a 5-year follow-up.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Recombinant Proteins; Recurrence; Ribavirin; Serbia; Substance Abuse, Intravenous; Treatment Outcome | 2013 |
Chronic rejection associated with antiviral therapy for recurrent hepatitis C after living-donor liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Female; Fibrosis; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Interferons; Liver Failure; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Female; Genetic Predisposition to Disease; Genotype; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polymorphism, Single Nucleotide; Recurrence; Ribavirin; Severity of Illness Index; Young Adult | 2013 |
Hepatitis C virus late relapse after sustained virologic response from interferon and ribavirin treatment as confirmed by RNA sequencing.
Topics: Cluster Analysis; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Middle Aged; Phylogeny; Recurrence; Ribavirin; RNA, Viral; Sequence Analysis, RNA; Sequence Homology; Viral Envelope Proteins; Viremia | 2014 |
Does chemotherapy cause viral relapse in cancer patients with hepatitis C infection successfully treated with antivirals?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin | 2014 |
Liver transplantation in a child with multifocal hepatocellular carcinoma hepatitis C and management of post-transplant viral recurrence using boceprevir.
Topics: Adolescent; Carcinoma, Hepatocellular; Child; Graft Survival; Hepatitis C; Humans; Interferons; Liver Neoplasms; Liver Transplantation; Male; Polyethylene Glycols; Postoperative Complications; Proline; Recurrence; Ribavirin; Severe Combined Immunodeficiency | 2014 |
Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2014 |
OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naive patients.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2014 |
Efficiency of second pegylated interferon and ribavirin combination treatment for the relapsed hepatitis C virus infection in low-income countries.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Poverty; Recurrence; Retreatment; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Turkey; Viral Load | 2014 |
Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Maintenance Chemotherapy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Survival Rate; Time Factors | 2014 |
Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation.
Topics: Antiviral Agents; Chromatography, Liquid; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Humans; Immunosuppression Therapy; Interferon-alpha; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Statistics, Nonparametric; Tacrolimus; Tandem Mass Spectrometry | 2015 |
Hepatitis C treatment & management.
Topics: Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Uridine Monophosphate | 2014 |
Boceprevir in liver transplant recipients.
Topics: Adult; Aged; Analysis of Variance; Creatinine; Drug Monitoring; Female; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Transplant Recipients | 2015 |
Telaprevir in treatment of recurrent hepatitis C infection in liver transplant recipients.
Topics: Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Time Factors; Treatment Outcome; Viral Load | 2014 |
ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type.
Topics: Adult; Aged; Anemia; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrophosphatases; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
Topics: Adult; Aged; Antiviral Agents; Female; Gene Expression Profiling; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interleukins; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; Transplant Recipients; Treatment Outcome; Young Adult | 2014 |
Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
Topics: Adult; Aged; Antiviral Agents; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Longitudinal Studies; Male; Middle Aged; Molecular Epidemiology; Prevalence; Recurrence; Ribavirin; Thailand; Treatment Outcome | 2014 |
Case report of successful treatment of fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin after liver transplantation.
Topics: Antiviral Agents; Biopsy; Cholestasis, Intrahepatic; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2014 |
Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Male; Recurrence; Ribavirin; Sequence Analysis, RNA; Treatment Failure; Viral Proteins | 2015 |
[Treatment of recurrent HCV infection after liver transplantation].
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Recurrence; Ribavirin; Survival Analysis; Treatment Outcome | 2013 |
Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Silybin; Silymarin | 2014 |
Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2015 |
Consensus guidelines for the management of hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Saudi Arabia | 2003 |
Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: a prospective cohort study.
Topics: Adult; Antiviral Agents; Coinfection; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation.
Topics: Aged; Antiviral Agents; Drug Combinations; Hepatitis C; Humans; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective.
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Waiting Lists | 2015 |
Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Feasibility Studies; Female; Genotype; Germany; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Oligopeptides; Recurrence; Retrospective Studies; Ribavirin; Tacrolimus; Time Factors; Treatment Outcome; Virus Activation | 2015 |
Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse.
Topics: Adult; Aged; Antiviral Agents; Feces; Female; Hepatitis E; Hepatitis E virus; Humans; Male; Middle Aged; Organ Transplantation; Recurrence; Ribavirin; Treatment Outcome; Virus Shedding | 2015 |
Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus-coinfected liver transplant recipients.
Topics: Antiviral Agents; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2015 |
Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study.
Topics: Aged; Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Time Factors; Transplant Recipients; Treatment Outcome | 2015 |
Do variations in the ITPA gene determine the risk of hepatitis C virus relapse?
Topics: Hepacivirus; Hepatitis C, Chronic; Humans; Polymorphism, Genetic; Pyrophosphatases; Recurrence; Ribavirin | 2014 |
Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infect
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Recurrence; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine; Viral Load | 2015 |
Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation.
Topics: Adult; Antiviral Agents; Coinfection; Cyclosporine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Tacrolimus; Viral Load | 2015 |
Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful?
Topics: Administration, Oral; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Recurrence; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation.
Topics: Adult; Aged; Analysis of Variance; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2015 |
Retreatment with peginterferon and ribavirin in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2015 |
Incidence and antiviral response of hepatitis C virus reactivation in lupus patients undergoing immunosuppressive therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Glucocorticoids; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Incidence; Interferon-alpha; Lupus Erythematosus, Systemic; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load; Virus Activation | 2015 |
Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant.
Topics: Aged; Antiviral Agents; Female; Genotype; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate | 2015 |
Genotypes of hepatitis C virus in relapsed and non-respondent patients and their response to anti-viral therapy in district Mardan, Khyber Pakhtunkhawa, Pakistan.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Pakistan; Prognosis; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Young Adult | 2015 |
[Overwhelming postsplenectomy infection during combination therapy with interferon ribavirin after living donor liver transplantation for hepatitis C: a case report].
Topics: Critical Care; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Liver Transplantation; Living Donors; Middle Aged; Pneumococcal Infections; Postoperative Complications; Recurrence; Ribavirin; Splenectomy | 2015 |
Responses to peginterferon alfa-2a vs alfa-2b plus ribavirin in a Mexican population with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Blood Chemical Analysis; Cohort Studies; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mexico; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Survival Rate | 2015 |
Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
Topics: Adult; Allografts; Antiviral Agents; Biopsy; Cholestasis, Intrahepatic; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Liver Cirrhosis; Liver Transplantation; Living Donors; Male; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome | 2014 |
Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.
Topics: Antiviral Agents; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Preoperative Care; Recurrence; Reoperation; Ribavirin; Sofosbuvir | 2015 |
Triple therapy using direct-acting agents for recurrent hepatitis C after liver transplantation: a single-center experience.
Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Simeprevir; Treatment Outcome | 2015 |
Mycophenolate mofetil may induce prolonged severe anemia during pegylated-interferon/ribavirin/simeprevir therapy in liver transplant recipients.
Topics: Aged; Anemia; Antiviral Agents; Erythrocyte Transfusion; Female; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Middle Aged; Mycophenolic Acid; Recurrence; Ribavirin; Simeprevir; Tacrolimus | 2015 |
Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; Young Adult | 2015 |
Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Valine; Viral Load; Viremia | 2015 |
Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus.
Topics: Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Male; Middle Aged; New York City; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; Time Factors; Treatment Outcome; Viral Load; Virus Activation | 2015 |
Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Survival Rate; Treatment Outcome; Viral Load | 2015 |
Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure.
Topics: Aged; Antiviral Agents; Carrier Proteins; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Japan; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Simeprevir; Treatment Failure; Viral Nonstructural Proteins | 2015 |
Successful treatment with telaprevir of post-transplant fibrosing cholestatic hepatitis C in an HIV co-infected patient.
Topics: Adult; Antiviral Agents; Cholestasis, Intrahepatic; Coinfection; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Oligopeptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2015 |
Clinical decompensation after achieving SVR with sofosbuvir, daclatasvir and ribavirin in a patient with recurrent HCV post-liver transplant.
Topics: Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Hepatitis B virus; Hepatitis C; Humans; Imidazoles; Liver Transplantation; Male; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Valine; Viral Load; Virus Activation | 2015 |
Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Cholestasis, Intrahepatic; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Survival; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Matched-Pair Analysis; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2015 |
Treatment Outcomes and Predictors of Response in Treatment-Naive HCV Patients Treated with Peginterferon Alfa/Ribavirin in Real-World Italian Clinics: Sub-Analysis from the PROPHESYS Cohort.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Databases, Factual; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Italy; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; Time Factors; Treatment Outcome; White People; Young Adult | 2014 |
Treatment of autochthonous acute hepatitis E with short-term ribavirin: a multicenter retrospective study.
Topics: Acute Disease; Aged; Aged, 80 and over; Antiviral Agents; Drug Administration Schedule; Female; France; Genotype; Hepatitis E; Hepatitis E virus; Humans; Immunocompromised Host; Male; Middle Aged; Opportunistic Infections; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2016 |
Sofosbuvir-based therapy cures hepatitis C virus infection after prior treatment failures in a patient with concurrent lymphoma.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Recurrence; Ribavirin; Sofosbuvir; Time Factors; Treatment Failure; Treatment Outcome | 2015 |
Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.
Topics: Antiviral Agents; Asia; Asian People; Australia; Biomarkers; Chi-Square Distribution; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Proline; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Failure; Viral Load; White People | 2015 |
Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients.
Topics: Adult; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Young Adult | 2016 |
The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection.
Topics: Adult; Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Sensitivity and Specificity; Treatment Outcome; Young Adult | 2015 |
Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Cholesterol; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Recurrence; Ribavirin; Sofosbuvir | 2016 |
Interferon-Free Sofosbuvir-Based Anti-HCV Therapy After Liver Transplantation.
Topics: Antiviral Agents; Female; Graft Survival; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2015 |
Genotype 3 and higher low-density lipoprotein levels are predictors of good response to treatment of recurrent hepatitis C following living donor liver transplantation.
Topics: Antiviral Agents; Female; Follow-Up Studies; Forecasting; Genotype; Hepatitis C; Humans; Interferon-alpha; Lipoproteins, LDL; Liver Transplantation; Living Donors; Male; Middle Aged; Recurrence; Ribavirin; Time Factors; Treatment Failure; Treatment Outcome | 2015 |
Hepatitis C Virus Deletion Mutants Are Found in Individuals Chronically Infected with Genotype 1 Hepatitis C Virus in Association with Age, High Viral Load and Liver Inflammatory Activity.
Topics: Adult; Age Factors; Aged; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Polyethylene Glycols; Prevalence; Recombinant Proteins; Recurrence; Ribavirin; Sequence Deletion; Viral Envelope Proteins; Viral Load; Viral Proteins | 2015 |
Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Costs; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Economic; Phenotype; Proline; Recurrence; Ribavirin; Risk Factors; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; United States; Uracil; Valine; Viral Load; Virus Activation | 2016 |
Consensus Interferon for Recurrent Hepatitis C Infection in Nonresponders to Peginterferon and Ribavirin After Liver Transplant.
Topics: Antiviral Agents; Hepatitis C; Humans; Interferons; Liver Transplantation; Recurrence; Ribavirin | 2015 |
Analysis of the Enzymatic Activity of an NS3 Helicase Genotype 3a Variant Sequence Obtained from a Relapse Patient.
Topics: Antiviral Agents; Binding Sites; Biocatalysis; Cell Line, Tumor; DNA; DNA Helicases; Escherichia coli; Genotype; Hepacivirus; Hepatitis C; Host-Pathogen Interactions; Humans; Interferon-alpha; Middle Aged; Mutation, Missense; Recombinant Proteins; Recurrence; Ribavirin; RNA; Viral Nonstructural Proteins; Virus Replication | 2015 |
Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Canada; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Young Adult | 2016 |
Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Topics: Aged; Antiviral Agents; Carbamates; Compassionate Use Trials; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Diseases; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Patient Safety; Polymorphism, Genetic; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome | 2016 |
Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Viral Load | 2017 |
Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.
Topics: Aged; Antiviral Agents; Biopsy; Canada; Creatinine; Female; Fibrosis; Genotype; Glomerular Filtration Rate; Hepatitis C; Humans; Interferons; Kidney; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir | 2016 |
Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C; Humans; Kaplan-Meier Estimate; Liver Failure; Liver Transplantation; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Recurrence; Ribavirin; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome; Virus Activation | 2016 |
Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience.
Topics: Adolescent; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Young Adult | 2016 |
[Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sensitivity and Specificity; Sustained Virologic Response; Tandem Mass Spectrometry; Treatment Outcome; Viral Load | 2016 |
[Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy].
Topics: Anti-Retroviral Agents; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Immunotherapy; Interferon-alpha; Male; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Standard of Care; Sustained Virologic Response; Treatment Outcome; Viral Load | 2016 |
Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Transplant Recipients; Treatment Outcome; Valine | 2016 |
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Middle Aged; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Treatment Failure | 2016 |
Safety and effectiveness of response-guided therapy using pegylated interferon and ribavirin for chronic hepatitis C virus infection in patients on maintenance dialysis.
Topics: Adolescent; Adult; Antiviral Agents; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Renal Dialysis; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2017 |
Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Liver Cirrhosis; Male; Middle Aged; Prognosis; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Sofosbuvir; Treatment Failure; Uridine Monophosphate | 2017 |
Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis.
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2017 |
Nursing Problems in Care of a Patient with Very Early HCV Infection Recurrence After Liver Transplantation: A Case Report.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Liver Failure; Liver Transplantation; Oligopeptides; Postoperative Complications; Recurrence; Reoperation; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2016 |
Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C.
Topics: Antigens, Viral; Antiviral Agents; Automation; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunoassay; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Reagent Kits, Diagnostic; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2016 |
Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.
Topics: Aged; Antiviral Agents; Benzimidazoles; Calcineurin Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Liver Transplantation; Male; Middle Aged; Pragmatic Clinical Trials as Topic; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2016 |
Porphyrin Elevation in a Patient on Treatment With Simeprevir: Could It Be a Possible Explanation for Simeprevir-Associated Photosensitivity?
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Graft Rejection; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Photosensitivity Disorders; Porphyrins; Recurrence; Ribavirin; Simeprevir; Sofosbuvir | 2016 |
Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2017 |
Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Limit of Detection; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load; Virus Replication | 2017 |
Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Postoperative Period; Preoperative Period; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2017 |
Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir | 2017 |
Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Biliary Atresia; Budd-Chiari Syndrome; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Infant; Liver; Liver Cirrhosis; Liver Transplantation; Male; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate | 2017 |
Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2017 |
Hepatitis C "true" late relapse beyond 48weeks of sustained virologic response after direct acting antiviral therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Recurrence; Ribavirin; Sustained Virologic Response; Treatment Outcome | 2017 |
Filling the gap between clinical trials and real life in the treatment of severe HCV recurrence after liver transplantation.
Topics: Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Recurrence; Ribavirin | 2017 |
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.
Topics: Aged; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Italy; Male; Middle Aged; Mutation; Recurrence; Ribavirin; Sequence Analysis, DNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins | 2017 |
Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Transplantation; Living Donors; Male; Middle Aged; Postoperative Period; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Nonstructural Proteins | 2017 |
Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sweden; Treatment Outcome; Valine | 2017 |
Liver transplantation for fulminant genotype 2a/c hepatitis C virus marked by a rapid recurrence followed by cure.
Topics: Acute Disease; Administration, Oral; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Liver Failure, Acute; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Risk Factors; Sofosbuvir; Valine | 2017 |
Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia.
Topics: Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome | 2017 |
Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
Topics: Adult; Antiviral Agents; Biopsy; Dose-Response Relationship, Drug; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Graft Survival; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Survival Analysis; Treatment Outcome | 2008 |
Recurrence of HCV infection in a sustained responder after chemotherapy for non-Hodgkin's lymphoma: successful retreatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2008 |
Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Weight; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Hispanic or Latino; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; Treatment Outcome | 2008 |
Impact of pegylated interferon and ribavirin treatment on graft survival in liver transplant patients with recurrent hepatitis C infection.
Topics: Antiviral Agents; Female; Graft Rejection; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Proportional Hazards Models; Recombinant Proteins; Recurrence; Regression Analysis; Ribavirin; Risk; Treatment Outcome | 2008 |
HCV RNA in peripheral blood cell subsets in HCV-HIV coinfected patients at the end of PegIFN/RBV treatment is associated with virologic relapse.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Leukocytes, Mononuclear; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral | 2009 |
High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
Topics: Antiviral Agents; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Nucleosides; Polyethylene Glycols; Prodrugs; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2008 |
Peginterferon plus Ribavirin for chronic hepatitis C in opiate addicts on methadone/buprenorphine maintenance therapy.
Topics: Adolescent; Adult; Antiviral Agents; Buprenorphine; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Methadone; Middle Aged; Narcotics; Patient Compliance; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Substance Abuse, Intravenous; Treatment Outcome; Young Adult | 2009 |
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Viremia | 2009 |
[Protocol for the antiviral therapy of chronic hepatitis C].
Topics: Algorithms; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2008 |
IFNalpha-induced recurrence of Graves' disease ten years after thyroidectomy in chronic viral hepatitis C. Case report.
Topics: Antiviral Agents; Drug Therapy, Combination; Graves Disease; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Thyroidectomy; Thyrotoxicosis; Thyrotropin; Thyroxine | 2008 |
Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation.
Topics: Adult; Antiviral Agents; Body Weight; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin | 2009 |
[Treatment with pegylated interferon and ribavirin in a patient with fibrosing cholestatic hepatitis due to recurrent hepatitis C after liver transplantation].
Topics: Antiviral Agents; Cholestasis, Intrahepatic; Combined Modality Therapy; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Tomography, X-Ray Computed | 2008 |
Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy.
Topics: Adult; Antiviral Agents; Dialysis; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2009 |
IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection.
Topics: Adult; Antiviral Agents; Biomarkers; Chemokine CXCL10; Dose-Response Relationship, Drug; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Inflammation; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Sensitivity and Specificity; Viral Load | 2008 |
Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.
Topics: Adult; Aged; Antiviral Agents; Bacterial Infections; Carcinoma, Hepatocellular; Female; Hepatitis C; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Peritonitis; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Safety; Time Factors; Viral Load; Waiting Lists; Young Adult | 2009 |
Re-treatment with peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy.
Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2009 |
[Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Viremia | 2009 |
Elevations in alanine aminotransferase levels late in the course of antiviral therapy in hepatitis C virus RNA-negative patients are associated with virological relapse.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2009 |
Treatment for recurrent hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Biopsy; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Viral Load | 2009 |
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin.
Topics: Aged; Antiviral Agents; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2009 |
Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation.
Topics: Antiviral Agents; Case-Control Studies; Female; Graft Survival; Hepatitis C; Humans; Interferon Type I; Kaplan-Meier Estimate; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome | 2009 |
Sustained virologic response following HCV eradication in two brothers with X-linked agammaglobulinaemia.
Topics: Adult; Agammaglobulinemia; Antiviral Agents; Comorbidity; Drug Contamination; Genetic Diseases, X-Linked; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Recurrence; Ribavirin; Siblings | 2009 |
Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Probability; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment; ROC Curve; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome; Viral Load | 2010 |
Maintenance ribavirin monotherapy delays fibrosis progression in liver transplant recipients with recurrent hepatitis C at high risk of progression.
Topics: Antiviral Agents; Disease Progression; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Prospective Studies; Recurrence; Ribavirin | 2010 |
Peginterferon alfa-2b or alfa-2a with ribavirin for hepatitis C.
Topics: Antiviral Agents; Asian People; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Recurrence; Ribavirin | 2009 |
Lack of killer immunoglobulin-like receptor 2DS2 (KIR2DS2) and KIR2DL2 is associated with poor responses to therapy of recurrent hepatitis C virus in liver transplant recipients.
Topics: Antiviral Agents; Bacterial Infections; Drug Resistance, Viral; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Receptors, KIR; Receptors, KIR2DL2; Recombinant Proteins; Recurrence; Ribavirin | 2009 |
[The study of optimal treatment in patients with refractory chronic hepatitis C].
Topics: Administration, Cutaneous; Administration, Oral; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load | 2009 |
[Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Antiviral Agents; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2009 |
Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Body Mass Index; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2010 |
Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antiviral Agents; Drug Tolerance; Female; Follow-Up Studies; Genotype; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Survival Rate; Tacrolimus; Time Factors; Tissue Donors; Treatment Outcome | 2009 |
The benefits of interferon treatment in patients without sustained viral response after living donor liver transplantation for hepatitis C.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Female; Genotype; Graft Survival; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Living Donors; Male; Middle Aged; Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Survival Rate | 2009 |
What now? Responding to relapse in hepatitis C.
Topics: Alcohol Drinking; Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Nurse Practitioners; Patient Education as Topic; Polyethylene Glycols; Primary Health Care; Recombinant Proteins; Recurrence; Referral and Consultation; Ribavirin; Risk Factors; United States; Viral Load | 2007 |
Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2010 |
Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2010 |
[Peginterferon-alfa-2b or -alfa-2a and ribavirin combined treatment in hepatitis C infection].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; United States; Viral Load | 2010 |
Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: Reversion by anti-viral treatment.
Topics: Antimicrobial Cationic Peptides; Antiviral Agents; Cell Degranulation; Cytokines; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Killer Cells, Natural; Lymphocyte Count; Peptides; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2010 |
Maintenance ribavirin monotherapy: the case for post-transplantation recurrent hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Immunocompromised Host; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin | 2010 |
[Retreatment options for patients with chronic hepatitis C].
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; RNA, Viral | 2009 |
[Treatment of recurrent hepatitis C infection after liver transplantation].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2009 |
[Treatment of relapsers].
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2005 |
Identifying HCV genotype 1 patients at risk of relapse.
Topics: Adult; Age Distribution; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; White People | 2010 |
Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Regression Analysis; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2010 |
Hepatitis C virus recurrence after liver transplantation: analysis of factors related to sustained viral response.
Topics: Adult; Antiviral Agents; Drug Tolerance; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viral Load | 2010 |
Treating hepatitis C in patients with cirrhosis: the effort is worth it.
Topics: Antiviral Agents; Disease Progression; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reproducibility of Results; Ribavirin; Treatment Outcome | 2010 |
Are viral or host factors predictive of response to interferon-ribavirin in transplant patients with hepatitis C?
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Multivariate Analysis; Mutation; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Reoperation; Ribavirin | 2010 |
Flexible and individualized treatment to achieve sustained viral response for recurrent hepatitis C in liver transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Drug Monitoring; Drug Therapy; Female; Follow-Up Studies; Hepatitis C; Humans; Interferons; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Transplantation; Treatment Outcome; Viral Load | 2010 |
Transient reappearance of serum hepatitis C virus RNA observed by real-time PCR during antiviral therapy with peginterferon and ribavirin: Reappearance of references published in 2005-2009.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Serum | 2010 |
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.
Topics: Antiviral Agents; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Predictive Value of Tests; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Load; Viremia | 2010 |
Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2010 |
Antiviral treatment of chronic hepatitis C in clinical routine.
Topics: Adult; Antiviral Agents; Austria; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2010 |
[Retreatment with peginterferon plus ribavirin in chronic hepatitis C patients: our own experiences].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Ribavirin | 2010 |
An economic analysis of antiviral therapy in patients with advanced hepatitis C virus disease: still not there!
Topics: Antiviral Agents; Cost Savings; Decision Support Techniques; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Markov Chains; Patient Selection; Quality-Adjusted Life Years; Recurrence; Ribavirin; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2010 |
Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Topics: Antiviral Agents; Carcinoma, Hepatocellular; Cost Savings; Decision Support Techniques; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Genotype; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Markov Chains; Middle Aged; Patient Selection; Quality-Adjusted Life Years; Recurrence; Ribavirin; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Viral Load | 2010 |
Genetic and biochemical diversity in the HCV NS5B RNA polymerase in the context of interferon α plus ribavirin therapy.
Topics: Antiviral Agents; DNA-Directed RNA Polymerases; Drug Therapy, Combination; Genetic Variation; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Recurrence; Ribavirin; RNA-Binding Proteins; RNA, Viral; Viral Nonstructural Proteins | 2011 |
Risk factors for relapse in chronic hepatitis C patients who have achieved end of treatment response.
Topics: Adult; Age Factors; Antiviral Agents; Biopsy; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Logistic Models; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Republic of Korea; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Prevalence; Prisoners; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; South Australia; Substance Abuse, Intravenous; Time Factors; Treatment Outcome; Viral Load | 2010 |
Reinfection with hepatitis C virus following sustained virological response in injection drug users.
Topics: Adult; Antiviral Agents; British Columbia; Community Health Centers; Drug Therapy, Combination; Drug Users; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Remission, Spontaneous; Ribavirin; RNA, Viral; Substance Abuse, Intravenous; Time Factors; Treatment Outcome; Viral Load | 2010 |
[Reactivation of tuberculosis during dual therapy with pegylated interferon and ribavirin for chronic hepatitis C].
Topics: Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Virus Activation | 2010 |
Is the interferon-α-triggered depressive episode a self-limited kind of depression? Four cases of persistent affective symptoms after antiviral treatment in HCV-infected individuals.
Topics: Antiviral Agents; Depressive Disorder, Major; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Hospitals, University; Humans; Interferon alpha-2; Interferon-alpha; Long-Term Care; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Substance Withdrawal Syndrome | 2010 |
Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus.
Topics: Amino Acid Sequence; Antiviral Agents; Female; Hepacivirus; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Molecular Sequence Data; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins | 2010 |
Rapid prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48h after the start of treatment with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA Stability; RNA, Viral; Treatment Outcome | 2010 |
Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
Topics: Adult; Antiviral Agents; Drug Carriers; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Polymorphism, Genetic; Recombinant Proteins; Recurrence; Ribavirin; RNA, Messenger; RNA, Viral; Tissue Donors; Treatment Outcome | 2010 |
Treatment of recurrent hepatitis C post-liver transplantation.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Graft Survival; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Practice Guidelines as Topic; Recurrence; Ribavirin; Treatment Outcome | 2010 |
Aggressive use of ribavirin and prolonged course of peginterferon to improve the rate of viral response in liver transplant patients with recurrent hepatitis C viral infection.
Topics: Adult; Antiviral Agents; Blood Transfusion; Drug Administration Schedule; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Genotype; Hematinics; Hemolysis; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Pennsylvania; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
How sustained is sustained viral response in patients with hepatitis C virus infection?
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Life Tables; Liver Cirrhosis; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2010 |
Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses.
Topics: Adult; Aged; Cohort Studies; Cross-Sectional Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Antibodies; Hepatitis C Antigens; Hepatitis C, Chronic; Humans; Immunity, Cellular; Interferons; Limit of Detection; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; T-Lymphocytes | 2011 |
Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C.
Topics: Aged; Antiviral Agents; Chicago; Drug Therapy, Combination; Female; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Liver Transplantation; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.
Topics: Adult; Antiviral Agents; China; Drug Evaluation; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2011 |
Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Young Adult | 2012 |
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Tissue Donors; Treatment Outcome | 2011 |
Human cytomegalovirus infection inhibits response of chronic hepatitis-C-virus-infected patients to interferon-based therapy.
Topics: Adult; Antibodies, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; Disease Progression; DNA, Viral; Drug Therapy, Combination; Egypt; Female; Genotype; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Envelope Proteins; Viral Load; Virus Activation | 2011 |
Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study.
Topics: Adult; Antiviral Agents; Biopsy; Drug Therapy, Combination; Egypt; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Liver; Logistic Models; Male; Middle Aged; Nitric Oxide; Nitric Oxide Synthase Type II; Odds Ratio; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Risk Assessment; Risk Factors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2010 |
Hepatitis C recurrence: influence of serum cholesterol levels and liver steatosis on antiviral therapy.
Topics: Antiviral Agents; Body Mass Index; Cholesterol; Fatty Liver; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Triglycerides; Viral Load | 2011 |
Treatment of genotype 4 hepatitis C recurring after liver transplantation using a combination of pegylated interferon alfa-2a and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2011 |
Clinicopathological features of hepatitis C virus disease after living donor liver transplantation: relationship with in situ hybridisation data.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Drug Therapy, Combination; End Stage Liver Disease; Female; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Immunosuppressive Agents; In Situ Hybridization; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin | 2011 |
Hepatitis C virus genotypes circulating in district Swat of Khyber Pakhtoonkhaw, Pakistan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Child; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Male; Middle Aged; Pakistan; Prevalence; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Young Adult | 2011 |
Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Mutation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Core Proteins; Viral Load | 2011 |
The use of psychoeducation for a patient with hepatitis C and psychiatric illness in preparation for antiviral therapy: a case report and discussion.
Topics: Adaptation, Psychological; Alcoholism; Antiviral Agents; Awareness; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Middle Aged; Patient Education as Topic; Problem Solving; Psychotherapy; Psychotherapy, Group; Recombinant Proteins; Recurrence; Ribavirin; Social Support; Substance Abuse, Intravenous; Suicidal Ideation | 2011 |
Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Area Under Curve; Decision Support Techniques; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; ROC Curve; Time Factors; Treatment Failure; Viral Load | 2011 |
Five-year follow-up of patients with chronic C hepatitis and sustained virological response.
Topics: Adult; Antiviral Agents; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2011 |
Ribavirin concentration in the later stages of 48 week pegylated interferon-alpha2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response.
Topics: Adult; Aged; Antiviral Agents; Chromatography, High Pressure Liquid; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Serum; Treatment Outcome; Viral Load | 2011 |
Role of ribavirin in hepatitis flare in HCV-infected patients with B cell non Hodgkin's lymphoma treated with rituximab-containing regimens.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antiviral Agents; Female; Hepatitis C; Humans; Immunologic Factors; Lymphoma, B-Cell; Male; Middle Aged; Recurrence; Ribavirin; Rituximab | 2011 |
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients.
Topics: Aged; Analysis of Variance; Antiviral Agents; Asian People; Chi-Square Distribution; Drug Therapy, Combination; Female; Gene Frequency; Hepacivirus; Hepatitis C; Heterozygote; Homozygote; Humans; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Pharmacogenetics; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Recurrence; Republic of Korea; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2011 |
[Durability of sustained virologic response in chronic hepatitis C: analysis of factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral | 2011 |
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Polymorphism, Genetic; Recombinant Proteins; Recurrence; Ribavirin | 2011 |
Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Biomarkers; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Silybin; Silymarin; Time Factors; Treatment Failure; Viral Load | 2011 |
Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retreatment; Retrospective Studies; Ribavirin; Treatment Outcome; United States; United States Department of Veterans Affairs; Viral Load | 2011 |
Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Drug Therapy, Combination; False Negative Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Japan; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Predictive Value of Tests; Real-Time Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2012 |
Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Asian People; Child; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Young Adult | 2011 |
Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Chi-Square Distribution; Drug Therapy, Combination; Female; Gene Frequency; Haplotypes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Patient Selection; Phenotype; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Spain; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2012 |
Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin.
Topics: Adult; Aged; Anemia, Hemolytic; Antiviral Agents; Creatinine; Drug Administration Schedule; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Inosine Triphosphatase; Interferon-alpha; Male; Medication Adherence; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Pyrophosphatases; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2011 |
Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Polymerase Chain Reaction; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Young Adult | 2011 |
Achievement of sustained viral response after switching treatment from pegylated interferon α-2b to α-2a and ribavirin in patients with recurrence of hepatitis C virus genotype 1 infection after liver transplantation: a case report.
Topics: Amino Acid Substitution; Antiviral Agents; Drug Therapy; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sequence Deletion; Treatment Outcome; Viral Load | 2012 |
Complete early virological response was highly achieved by double filtration plasmapheresis plus IFN-beta induction therapy for HCV-1b patients with relapse or no response after previous IFN therapy.
Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Female; Filtration; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Ribavirin priming improves the virological response to antiviral treatment in transplanted patients with recurrent hepatitis C: a pilot study.
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferons; Liver Transplantation; Male; Middle Aged; Pilot Projects; Premedication; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2011 |
IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferons; Interleukins; Male; Middle Aged; Polymorphism, Genetic; Recurrence; Ribavirin; Survival Analysis; Treatment Outcome | 2011 |
Importance of minimal residual viremia for relapse prediction in patients with chronic hepatitis C genotype 1 infection.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Assessment; Viral Load; Viremia | 2011 |
Pegylated interferon-α monotherapy leads to low response rates in HIV-infected patients with acute hepatitis C.
Topics: Adult; Alleles; Antiviral Agents; Cohort Studies; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Biomarkers; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Factors; RNA, Viral; Substance Abuse, Intravenous; Superinfection; Treatment Outcome | 2012 |
Very low viral load (VLVL) relapse following treatment of naïve patients with chronic hepatitis C.
Topics: Adult; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Intravenous silibinin as 'rescue treatment' for on-treatment non-responders to pegylated interferon/ribavirin combination therapy.
Topics: Adult; Antioxidants; Antiviral Agents; Austria; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Injections, Intravenous; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Silybin; Silymarin; Treatment Outcome; Viral Load; Virus Replication | 2011 |
Double-Filtration Plasmapheresis plus Interferon-β for HCV-1b Patients with Non-Sustained Virological Response to Previous Combination Therapy.
Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-beta; Interferons; Interleukins; Male; Middle Aged; Plasmapheresis; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
Topics: Aged; Antiviral Agents; Biomarkers; Biopsy; Drug Therapy, Combination; Female; Germany; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2011 |
Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Models, Statistical; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment; Sensitivity and Specificity; Treatment Outcome; Viral Load | 2012 |
Treatment and follow up of children with chronic hepatitis C in Albania.
Topics: Administration, Oral; Adolescent; Albania; Antiviral Agents; Child; Child, Preschool; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
Topics: Adult; Aged; Antiviral Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Longitudinal Studies; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Quality of Life; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2012 |
Influence of HLA alleles in response to treatment with pegylated interferon-alpha and ribavirin in patients with chronic hepatitis C.
Topics: Adult; Alleles; Drug Therapy, Combination; Female; Follow-Up Studies; Genes, MHC Class I; Genes, MHC Class II; Genotype; Hepacivirus; Hepatitis C, Chronic; Histocompatibility Testing; HLA-DRB1 Chains; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
Hepatic Methionine-enkephalin may interfere with response to antiviral therapy in chronic hepatitis C.
Topics: Adult; Antiviral Agents; Biomarkers; Drug Therapy, Combination; Enkephalin, Methionine; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Receptors, Opioid, delta; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Failure | 2012 |
Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Patient Compliance; Polyethylene Glycols; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Sex Factors; Treatment Outcome; Viral Load | 2012 |
Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Confidence Intervals; Donor Selection; End Stage Liver Disease; Female; Genetic Testing; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Liver Transplantation; Logistic Models; Male; Middle Aged; Odds Ratio; Polyethylene Glycols; Polymorphism, Single Nucleotide; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.
Topics: Aged; Analysis of Variance; Antiviral Agents; Dose-Response Relationship, Drug; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome; Viral Load | 2012 |
Tuberculosis screening before anti-hepatitis C virus therapy in prisons.
Topics: Adult; Antiviral Agents; Hepatitis C; Humans; Interferon-alpha; Male; Mass Screening; Polyethylene Glycols; Prisoners; Radiography; Recombinant Proteins; Recurrence; Ribavirin; Tuberculosis, Pulmonary | 2012 |
Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR.
Topics: Adult; Antiviral Agents; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2012 |
[Position paper of the Catalan Society of Gastroenterology: treatment of Genotype 1 Chronic Hepatitis C Virus with Triple Therapy].
Topics: Antiviral Agents; Biopsy; Contraindications; Diagnostic Imaging; Drug Therapy, Combination; Genotype; Health Services Accessibility; Hepacivirus; Hepatitis C, Chronic; Humans; Informed Consent; Interferon Type I; Interferons; Interleukins; Liver Cirrhosis; Oligopeptides; Patient Care Team; Polyethylene Glycols; Proline; Protease Inhibitors; Recurrence; Ribavirin; Viral Load | 2012 |
Comprehensive analysis for viral elements and interleukin-28B polymorphisms in response to pegylated interferon plus ribavirin therapy in hepatitis C virus 1B infection.
Topics: Adolescent; Adult; Aged; Alleles; Antiviral Agents; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Interleukins; Japan; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Open Reading Frames; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Nonstructural Proteins | 2012 |
Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation.
Topics: Alkaline Phosphatase; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cholestasis; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Liver Failure; Liver Transplantation; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Recurrence; Reoperation; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Valine; Viral Load | 2012 |
Impact of ribavirin dose on retreatment of chronic hepatitis C patients.
Topics: Adult; Age Factors; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2012 |
Long-term antiviral treatment for recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Survival Rate | 2012 |
Liver-kidney recipients with chronic viral hepatitis C treated with interferon-alpha.
Topics: Acute Disease; Adult; Aged; Biopsy; Female; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferon-alpha; Kidney Transplantation; Liver; Liver Failure; Liver Transplantation; Male; Middle Aged; Recurrence; Renal Insufficiency; Retrospective Studies; Ribavirin; Steroids; Transaminases; Treatment Outcome | 2012 |
Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence.
Topics: Aged; Antiviral Agents; Cyclosporine; Disease Management; Drug Therapy, Combination; Everolimus; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Recurrence; Ribavirin; Sirolimus; Tacrolimus; Viral Load | 2012 |
Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data.
Topics: Aged; Antiviral Agents; Biomarkers; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Feasibility Studies; Female; Germany; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Oligopeptides; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2012 |
Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2013 |
[Long-term assessment of relapse and associated risk factors in chronic hepatitis C patients treated with interferon and ribavirin].
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Outcome; Young Adult | 2012 |
Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.
Topics: Adult; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Treatment Outcome; Viral Load | 2013 |
Approach to the treatment-experienced patient with hepatitis C virus genotype 1 infection.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Recurrence; Ribavirin; RNA, Viral; Viral Load | 2012 |
Treatment of chronic hepatitis C with pegylated interferon-α in a patient with recurrent autoimmune thrombotic thrombocytopenic purpura.
Topics: ADAM Proteins; ADAMTS13 Protein; Antiviral Agents; Autoantibodies; Autoimmune Diseases; Biopsy; Female; Hepatitis C, Chronic; Hepatomegaly; Humans; Interferon-alpha; Middle Aged; Polyethylene Glycols; Purpura, Thrombotic Thrombocytopenic; Recombinant Proteins; Recurrence; Ribavirin; Splenomegaly; von Willebrand Factor | 2013 |
Recurrence of hepatitis C virus infection during pityriasis rosea.
Topics: Adult; Antiviral Agents; Biopsy; DNA, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Herpesvirus 6, Human; Herpesvirus 7, Human; Humans; Interferon-alpha; Pityriasis Rosea; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Virus Activation | 2013 |
Acute hepatitis B in a patient with OLT during treatment with peg-interferon and ribavirin for hepatitis C recurrence.
Topics: Aged; Antibodies, Viral; Antiviral Agents; Drug Therapy, Combination; Guanine; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Superinfection; Treatment Outcome; Viral Load | 2012 |
Triple therapy with boceprevir or telaprevir for prior HCV non-responders.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Protease Inhibitors; Recombinant Proteins; Recurrence; Retreatment; Ribavirin | 2012 |
Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers.
Topics: Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; Graft Rejection; Graft Survival; Hepatitis C, Chronic; Humans; Interferon-alpha; Italy; Kaplan-Meier Estimate; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Regression Analysis; Retreatment; Retrospective Studies; Ribavirin; Risk Assessment; Survival Analysis; Treatment Outcome | 2013 |
Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy.
Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Statistics, Nonparametric; Time Factors; Treatment Failure | 2012 |
Liver transplantation for HCV cirrhosis; cautious optimism after 10 years of experience.
Topics: Adult; Combined Modality Therapy; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Recurrence; Reoperation; Ribavirin; Survival Rate; Treatment Outcome | 2012 |
Peginterferon Alfa-2a plus ribavirin in Japanese patients infected with hepatitis C virus genotype 2 who failed previous interferon therapy.
Topics: Aged; Antiviral Agents; Drug Synergism; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Interferons; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA; Treatment Outcome | 2013 |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Coinfection; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Mutation; Polyethylene Glycols; Promoter Regions, Genetic; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Core Proteins | 2013 |
Postoperative peg-interferon plus ribavirin is associated with reduced recurrence of hepatitis C virus-related hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Cohort Studies; Female; Hepatitis C; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols; Postoperative Period; Proportional Hazards Models; Recombinant Proteins; Recurrence; Ribavirin; Taiwan | 2013 |
[What is expected from the novel triple combination antiviral treatment of patients infected with hepatitis C virus genotype 1?].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hungary; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Recombinant Proteins; Recurrence; Retreatment; Retrospective Studies; Ribavirin; Treatment Outcome; Waiting Lists | 2013 |
I favor therapy for hepatitis C virus recurrence after transplantation.
Topics: Acute Disease; Antiviral Agents; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferon-alpha; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin; RNA, Viral | 2002 |
[What therapy is meaningful in chronic hepatitis C and resection of hepatocellular carcinoma for recurrence prophylaxis?].
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Recurrence; Ribavirin | 2002 |
[ROC curve analysis of factors predictive of response to treatment with interferon plus ribavirin in patients with chronic hepatitis C relapse after previous interferon treatment].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Male; Predictive Value of Tests; Recurrence; Ribavirin; ROC Curve | 2002 |
Discordance between ALT values and fibrosis in liver transplant recipients treated with ribavirin for recurrent hepatitis C.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Erythropoietin; Female; Fibrosis; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; Time Factors | 2003 |
Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2003 |
Combination therapy of interferon alpha-2B and ribavirin for recurrent hepatitis C after liver transplantation.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viremia | 2003 |
[Recurrence after customary hepatitis C therapy. Those patients are now treatable, too].
Topics: Antiviral Agents; Clinical Trials, Phase III as Topic; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Viral Load | 2003 |
Duration of antiviral therapy for cholestatic HCV recurrence may need to be indefinite.
Topics: Antiviral Agents; Bilirubin; Cholestasis; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Remission Induction; Ribavirin; RNA, Viral; Viremia | 2003 |
Treatment of recurrent hepatitis C in liver transplant recipients: is there any histologic benefit?
Topics: Adult; Antiviral Agents; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Failure | 2003 |
Recurrent allograft HCV presenting as acute cellular rejection: successful management with interferon and ribavirin alone.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Aspartate Aminotransferases; Female; Glucocorticoids; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Prednisolone; Recombinant Proteins; Recurrence; Ribavirin | 2003 |
Nonresponders of interferon/ribavirin treatment for recurrent hepatitis C following liver transplantation.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver Function Tests; Liver Transplantation; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2003 |
Management of severe acute respiratory syndrome: the Hong Kong University experience.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hong Kong; Humans; Male; Middle Aged; Patient Care Planning; Recurrence; Ribavirin; Severe Acute Respiratory Syndrome; Severe acute respiratory syndrome-related coronavirus; Treatment Outcome | 2003 |
A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Virus Activation | 2003 |
Daily interferon alpha-2B and ribavirin combination therapy for liver transplant patients with chronic hepatitis C infection.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2003 |
Severe acute respiratory syndrome: Relapse? Hospital infection?
Topics: Antiviral Agents; Cross Infection; Female; Hong Kong; Humans; Middle Aged; Recurrence; Ribavirin; Severe Acute Respiratory Syndrome | 2003 |
Controversies in the management of hepatitis C virus infection after liver transplantation.
Topics: Antiviral Agents; Contraindications; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Transplantation, Homologous; Virus Replication | 2003 |
Treatment of patients with hepatitis C virus on the waiting list.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver; Liver Transplantation; Recurrence; Ribavirin; RNA, Viral; Waiting Lists | 2003 |
How can we identify better those with recurrent hepatitis C who will respond to therapy? What are the optimal treatment regimen and treatment duration?
Topics: Antiviral Agents; Creatinine; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Patient Selection; Polyethylene Glycols; Postoperative Period; Recombinant Proteins; Recurrence; Ribavirin | 2003 |
[Combined interferon-alfa-2b and ribavirin therapy in patients with recurrent chronic hepatitis c after liver transplantation].
Topics: Adult; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Bilirubin; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome | 2003 |
Late relapse in chronic hepatitis C after sustained viral response to interferon and ribavirin.
Topics: Adult; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Time Factors | 2004 |
Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C.
Topics: Antiviral Agents; Drug Carriers; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral | 2004 |
Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug Tolerance; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2004 |
Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain rea
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Load | 2004 |
Reversible decompensated liver disease as a possible complication of pegylated-interferon alfa 2b and ribavirin for recurrent hepatitis C.
Topics: Adult; Antiviral Agents; Chemical and Drug Induced Liver Injury; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2004 |
Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Viremia | 2004 |
Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Biopsy; Data Interpretation, Statistical; Drug Therapy, Combination; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2004 |
Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
Topics: Adult; Antiviral Agents; Biopsy; Genotype; Graft Rejection; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Interferons; Liver Transplantation; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Transplantation, Homologous | 2004 |
Outcomes of acute rejection after interferon therapy in liver transplant recipients.
Topics: Adult; Antiviral Agents; Female; Graft Rejection; Hepatitis C; Humans; Interferons; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome | 2004 |
Carriage of the apolipoprotein E-epsilon4 allele and histologic outcome of recurrent hepatitis C after antiviral treatment.
Topics: Alleles; Antiviral Agents; Apolipoproteins E; Disease Progression; Female; Hepacivirus; Hepatitis C, Chronic; History, 16th Century; Humans; Interferons; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; Recurrence; Ribavirin | 2004 |
Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy.
Topics: Acute Disease; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Ribavirin; Treatment Outcome | 2004 |
Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin | 2004 |
Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients.
Topics: Adult; Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2005 |
The long-term effects of immune suppression on liver transplant recipients with recurrent hepatitis C viral infection.
Topics: Antiviral Agents; Biopsy; Hepatitis C; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Transplantation; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Survival Analysis; Treatment Outcome | 2004 |
Ribavirin monotherapy increases sustained response rate in relapsers of end treatment virologic responders.
Topics: Adult; Antiviral Agents; Cost Savings; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2005 |
Sexually transmitted reinfection with a new hepatitis C genotype during pegylated interferon and ribavirin therapy.
Topics: Antiviral Agents; Genotype; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Homosexuality, Male; Humans; Interferon alpha-2; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Unsafe Sex | 2005 |
Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy.
Topics: Adult; Antiviral Agents; Biopsy; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Logistic Models; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Statistics, Nonparametric; Treatment Outcome | 2005 |
Pilot study of interferon gamma for chronic hepatitis C.
Topics: Antiviral Agents; Blood Cell Count; Dose-Response Relationship, Drug; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferon-gamma; Male; Middle Aged; Pilot Projects; Recurrence; Ribavirin; RNA, Viral; Transaminases; Treatment Failure | 2005 |
The optimal treatment strategy for chronic hepatitis C.
Topics: Antiviral Agents; Chronic Disease; Hepatitis C; Humans; Interferons; Models, Theoretical; Polyethylene Glycols; Recurrence; Ribavirin; Time Factors; Treatment Outcome | 2005 |
Partial splenic embolization for the treatment of hypersplenism in liver transplanted patients with hepatitis C virus recurrence before peg-interferon plus ribavirin.
Topics: Antiviral Agents; Drug Therapy, Combination; Embolization, Therapeutic; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Spleen; Treatment Outcome | 2005 |
Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Female; Hepatitis C; Humans; Immunosuppressive Agents; Infections; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2005 |
Lack of evidence for ribavirin monotherapy efficacy on liver fibrosis in hepatitis C virus positive renal transplant patients.
Topics: Antiviral Agents; Hepatitis C; Humans; Kidney Transplantation; Recurrence; Reproducibility of Results; Ribavirin | 2005 |
Interstitial pneumonia recurrence during chronic hepatitis C treatment.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lung Diseases, Interstitial; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Tomography, X-Ray Computed | 2005 |
Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome; Viral Load | 2005 |
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2005 |
Recurrence of hepatitis C after liver transplantation.
Topics: Antiviral Agents; Hepatitis C; Humans; Immunosuppression Therapy; Interferons; Liver Transplantation; Prognosis; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment | 2005 |
Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen.
Topics: Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppression Therapy; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 2006 |
Splenectomy and preemptive interferon therapy for hepatitis C patients after living-donor liver transplantation.
Topics: Antiviral Agents; Feasibility Studies; Hepatitis C; Humans; Interferons; Liver Transplantation; Living Donors; Pilot Projects; Platelet Count; Recurrence; Ribavirin; Splenectomy | 2005 |
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Cadaver; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Living Donors; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Survival Rate; Viral Core Proteins; Viral Load | 2005 |
Relapse response to interferon and ribavirin in liver transplant recipient with hepatitis C recurrence.
Topics: Adult; Antiviral Agents; Blood Transfusion; Hepatitis C; Humans; Interferons; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin | 2005 |
Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
Topics: Adolescent; Adult; Antiviral Agents; Bilirubin; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2005 |
Pure red cell aplasia associated with concomitant use of mycophenolate mofetil and ribavirin in post-transplant recurrent hepatitis C.
Topics: Antiviral Agents; Hepatitis C; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Mycophenolic Acid; Recurrence; Red-Cell Aplasia, Pure; Ribavirin | 2006 |
Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy.
Topics: Adult; Alanine Transaminase; alpha-Fetoproteins; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Male; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
[Recurrent hepatitis C after liver transplantation: Erythropoietin allows maintenance of antiviral treatment].
Topics: Anemia; Antiviral Agents; Drug Therapy, Combination; Erythropoietin; Hepatitis C; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Multicenter Studies as Topic; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viral Load | 2006 |
Declining sustained virological response in hepatitis C.
Topics: Adult; Aged; Antiviral Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome | 2006 |
Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience.
Topics: Antiviral Agents; Drug Therapy, Combination; Follow-Up Studies; Hepatitis C; Humans; Interferon-alpha; Italy; Liver Transplantation; Patient Dropouts; Recurrence; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome; Viral Load | 2006 |
The impact of nonalcoholic fatty liver disease and the metabolic syndrome on progression of fibrosis in patients with recurrent HCV after liver transplantation.
Topics: Adult; Antiviral Agents; Biopsy; Cholesterol, HDL; Disease Progression; Fatty Liver; Female; Hepatitis C; Humans; Liver Cirrhosis; Living Donors; Male; Metabolic Syndrome; Middle Aged; Postoperative Complications; Recurrence; Retrospective Studies; Ribavirin; Triglycerides | 2006 |
High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?
Topics: Aged; Alanine Transaminase; Antibodies, Antinuclear; Antiviral Agents; Female; Graft Rejection; Hepatitis C; Hepatitis C Antibodies; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Mitochondria; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral | 2007 |
Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Biopsy; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Transplantation, Homologous; Treatment Outcome | 2006 |
Relapse to opioid use after treatment of chronic hepatitis C with pegylated interferon and ribavirin.
Topics: Antiviral Agents; Behavior, Addictive; Cocaine-Related Disorders; Comorbidity; Drug Administration Schedule; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferons; Male; Methadone; Middle Aged; Opioid-Related Disorders; Patient Care Planning; Recurrence; Ribavirin; Risk Assessment; Substance Abuse, Intravenous; Treatment Outcome | 2006 |
Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection.
Topics: Adult; Aged; Antiviral Agents; Base Sequence; Clone Cells; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Molecular Sequence Data; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Viral Load | 2006 |
Pegylated interferon (PEG-IFN) alfa-2b and ribavirin for recurrent hepatitis C (genotype 1) after liver transplantation: relationship with steatosis.
Topics: Adult; Antiviral Agents; Body Mass Index; Cholesterol; Drug Therapy, Combination; Fatty Liver; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; Triglycerides | 2006 |
Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.
Topics: Adult; Antidepressive Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Male; Mental Disorders; Polyethylene Glycols; Prospective Studies; Quality of Life; Recombinant Proteins; Recurrence; Ribavirin; Treatment Refusal | 2007 |
Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; gamma-Glutamyltransferase; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kidney Failure, Chronic; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2006 |
High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Kinetics; Male; Middle Aged; Polyethylene Glycols; Predictive Value of Tests; Recombinant Proteins; Recurrence; Retreatment; Ribavirin; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2007 |
Sustained resolution of fibrosing cholestatic hepatitis C despite viremic relapse after stopping pegylated interferon and ribavirin therapy.
Topics: Antiviral Agents; Cholestasis, Intrahepatic; Fibrosis; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; Viremia | 2007 |
Cryptosporidiosis in a patient on PEG-interferon and ribavirin for recurrent hepatitis C after living donor liver transplantation.
Topics: Antiviral Agents; Cryptosporidiosis; Enterocolitis; Graft Rejection; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Opportunistic Infections; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2007 |
Combined antiviral therapy for recurrent hepatitis C virus after liver transplantation.
Topics: Aged; Antiviral Agents; Dose-Response Relationship, Drug; Female; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin | 2007 |
Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Cohort Studies; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
A 5-year prospective study of the late resolution of chronic hepatitis C after antiviral therapy.
Topics: Adult; Aged; Antiviral Agents; Case-Control Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-gamma; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: difficult to manage but essential for success.
Topics: Antiviral Agents; Clinical Trials as Topic; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Postoperative Complications; Recurrence; Ribavirin | 2007 |
[Mesenteric vein thrombosis and protein C and S deficiency in a patient with chronic hepatitis C on treatment with interferon and ribavirin].
Topics: Aged; Antiviral Agents; Drug Therapy, Combination; Fatal Outcome; Gram-Negative Bacterial Infections; Hemoperitoneum; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Mesenteric Vascular Occlusion; Mesenteric Veins; Pneumonia, Bacterial; Polyethylene Glycols; Protein C Deficiency; Protein S Deficiency; Recurrence; Respiration, Artificial; Ribavirin; Stenotrophomonas maltophilia; Thrombectomy; Thrombophilia; Venous Thrombosis | 2007 |
Antiviral therapy for hepatitis C virus recurrence after liver transplantation in HIV-infected patients: outcome in the Bonn cohort.
Topics: Administration, Oral; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 2007 |
Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C.
Topics: Adult; Analysis of Variance; Anemia; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Postoperative Complications; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome | 2007 |
Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.
Topics: Adult; Antiviral Agents; Biopsy; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Hepacivirus; Hepatitis C, Chronic; Humans; Incidence; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Prognosis; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Survival Rate | 2007 |
Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Patient Selection; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; RNA, Viral; Treatment Failure; Viral Load | 2007 |
Recurrent myocardial ischaemia during combination antiviral therapy in a patient with chronic hepatitis C and normal aminotransferase levels.
Topics: Alanine Transaminase; Antiviral Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Follow-Up Studies; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Male; Middle Aged; Monitoring, Physiologic; Myocardial Ischemia; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Risk Assessment; Severity of Illness Index | 2008 |
Development of hepatic granulomas in patients receiving pegylated interferon therapy for recurrent hepatitis C virus post liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Biopsy; Female; Granuloma; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver; Liver Diseases; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Sarcoidosis | 2008 |
[The recurrence of hepatitis C virus after liver transplantation].
Topics: Adult; Antiviral Agents; Disease-Free Survival; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferons; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Recurrence; Reoperation; Retrospective Studies; Ribavirin; Time Factors; Treatment Outcome | 2007 |
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV.
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2007 |
Multiple, repeated filgrastim treatment cycles to recover severe, recurring pegylated interferon-related neutropenia.
Topics: Adult; Antiviral Agents; Filgrastim; Genotype; Granulocyte Colony-Stimulating Factor; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2007 |
Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis C; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Risk Assessment; Survival Rate; Time Factors | 2008 |
[Clinical outcome after living donor liver transplantation in patients with hepatitis C virus-associated cirrhosis].
Topics: Adult; Aged; Antiviral Agents; Combined Modality Therapy; Female; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Severity of Illness Index; Treatment Outcome | 2007 |
Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
Topics: Antiviral Agents; Biopsy; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Failure; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Treatment Outcome | 2008 |
Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response.
Topics: Adult; Aged; Antiviral Agents; Cryoglobulinemia; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Vasculitis; Virus Replication | 2008 |
Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation.
Topics: Aged; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome | 2007 |
Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; Humans; Immunosuppressive Agents; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Living Donors; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Time Factors; Treatment Outcome | 2008 |
Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.
Topics: Adult; Antiviral Agents; Conserved Sequence; Evolution, Molecular; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Mutation; Open Reading Frames; Recurrence; Ribavirin; Treatment Failure; Viral Proteins | 2008 |
New approaches to the treatment of hepatitis C virus infection after liver transplantation using ribavirin.
Topics: Antiviral Agents; Aspartate Aminotransferases; Graft Survival; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral | 1995 |
Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation.
Topics: Administration, Oral; Adult; Alanine Transaminase; Antiviral Agents; Bone Marrow Transplantation; Child; Hepacivirus; Hepatic Veno-Occlusive Disease; Hepatitis C; Humans; Recurrence; Ribavirin; Risk Factors; RNA, Viral; Safety; Time Factors; Transplantation, Homologous | 1996 |
Subfulminant syncytial giant cell hepatitis: recurrence after liver transplantation treated with ribavirin.
Topics: Acute Disease; Adult; Antiviral Agents; Biopsy; Follow-Up Studies; Giant Cells; Hepatitis; Humans; Liver Failure; Liver Transplantation; Male; Recurrence; Ribavirin | 1997 |
Incidence and treatment of recurrent hepatitis C after liver transplantation.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; Humans; Incidence; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Ribavirin | 1996 |
Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Pilot Projects; Recurrence; Ribavirin; RNA, Viral | 1997 |
Ribavirin and interferon for recurrent posttransplantation HCV infection: to treat or not to treat?
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Recurrence; Ribavirin | 1997 |
The University of Toronto liver transplant program.
Topics: Adult; Alprostadil; Antiviral Agents; Child; Graft Survival; Hepatitis B; Hepatitis C; Hospitals, University; Humans; Immunization, Passive; Immunoglobulins; Immunosuppression Therapy; Lamivudine; Liver Neoplasms; Liver Transplantation; Ontario; Patient Selection; Recurrence; Retrospective Studies; Ribavirin; Survival Rate; Transplantation, Heterologous | 1996 |
Ribavirin therapy for adenovirus pneumonia in an AIDS patient.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Adult; AIDS-Related Opportunistic Infections; Antibodies, Viral; Antiviral Agents; Biopsy; CD4 Lymphocyte Count; Fatal Outcome; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Pneumonia, Viral; Recurrence; Ribavirin; Tomography, X-Ray Computed | 1997 |
RSV, recurrent wheezing, and ribavirin.
Topics: Antiviral Agents; Asthma; Bronchial Hyperreactivity; Bronchiolitis; Humans; Infant; Recurrence; Respiratory Sounds; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus, Human; Ribavirin | 1998 |
Interferon alpha with ribavirin for the treatment of chronic hepatitis C in non-responders or relapsers to interferon monotherapy.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Combined Modality Therapy; Drug Resistance; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Treatment Outcome | 1998 |
Effects of ribavirin on hepatitis C-associated nephrotic syndrome in four liver transplant recipients.
Topics: Antiviral Agents; Drug Tolerance; Female; Glomerulonephritis; Hepatitis C; Humans; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Nephrotic Syndrome; Recurrence; Ribavirin; Viremia | 1998 |
[Therapy of recurrent hepatitis C after liver transplantation].
Topics: Combined Modality Therapy; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Pilot Projects; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin | 1998 |
Combination therapy of chronic hepatitis C: an important step but not the final goal!
Topics: Antiviral Agents; Combined Modality Therapy; Hepatitis C, Chronic; Humans; Liver Transplantation; Recurrence; Ribavirin; Treatment Outcome | 1998 |
[Severe relapse of hepatitis C following liver transplantation. Successful treatment with a combination of interferon-alpha and ribavirin].
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Recombinant Proteins; Recurrence; Ribavirin; Severity of Illness Index; Treatment Outcome | 1999 |
Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Logistic Models; Male; Polymerase Chain Reaction; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; ROC Curve; Treatment Outcome | 2000 |
Management of interferon relapsers.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Recurrence; Ribavirin; RNA, Viral; Viral Load | 1999 |
[Hepatitis C more dangerous than AIDS. At last a breakthrough in therapy using the new combination treatment].
Topics: Antiviral Agents; Drug Therapy, Combination; Germany; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Recombinant Proteins; Recurrence; Ribavirin | 1999 |
Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C.
Topics: Antiviral Agents; Hepatitis C, Chronic; Humans; Immunologic Factors; Interferon-alpha; Male; Middle Aged; Psoriasis; Recurrence; Ribavirin | 2000 |
Successful rescue of severe recurrent hepatitis C with interferon and ribavirin in a liver transplant patient.
Topics: Alanine Transaminase; Drug Therapy, Combination; Hepatitis C; Humans; Interferons; Liver Transplantation; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral | 2000 |
Combination of interferon-alpha and ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome | 2000 |
Ribavirin: new preparation. An advance, but still no cure-all.
Topics: Anemia, Hemolytic; Antiviral Agents; Clinical Trials as Topic; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Europe; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome; United States | 2000 |
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
Topics: Adult; Anemia; Antiviral Agents; CD4 Lymphocyte Count; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Polymerase Chain Reaction; Recurrence; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load | 2000 |
Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts the type of response.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Outcome Assessment, Health Care; Predictive Value of Tests; Recurrence; Ribavirin; RNA, Viral; Time Factors; Treatment Outcome | 2001 |
[When standard therapy fails. New therapy options in chronic hepatitis C].
Topics: Drug Administration Schedule; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Randomized Controlled Trials as Topic; Recombinant Proteins; Recurrence; Ribavirin; Treatment Failure | 2001 |
Monitoring virological responses to interferon-ribavirin and interferon monotherapy of chronic hepatitis C re-treated due to relapse or non-response.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Treatment Failure; Viral Load; Viremia | 2001 |
Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin.
Topics: Adult; Aged; Antiviral Agents; Disease Progression; Female; Granulocyte Colony-Stimulating Factor; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Viral Load | 2001 |
Interferon-alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Antiviral Agents; Female; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Ribavirin; RNA, Viral; Transaminases; Viral Load | 2001 |
Combination therapy with interferon-alpha 2b and ribavirin for the treatment of relapse patients and non-responders with chronic HCV infection.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; Treatment Outcome | 2001 |
Interferon alpha 2B and ribavirin in severe recurrent cholestatic hepatitis C.
Topics: Adult; Antiviral Agents; Cholestasis; Drug Therapy, Combination; Fatal Outcome; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin; Severity of Illness Index | 2001 |
Treatment of hepatitis C infection in injection drug users.
Topics: Adult; Alanine Transaminase; Female; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Opioid-Related Disorders; Patient Compliance; Polymerase Chain Reaction; Prospective Studies; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Sex Characteristics; Substance Abuse, Intravenous; Treatment Outcome | 2001 |
Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; Humans; Injections, Subcutaneous; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Recurrence; Ribavirin; Statistics, Nonparametric; Treatment Outcome | 2001 |
Interferon-alpha plus ribavirin and amantadine in patients with post-transplant hepatitis C: results of a pilot study.
Topics: Aged; Amantadine; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Pilot Projects; Recurrence; Ribavirin; Treatment Outcome | 2001 |
Probable reinfection with hepatitis C virus in a chronic hepatitis C patient with a sustained response to combination therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity; Interferon alpha-2; Interferon-alpha; Liver; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Viremia | 2001 |
Hepatitis C: who should you treat and how?
Topics: Amantadine; Antiviral Agents; Decision Making; Decision Trees; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Liver Cirrhosis; Polyethylene Glycols; Recombinant Proteins; Recurrence; Ribavirin | 2002 |
Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study.
Topics: Adult; Antiviral Agents; Drug Administration Schedule; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon Type I; Interferon-alpha; Logistic Models; Male; Pilot Projects; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors | 2002 |
Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy.
Topics: Adult; Aged; Anemia; Antiviral Agents; Clinical Protocols; Drug Therapy, Combination; Erythrocyte Transfusion; Erythropoietin; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Postoperative Complications; Recombinant Proteins; Recurrence; Ribavirin | 2002 |
[Why is there a poor response to combined therapy with interferon alfa 2b and ribavirin in patients with chronic hepatitis C?].
Topics: Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin | 2002 |
Long-term combination of interferon alfa-2b and ribavirin for hepatitis C recurrence in liver transplant patients.
Topics: Adult; Antiviral Agents; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Function Tests; Liver Transplantation; Middle Aged; Recombinant Proteins; Recurrence; Ribavirin; RNA, Viral; Time Factors; Viremia | 2001 |